,,,,,,,,,,,,,,New,,,,86.45833333,,,,New,,Updated,New,New,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Intervention details,,,,,,,Scenario 5 with donor-funded interventions fixed,,,,Cost-effectiveness evidence,,,,,,,,,,,,,,,Eligible population and coverage,,,,,,,,,Maximum feasible coverage,,,,,Consumables cost,,,,,,,,,,,,HR Need,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Source of data,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,NA,Malawi - Final,NA,NA,NA,Uganda - 2021,NA,NA,NA,NA,NA,NA,New columns created to get data from Uganda sheet,,,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - 2016,Malawi - 2016,Malawi - 2016,Uganda - 2021,Malawi - Final 2021, Malawi - Final 2021 ,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - 2016,Uganda - 2021,Malawi - Final,Malawi - Final,,Uganda - 2021,Uganda - 2021,Uganda - 2021,Uganda - 2021,Uganda - 2021,Uganda - 2021,Uganda - 2021,Malawi - 2016,Intermediate step,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - Final,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,Malawi - 2018,,,,,,,,Extracts from Tufts database for interventions which were not included in the Uganda HBP tool,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Variable name for R code,code,category,package,intervention_name_old,int_for_matching,intervention,int_for_matching2,int_for_matching3,level,int_uganda,notes,ce_country,ce_source,who_choice,ce_intervention,ce_comparator,,,,ce_dalys_raw,ce_cost_raw,ce_dalys,ce_cost,ce_icer,update_cost,currency,pop_oldmalawi_cat,pop_oldmalawi_size,pop_oldmalawi_pin,pop_uganda_pin,pop_cat, pop_size ,pop_pin,,pop_cases,feascov_oldmalawi,feascov_uganda,feascov,feascov_source,feascov_min,conscost_uganda_community,conscost_uganda_outreach,conscost_uganda_clinic,conscost_uganda_hospital,conscost_uganda_manual,conscost_uganda_source,conscost_uganda_avg,conscost_oldmalawi,conscost_old,conscost_new,conscost,finalsource,hr_medoff,hr_clinoff,hr_medass,hr_nuroff,hr_nurtech,hr_pharm,hr_pharmtech,hr_pharmass,hr_laboff,hr_labtech,hr_labass,hr_comm,hr_dentoff,hr_dentther,hr_dentass,hr_ment,hr_nutri,hr_radio,hr_radiotech,hr_sono,hr_radiother,donor_funded,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Descriptive variable name,Intervention code,Category,Intervention Package,Intervention,Cleaned intervention name for matching,Final Intervention name,Intervention name for matching with cost file,Intervention for WFOM match,Level of intervention,Mapping to Uganda tool/2016 EHP tool,Notes,Country,Source,WHO-CHOICE,Name of Intervention in paper,Comparator,DALYs averted per person,Cost per person,Units (cost),DALYs averted per patient,Cost per case (2019 USD),DALYs averted per patient (adjusted),Cost per case (2020 USD) (adjusted),ICER (calculated),Update cost based on currency,Currency,Target population category - Malawi,Target population size_2021,PIN_2021,PIN_2021,Target population category, Target population size_2021 ,PIN_2021,Source of PIN,Eligible cases _2021,Maximum feasible coverage_2021 (demand and supply constraints),Maximum feasible coverage_2020 (demand and supply constraints),Maximum feasible coverage_2021 (demand constraint),Source,Maximum feasible coverage (minimum of 2016/2021 estimate),Community,Outreach,Clinic,Hospital,Cost if manual input,Source if manual entry for cost,"Average Consumables cost across levels (2016), 2019 USD","Consumables cost (2016), 2019 USD",Consumables cost (USD),,,,Medical officer,Clinical Officer,Nurse Officer,Md Wife Tech,Med. Assistant,Pharmacist,Pharm Technician,Pharm Assist,Lab Officer,Lab Technocian,Lab Assist,Community Health Worker,Dental Officer,Dental Therapist,Dental Assistant,Mental Health Staff,Nutrition Staff,Radiographer,Radiography Technician,Sonographer,Radiotherapy Technician,Donor-funded,Status of CE evidence,Status of case numbers,Status of drug costs,Status of HR Need Estimate,Status of drug costs - detailed,Action on previous HBP intervention,RatioID,InterventionPhrase,InterventionParagraph,Comparator,Comparator_type,Country,DALYFinal,DALYinCurrentUSDollars,DALYsAvertedPerPerson,InterventionDirectCosts,ComparatorTotalCosts,TotalCosts,InterventionDirectCostsPerPerson,ComparatorDirectCostsPerPerson,DirectCostsPerPerson,CostQALYText,PrimAuthLastName,PubYear,CurrencyCountry,YearOfCurrency,Title,DALYs averted,Cost,per capita,DALYs averted per patient,Cost per patient,Currency,ICER,Final decision on CE,Further notes on target population and cost
,001,Child Health,ARIs, ICCM Fast breathing Pneumonia treatment (infants), ICCM Fast breathing Pneumonia treatment (infants),ICCM Fast breathing Pneumonia treatment (infants),,,Community,,,,,,,,,,,,,,,,,,,,,,Children 1-12 months," 599,135 ",140%,GBD URI/LRI; https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12481,838789,,,47%,Ng'ambi 2020 child,47%,,,,,,,,,,1.072464,1.072464,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 027),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,002,Child Health,ARIs,IMCI Pneumonia treatment (children),IMCI Pneumonia treatment (children),Community-based management of neonatal pneumonia,,Community-based intervention,Community,,,Multiple Countries,Adam(2005);Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,per capita,Community based management of neonatal pneumonia,,,,,0.010288069,0.010288069,0.061392164,0.02780288,0.453,Yes,2000 Int$,,,,,Children 1-59 months," 2,289,849 ",140%,GBD URI/LRI; https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12481,3205788.6,87.00%,,47%,Ng'ambi 2020 child,47%,,,,,,,,,,12.4352772,12.4352772,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Complete,Complete,Complete,Incomplete,,2005-01-00265-01,Community based management of neonatal pneumonia,Community based management of neonatal pneumonia (95%),,None,Multiple Countries,1,1.50296748,0,0,0,0,0,0,0,0,Adam,2005,United States,2000,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,1000000,1000000,per capita,0.010288069,0.010288069,2000 Int $,,,
,003,Child Health,ARIs,IMCI Pneumonia treatment (children),IMCI Pneumonia treatment (children),IMCI Pneumonia treatment (children),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",140%,GBD URI/LRI; https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12481,3205788.6,,,47%,Ng'ambi 2020 child,47%,,,,,,,,,,12.4352772,12.4352772,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 027),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,004,Child Health,ARIs,IMCI Pneumonia treatment (children >5years),IMCI Pneumonia treatment (children >5years),IMCI Pneumonia treatment (children >5years),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 5-14 years," 5,619,431 ",140%,GBD URI/LRI; https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12481,7867203.4,,,47%,Ng'ambi 2020 child,47%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 027),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,005,Child Health,ARIs,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",1%,GBD LRI,27478.188,,,60%,Ng'ambi 2020 child/+increase for severity,60%,,,,,,,,,,21.7611576,21.7611576,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 027),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,006,Child Health,ARIs,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",1%,GBD LRI,27478.188,,,60%,Ng'ambi 2020 child/+increase for severity,60%,,,,,,,,,,21.7611576,21.7611576,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 027),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,007,Child Health,IMNCI,Possible Serious Bacterial Infection Treatment (PSBI),Possible Serious Bacterial Infection Treatment (PSBI),Community-based management of Possible Serious Bacterial Infection (PSBI),,Community-based intervention,Primary,,,Ethiopia,Mathewos(2017);Community-Based Interventions for Newborns in Ethiopia (COMBINE): Cost-effectiveness analysis,,Government’s Health Extension Program plus management of possible serious bacterial infection with Health Extension Workers and a volunteer Community Health Worker. Includes community-based interventions for newborns: newborns treated with daily gentamycin injections and oral amoxicillin; home visits and community education,,,,,484.7897225,108108.1081,484.7897225,118054.0541,243.516,Yes,2015 US$,,,,,Children 1-59 months," 2,289,849 ",0.030%,GBD PSBI,686.9547,,,71%,Ng'ambi 2020 child,71%,,,,,,,,,,9.338388,9.338388,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Complete,Complete,Complete,Incomplete,,2017-01-03768-01,Government’s Health Extension Program plus management of possible serious bacterial infection with Health Extension Workers and a volunteer Community Health Worker. Includes community-based interventions for newborns: newborns treated with daily gentamycin injections and oral amoxicillin; home visits and community education,Government’s Health Extension Program plus management of possible serious bacterial infection with Health Extension Workers and a volunteer Community Health Worker. Includes community-based interventions for newborns: newborns treated with daily gentamycin injections and oral amoxicillin; home visits and community education,,Other,Ethiopia,223,243.5051199,0,0,0,107279,0,0,0,0,Mathewos,2017,United States,2015,Community-Based Interventions for Newborns in Ethiopia (COMBINE): Cost-effectiveness analysis,481,107279,,418.5351271,93333.33333,2015 US $,223,CE evidence not appropriate,
,008,Child Health,Diarrhoeal Classification,ICCM management of diarrhea,ICCM management of diarrhea,ICCM management of diarrhea,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",290%,GBD diarrhea,6640562.1,,,60%,Ng'ambi 2020 child,60%,,,,,,,,,,3.26016,3.26016,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 028/029),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,009,Child Health,Diarrhoeal Classification,IMCI management of diarrhea ( children >5 years),IMCI management of diarrhea ( children >5 years),IMCI management of diarrhea ( children >5 years),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 5-14 years," 5,619,431 ",290%,GBD diarrhea,16296349.9,,,60%,Ng'ambi 2020 child,60%,,,,,,,,,,0.108072,0.108072,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 028/029),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,010,Child Health,Diarrhoeal Classification,Antibiotics for treatment of dysentery,Antibiotics for treatment of dysentery,Antibiotics for treatment of dysentery,,Under 5 Outpatient Visit,Secondary,Antibiotics for treatment of dysentery,,,WHO-CHOICE,0,,,,,,0.3,74.9659284,0.3,75.86551954,252.885,,,Children 1-59 months,"25,309",10.80%,10.90%,Children 1-59 months," 2,289,849 ",290%,GBD diarrhea,6640562.1,48.00%,46.00%,33%,https://journals.sagepub.com/doi/full/10.1177/2333794X19855468,33%,4.916376618,4.916376618,4.916376618,4.916376618,,,4.916376618,4.91637662,4.91637662,0.305424,0.305424,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,011,Child Health,Diarrhoeal Classification,IMCI management of severe dehydration,IMCI management of severe dehydration,IMCI management of severe dehydration,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",,,,,,100%,Ng'ambi 2020 child/+increase for severity,100%,,,,,,,,,,8.299152,8.299152,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,012,Child Health,Malaria,ICCM Malaria treament  (infants),Home management of fevers using antimalarial (artesunate- amodiaquine AAQ) - under 5,Community-based management of indicated malaria,"Uncomplicated (children, <15 kg)",Community-based intervention,Community,Home management of fevers using antimalarial (artesunate- amodiaquine AAQ) - under 5,,Ghana,Nonvignon (2012); Trop Med Int Health,per capita,Febrile children 2–59 months received artesunate–amodiaquine when taken to community health workers (CHWs) by their caregivers and diagnosed of having uncomplicated fever,None,,,,0.4103469,36.55526119,48.88837711,5252.325866,107.435,Yes,2009 US$,,,,,Children 1-12 months," 599,135 ",27%,WHO World Malaria Report 2020,160568.18,59.00%,,71%,Ng'ambi 2020 child,59%,,,,,,,,,,2.26938,2.26938,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Complete,Complete,Complete,Incomplete,,2012-01-01106-02,Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),,None,Ghana,114.21,137.7795173,0,0,0,0,0,0,0,0,Nonvignon,2012,United States,2009,Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian District,0.109972969,9.79681,per capita,0.4103469,36.55526119,2009 US $,89.0838,,
,013,Child Health,Malaria,IMCI Malaria treatment (children),IMCI Malaria treatment (children),IMCI Malaria treatment (children),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",27%,WHO World Malaria Report 2020,613679.532,,,71%,Ng'ambi 2020 child,71%,,,,,,,,,,5.5280094,5.5280094,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 116/117),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,014,Child Health,Malaria,IMCI Malaria treatment (children >5years),IMCI Malaria treatment (children >5years),IMCI Malaria treatment (children >5years),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 5-14 years," 5,619,431 ",27%,WHO World Malaria Report 2020,1506007.508,,,71%,Ng'ambi 2020 child,71%,,,,,,,,,,4.0899054,4.0899054,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 116/117),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,015,Child Health,Malaria,IMCI Treatment of severe Malaria,"Complicated (children, injectable artesunate)",Parenteral artesunate for severe malaria,,,Secondary,"Complicated (children, injectable artesunate)",,Uganda,Lubell (2011); Bull World Health Organ,0,Parental artesunate,Standard/Usual Care- Quinine dihyrocholride,,,,0.7,3.576,0.7,3.618912,5.170,,,Children 0-4 years,"20,962",0.30%,0.39%,Children 0-14 years," 7,909,282 ",1%,https://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1650-6/tables/2,55364.974,100.00%,100.00%,100%,increase severity,100%,12.88724775,12.88724775,12.88724775,12.88724775,,,12.88724775,12.8872478,12.8872478,8.2119276,8.2119276,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 125),,,,,Standard/Usual Care- Quinine dihyrocholride,,,,,,,,,,,,,,,,,,,,,,,,,
,016,Child Health,Malaria,IMCI Malaria treatment (children >5years),IMCI Malaria treatment (children >5years),IMCI Malaria treatment (children >5years),,,Secondary,,,,,,,,,,,,,,,,,,,,,,Children 5-14 years," 5,619,431 ",27%,WHO World Malaria Report 2020,1506007.508,,,71%,Ng'ambi 2020 child,71%,,,,,,,,,,4.0899054,4.0899054,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 116/117),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,017,Child Health,Malnutrition,CMAM Malnutrition treatment,CMAM Malnutrition treatment,CMAM Malnutrition treatment,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 0-14 years x incidence MAM and SAM," 261,005 ",100%,DHS/GBD child,261005,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 241),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,018,Maternal/Newborn and Reproductive Health,ICCM+CBMNC+Family Planning,Distribute FP commodities ,Distribute FP commodities ,Distribute family planning commodities ,,,Community,,,,,,Scenario 3 modern Family planning needs fulfilled by 75%,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 135-142),2018-01-04461-07,Scenario 3 modern Family planning needs fulfilled by 75%,Scenario 3 modern Family planning needs fulfilled by 75%,,Standard care,Uganda,-152.4804829,-164.4269803,0,0,68325400,-1515656,0,0,0,0,Zakiyah,2018,United States,2016,,,,,,,,,,
,019,Child Health,IMCI in the Community Inputs,Community IMCI Pneumonia treatment ,Community IMCI Pneumonia treatment ,Community based management of neonatal pneumonia,,,Community,,,,,,Community based management of neonatal pneumonia,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",140%,GBD URI/LRI; https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12481,3205788.6,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 002),2005-01-00265-01,Community based management of neonatal pneumonia,Community based management of neonatal pneumonia (95%),,None,Multiple Countries,1,1.50296748,0,0,0,0,0,0,0,0,Adam,2005,United States,2000,Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries,,,,,,,,,
,020,Child Health,IMCI in the Community Inputs,ICCM management of diarrhea,ICCM management of diarrhea,ICCM management of diarrhea,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",290%,GBD diarrhea,6640562.1,,,,,,,,,,,,,,,3.26016,3.26016,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 028/029),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,021,Child Health,IMCI in the Community Inputs,ICCM Malaria treament  (infants),ICCM Malaria treament  (infants),ICCM Malaria treament  (infants),,,Community,,,,,,,,,,,,,,,,,,,,,,Children 1-12 months," 599,135 ",27%,WHO World Malaria Report 2020,160568.18,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 116/117),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,022,Child Health,IMCI in the Community Inputs,CMBNC visit to PNC women,CMBNC visit to PNC women,CMBNC visit to PNC women,,,Community,,,,,,,,,,,,,,,,,,,,,,Live births," 620,346 ",100%,,620346,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,023,Child Health,IMCI in the Community Inputs,CMAM assess malnutrion,CMAM assess malnutrion,CMAM assess malnutrion,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 0-14 years," 7,909,282 ",100%,DHS/GBD child,7909282,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,024,Child Health,IMCI in the Community Inputs,CMAM Malnutrition treatment,CMAM Malnutrition treatment,CMAM Malnutrition treatment,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 0-14 x incidence MAM and SAM," 261,005 ",100%,DHS/GBD child,261005,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 241),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,025,Child Health,IMCI in the Community Inputs,Child protection - Screen for child abuse,Child protection - Screen for child abuse,Child protection - Screen for child abuse,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 0-14 years," 7,909,282 ",100%,,7909282,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,026,Child Health,IMCI in the Community Inputs,TB/HIV . Identify Child at risk of HIV,TB/HIV . Identify Child at risk of HIV,TB/HIV . Identify Child at risk of HIV,,,Community,,,,,,,,,,,,,,,,,,,,,,Children 0-14 years," 7,909,282 ",100%,,7909282,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,027,Child Health,IMCI in Priimary Inputs,IMCI Pneumonia treatment (children),Pneumonia treatment (children),Case management of childhood pneumonia,,Under 5 Outpatient Visit,Primary,Pneumonia treatment (children),,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Edejer et al. (2005),per capita,Case management of childhood pneumonia (CM) (95%),None,0.005096775,0.440658634,Int $ (2000),0.005096775,0.440658634,0.030414067,1.190853114,39.155,Yes,2000 Int$,Children 1-59 months,"25,273",2.80%,127.83%,Children 1-59 months," 2,289,849 ",140%,GBD URI/LRI; https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12481,3205788.6,87.00%,71.00%,70%,Ng'ambi 2020 child/+increase for severity,70%,0.155573794,0,0.155573794,0,,,0.155573794,0.55586542,0.55586542,12.4352772,12.4352772,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,028,Child Health,IMCI in Priimary Inputs,IMCI management of diarrhea,ORS and Zinc for diarrhea,ORS and Zinc for acute diarrhea,,Under 5 Outpatient Visit,Primary/Secondary,ORS and Zinc for diarrhea,,Tanzania,Robberstad (2004); Bulletin of WHO,0,ORS was combined with zinc for treatment of all children with acute diarrhoea,None,,,,0.03,3.45116,0.03,3.49257392,116.419,,,Children 1-59 months,,,220.00%,Children 1-59 months," 2,289,849 ",290%,GBD diarrhea,6640562.1,72.00%,70.00%,60%,Ng'ambi 2020 child,60%,,,,,1.107450926,Malawi HBP,1.107450926,,1.107450926,0.108072,0.108072,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,029,Child Health,IMCI in Priimary Inputs,IMCI management of diarrhea,Treatment of severe diarrhea,ORS and IV Fluid for severe diarrhea,,Under 5 Outpatient Visit,Primary/Secondary,Treatment of severe diarrhea,,Tanzania,Ruhago (2015); Cost Eff Resour Alloc,0,Current treatment of diarrhea (using oral rehydration salt (ORS) and intravenous (IV) fluid),"Standard/Usual Care- rotavirus vaccination (RV1)
salt (ORS) and intravenous (IV) fluid)",,,,0.59,58.9306,0.59,59.6377672,101.081,,,Children 1-59 months,"25,313",2.40%,2.40%,Children 1-59 months," 2,289,849 ",3%,Programmatic data,77854.866,100.00%,100.00%,100%,Ng'ambi 2020 child/+increase for severity,100%,2.087218855,2.087218855,2.087218855,2.087218855,,,2.087218855,2.08721885,2.08721885,0.108072,0.108072,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,"Standard/Usual Care- rotavirus vaccination (RV1)
salt (ORS) and intravenous (IV) fluid)",,,,,,,,,,,,,,,,,,,,,,,,,
,030,Child Health,IMCI in Priimary Inputs,IMCI management of diarrhea ( children >5 years),IMCI management of diarrhea ( children >5 years),IMCI management of diarrhea ( children >5 years),,,Primary,,,,,,,,,,,0.85,3.88,0.85,4.18264,4.921,Yes,2016 US$,,,,,Children 5-14 years," 5,619,432 ",,,,,,,,,,,,,,,,,,0.108072,0.108072,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,"remove - repetitive (028,029)",2014-01-02222-29,"Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)",,,Malawi,129,145.4159037,0.4622,0,0,0,0,0,0,0,Marseille,2014,United States,2012,,,,,,,,,,
,031,Child Health,IMCI in Priimary Inputs,IMCI Malaria treatment (children),IMCI Malaria treatment (children),IMCI Malaria treatment (children),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,849 ",,,,,,,,,,,,,,,,,,5.5280094,5.5280094,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 116/117),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,032,Child Health,IMCI in Priimary Inputs,IMCI Malaria treatment (children >5years),IMCI Malaria treatment (children >5years),IMCI Malaria treatment (children >5years),,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 0-14 years," 7,909,282 ",,,,,,,,,,,,,,,,,,4.0899054,4.0899054,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 116/117),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,033,Child Health,IMCI in Secondary Inputs,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,Inpatient pneumonia treatment,,,Secondary,,,,,,Pneumonia treatment as an inpatient,,,,,,,,,,,,,,,,Children 0-14 years," 7,909,282 ",,,,,,,,,,,,,,,,,,21.7611576,21.7611576,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence not appropriate,2008-01-01767-09,Pneumonia treatment as an inpatient,Pneumonia treatment as an inpatient,,None,Zimbabwe,130,0.650268684,0,0,0,0,0,0,0,0,Hansen,2008,Zimbabwe,1997,Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease,,,,,,,,CE evidence not appropriate,
,034,Child Health,IMCI in Secondary Inputs,Possible Serious Bacterial Infection Treatment (PSBI),Possible Serious Bacterial Infection Treatment (PSBI),Possible Serious Bacterial Infection Treatment (PSBI),,,Secondary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,9.338388,9.338388,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 007),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,035,Child Health,IMCI in Secondary Inputs,Antibiotics for treatment of dysentery,Antibiotics for treatment of dysentery,Antibiotics for treatment of dysentery,,,Secondary,Antibiotics for treatment of dysentery,,,WHO-CHOICE,0,,,,,,0.3,74.9659284,0.3,75.86551954,252.885,,,Children 1-59 months,"25,309",10.80%,10.90%,Children 1-59 months," 2,289,282 ",11%,Programmatic data,251821.02,48.00%,46.00%,60%,Ng'ambi 2020 child,48%,4.916376618,4.916376618,4.916376618,4.916376618,,,4.916376618,4.91637662,4.91637662,0.305424,0.305424,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetitive (010),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,036,Child Health,IMCI in Secondary Inputs,IMCI management of severe dehydration,IMCI management of severe dehydration,IMCI management of severe dehydration,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,8.299152,8.299152,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,037,Child Health,Malaria,IMCI Treatment of severe Malaria,IMCI Treatment of severe Malaria,IMCI Treatment of severe Malaria,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,8.2119276,8.2119276,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 125),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,038,Child Health,IMCI in Teritary Inputs,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,IMCI Treatment of severe pneumonia,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,21.7611576,21.7611576,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 033),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,039,Child Health,IMCI in Teritary Inputs,IMCI management of severe dehydration,IMCI management of severe dehydration,IMCI management of severe dehydration,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,8.299152,8.299152,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 011) - but no CE evidence found,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,040,Child Health,IMCI in Teritary Inputs,IMCI Treatment of severe Malaria,IMCI Treatment of severe Malaria,IMCI Treatment of severe Malaria,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,8.2119276,8.2119276,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 125),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,041,Child Health,Child Health Systems,ICCM Village Clinic Services,ICCM Village Clinic Services,ICCM Village Clinic Services,,,Community,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - primary care version in 042,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,042,Child Health,Child Health Systems,IMCI Facility level Services ,IMCI Facility level Services ,IMCI Facility level Services ,,,Primary,,,,,,Integrated management of childhood illness,,,,,0.85,3.88,0.85,4.18264,4.921,Yes,2016 US$,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - this intervention is not specific enough - the CE evidence related to diarrhea management,2017-01-03961-02,Integrated management of childhood illness,"Integrated management of childhood illness - zinc, retinol and low osmolarity ORS for moderate diarrhoea; zinc, ringers lactate IVF and retinol for severe diarrhoea",,None,Nigeria,4.6,4.960399488,0.85,0,0,0,0,0,0,0,Okafor,2017,United States,2016,Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model,,,,0.85,3.88,2016 US $,4.564705882,,
,043,Community Health,,"Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)",,,,"Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)",added from Uganda HBP,Uganda,Marseille (2014); BMJ Open,0,"Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)",None,,,,,,,,,Yes,2012 US$,,,,,Adults 15-49 years," 9,162,016 ",100%,CE paper,9162016,,,70%,same as other community outreach interventions,70%,,,,,,,0,,0,Not available,0,Uganda estimate (2020),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - broad intervention + no case numbers,2014-01-02222-29,"Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)","Integrated prevention campaign (IPC) against diarrhea (household water filters), malaria (bed-nets) and HIV (counseling, testing, cotrimoxazole prophylaxis, referral to treatment & condom distribution)",,None,Malawi,129,145.4159037,0.4622,0,0,0,0,0,0,0,Marseille,2014,United States,2012,Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries,,,,0.11,14.19,2012 US $,129,CE evidence not appropriate - intervention includes ART costs,
,044,"Eye, Ear and Skin",NA,Acute otitis media in under 5s,Acute otitis media in under 5s,Topical antibiotics for acute otitis media (under 5s),,Under 5 Outpatient Visit,Primary,Acute otitis media in under 5s,,,"Baltussen et al, 2012 http://www.bmj.com/content/344/bmj.e615",per capita,topical antibioticstopical antibiotics 50% coverage,,,,,0.186624305,3.732486095,51.98303154,532.9160071,10.252,Yes,2005 Int$,Children 0-59 months,"23,967",0.60%,,Children 1-59 months," 2,289,282 ",3%,GBD Otitis Media,68678.46,89.00%,,47%,Ng'ambi 2020 child,47%,,,,,,,0,0.99698903,0.99698903,0.263508,0.263508,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2012-01-01157-01,Topical antibiotics for Chronic otitis media control,Topical antibiotics for Chronic otitis media control 80% geographic coverage,,None,Multiple Countries,17,22.52835125,0.000638,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,0.00067,0.0134,per capita,0.186624305,3.732486095,2005 Int $,20,,
,045,"Eye, Ear and Skin",NA,Hearing Loss,Hearing Loss,Hearing Loss,,,Primary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,046,"Eye, Ear and Skin",NA,Wax removal,Wax removal,Wax removal,,,Primary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,0.26502,0.26502,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,047,"Eye, Ear and Skin",NA,Speech assessment,Speech assessment,Speech assessment,,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 1-59 months," 2,289,282 ",,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,048,"Eye, Ear and Skin",NA,Adenoidectomy ,Adenoidectomy ,Adenoidectomy ,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,049,"Eye, Ear and Skin",NA,Tonsillectomy,Tonsillectomy,Tonsillectomy,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,19.061712,19.061712,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,050,"Eye, Ear and Skin",NA,Neck Lipoma/Mass removal ,Neck Lipoma/Mass removal ,Neck Lipoma/Mass removal ,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,051,"Eye, Ear and Skin",NA,Superficial foreign body removal,Superficial foreign body removal,Superficial foreign body removal,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,7.67484,7.67484,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,052,"Eye, Ear and Skin",NA,Audiology screening and hearing aids,Audiology screening and hearing aids,Audiology screening and hearing aids,,,Teritary,,,,,per capita,Passive screening of all children and adults for hearing loss,,,,,0.001740058,1.299823689,#VALUE!,,,Yes,2005 Int$,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,#VALUE!,Incomplete,Incomplete,Incomplete,Incomplete,,2012-01-01157-11,Passive screening of all children and adults for hearing loss,"Passive screening of all children and adults for hearing loss, 80% geographic coverage",,None,Multiple Countries,747,989.9222581,0.001719,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,0.001719,1.284093,per capita,#VALUE!,#VALUE!,2005 Int $,747,,
,053,"Eye, Ear and Skin",NA,Deep foreign body removal,Deep foreign body removal,Deep foreign body removal,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,22.324728,22.324728,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,054,"Eye, Ear and Skin",NA,Head/Neck Surgery,Head/Neck Surgery,Head/Neck Surgery,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,19.061712,19.061712,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,055,"Eye, Ear and Skin",NA,Throat and Nasal Surgery,Throat and Nasal Surgery,Throat and Nasal Surgery,,,Teritary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,,,,,,,,,,,,,19.061712,19.061712,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,056,"Eye, Ear and Skin",NA,Treatment of conjunctivitis,Treatment of conjunctivitis,Treatment of conjunctivitis,,,,Treatment of conjunctivitis,,Zimbabwe,Hansen (2008); Cost Eff Resour Alloc,0,Bacterial conjunctivitis treatment as an outpatient,None,,,,0,,0,,,,,Direct entry,"4,830",100.00%,100.00%,Total Population," 18,898,441 ",1%,https://apps.who.int/iris/bitstream/handle/10665/264634/PMC2491216.pdf?sequence=1&isAllowed=y,226781.292,100.00%,100.00%,100%,"Ng'ambi 2020 child/adult, +increase for impairment",100%,0.019127442,0.019127442,0.019127442,0.019127442,,,0.019127442,0.01912744,0.01912744,3.71622,3.71622,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - CE evidence not appropriate,2008-01-01767-34,Bacterial conjunctivitis treatment as an outpatient,Bacterial conjunctivitis treatment as an outpatient,,None,Zimbabwe,235,1.175485699,0,0,0,0,0,0,0,0,Hansen,2008,Zimbabwe,1997,Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease,,,,,,,,CE evidence not appropriate,
,057,"Eye, Ear and Skin",NA,Trachoma mass drug administration,Trachoma mass drug administration,Trachoma mass drug administration,,Community-based intervention,,Trachoma mass drug administration,Treatment with tetracycline was even less cost-effective so only azythromycin was included,Uganda,Baltussen (2012); BMJ,per capita,"Mass treatment tetracycline ointment + trichiasis surgery for trachoma, 80% coverage",None,0.005885,0.82,Int $ (2005),0.005885,0.82,0.053875618,3.847926959,71.422,Yes,2005 Int$,Children 1-10 years,179,100.00%,100.00%,Children 1-10 years," 2,089,624 ",100%,,2089624,100.00%,80.00%,70%,"Ng'ambi 2020 child/adult, +increase for impairment",70%,,,,,0.530674104,CE paper - Baltussen et al.(2012)- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292524/,0.530674104,0,0,0.435804,0.435804,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2012-01-01157-21,Mass treatment azithromycin for trachoma,"Mass treatment azithromycin for trachoma, 80% coverage",,None,Multiple Countries,2076,2751.109247,0.000213,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,,,,,,,,,
,058,"Eye, Ear and Skin",NA,Trachoma surgery,Trachoma Trichiasis cases surgey,Trachoma surgery,,,,Trachoma Trichiasis cases surgey,added from Uganda HBP,Uganda,Baltussen (2012); BMJ,per capita,"Trachoma for trichiasis surgery, 80% geographic coverage",None,0.005843,0.42,Int $ (2005),0.005843,0.42,#VALUE!,,,Yes,2005 Int$,,,,5.00%,Children 1-10 years," 2,089,624 ",,,,,5.00%,70%,"Ng'ambi 2020 child/adult, +increase for impairment",70%,0,9.74556128,9.74556128,9.74556128,,CE paper - Baltussen et al.(2012)- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292524/,9.74556128,,9.74556128,Not available,9.74556128,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - based on Emi's recommendation,2012-01-01157-02,Trachoma for trichiasis surgery,"Trachoma for trichiasis surgery, 80% geographic coverage",,None,Multiple Countries,71,94.08899642,0.005843,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,,,,,,,,,
,059,"Eye, Ear and Skin",NA,Treatment of cataracts,Treatment of cataracts,Treatment of cataracts,,,,Treatment of cataracts,,,,per capita,Extracapsular cataract extraction with posterior chamber lens implant for cataract control,,,,,0.410284076,39.79755537,#VALUE!,,,Yes,2005 Int$,Total population,"179,478",0.50%,,Total Population," 18,898,441 ",,,,1.00%,,,,1%,,,,,,,0,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,#VALUE!,Incomplete,Complete,Incomplete,New data available,,2012-01-01157-05,Extracapsular cataract extraction with posterior chamber lens implant for cataract control,"Extracapsular cataract extraction with posterior chamber lens implant for cataract control, 80% geographic coverage",,None,Multiple Countries,116,153.7228674,0.005486,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,0.006447,0.625359,per capita,#VALUE!,#VALUE!,2005 Int $,97,,
,060,"Eye, Ear and Skin",,Aural toilets and topical antibiotics,Aural toilets and topical antibiotics,Aural toilets and topical antibiotics,,,,Aural toilets and topical antibiotics,added from Uganda HBP,Uganda,Baltussen (2009); Int J Audiol,0,"Aural toilet and topical antibiotics, 80% coverage",None,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,Not available,0,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,CE paper found,Incomplete,Complete,Incomplete,New data available,,2012-01-01157-49,Aural toilet for chronic otitis media control,"Aural toilet for chronic otitis media control, coverage 80%",,None,Multiple Countries,23,30.47953405,0.000453,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,,,,,,,,,
,061,HIV/AIDS,Diagnosis,HIV Testing Services,HIV Testing Services,Voluntary counselling and testing for HIV,,Voluntary Counseling and Testing Program - For HIV-Negative,Community/Primary,HIV Testing Services,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,Voluntary counselling and testing (95%) - Performed in primary care clinics for anyone requesting the services; includes training of health workers; based on rapid test; number of tests over five year period assumed to be twice average annual prevalence,Nothing,0.008848567,0.718503637,Int $ (2000),0.008848567,0.718503637,0.02714232,0.998113304,36.773,Yes,2000 Int$,Direct entry,"44,285",100.00%,100.00%,Total population," 18,898,441 ",33%,"NSP 2020-2025, annual target",6236485.53,100.00%,75.00%,100%,Uptake already factored into DHA estimate,100%,0,0,0,0,14.38800924,from Malawi HBP,14.38800924,14.3880092,14.3880092,2.202744,2.202744,New Malawi estimate (2021),0,0,0,20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,062,HIV/AIDS,Treatment ,ART,ART for men,ART for men,,HIV/AIDS Program - New Adult,Community/Primary,ART for men,,South Africa,Alistar et al. (2014),0,Universal ART (all identified HIV-infected individuals),ART only for those with <=350 cells/muL CD4 cell counts,,,,0.5862268,211.0248986,0.5862268,213.5571974,364.291,,,,,,100.00%,Male >15-65 years with HIV," 329,625 ",70%,prevalence 6.7% DHA,230737.5,,81.00%,90%,DHA report on 95-95-95,90%,0,0,152.7428491,152.7428491,,,152.7428491,104.020045,104.020045,84.096,84.096,New Malawi estimate (2021),0.143559344,13.72247086,13.72247086,38.68548936,35.53121452,0.45,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,ART only for those with <=350 cells/muL CD4 cell counts,,,,,,,,,,,,,,,,,,,,,,,,,
,063,HIV/AIDS,Treatment ,ART,ART for women,ART for women,ART for men,HIV/AIDS Program - New Adult,Community/Primary,ART for women,,South Africa,Alistar et al. (2014),0,Universal ART (all identified HIV-infected individuals),ART only for those with <=350 cells/muL CD4 cell counts,,,,0.5862268,211.0248986,0.5862268,213.5571974,364.291,,,,,,100.00%,Female >15-65 years with HIV," 596,747 ",70%,"prev 11.036%, DHA",417722.9,,85.00%,90%,DHA report on 95-95-95,90%,0,0,152.7428491,152.7428491,,,152.7428491,104.020045,104.020045,84.096,84.096,New Malawi estimate (2021),0.143559344,13.72247086,13.72247086,38.68548936,35.53121452,0.45,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,ART only for those with <=350 cells/muL CD4 cell counts,,,,,,,,,,,,,,,,,,,,,,,,,
,064,HIV/AIDS,Treatment ,Pediatric ART,Pediatric ART,Pediatric ART,,,Primary,Pediatric ART,,,,0,,,,,,,,,,,,,,,,100.00%,Children 0-14 years with HIV," 118,639 ",70%,preval 1.5% DHA,83047.3,,81.00%,86%,DHA report on 95-95-95,86%,0,0,117.4272988,117.4272988,,,117.4272988,104.020045,104.020045,81.06504,81.06504,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,065,HIV/AIDS,Treatment ,Secondline ARVs,ART (Second-Line Treatment) for adults without intensive monitoring,Second-line ART without intensive monitoring,,HIV/AIDS Program - Established Non Medically Complex,Primary,ART (Second-Line Treatment) for adults without intensive monitoring,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"No intensive monitoring, first and second line drugs (ANC coverage level) - monthly contact",Nothing,0.005663083,11.38633595,Int $ (2000),0.005663083,11.38633595,1.095533005,997.5470506,910.559,Yes,2000 Int$,30% of PLHIV,,,100.00%,Male >15 -65 years with HIV," 329,625 ",30%,prevalence 6.7% DHA,98887.5,,81.00%,90%,DHA report on 95-95-95,90%,,,,,1066.27,Costs from CE paper (only second line treatment cost) - Hogan et al. (2005) - https://www.bmj.com/content/331/7530/1431,1066.27,,1066.27,96.89874,96.89874,New Malawi estimate (2021),7,1.069333211,1.026565225,8.520945133,2.63216861,1.4,1.5,1.5,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,066,HIV/AIDS,Treatment ,Secondline ARVs,ART (Second-Line Treatment) for adults with intensive monitoring,Second-line ART with intensive monitoring,,HIV/AIDS Program - Established Medically Complex,,ART (Second-Line Treatment) for adults with intensive monitoring,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"Intensive monitoring, first and second line drugs (ANC coverage level) - weekly contact",Nothing,0.006193997,12.2906595,Int $ (2000),0.006193997,12.2906595,0.661871119,594.7774311,898.630,Yes,2000 Int$,30% of PLHIV,,,100.00%,Female >15-65 years with HIV," 596,747 ",30%,"prev 11.036%, DHA",179024.1,,85.00%,90%,DHA report on 95-95-95,90%,,,,,1574.27,"Costs from CE paper (assuming 4 CD4 tests, 4 viral load tests, 4 blood chemistry tests, 12 complete blood count tests per year) - Hogan et al. (2005) - https://www.bmj.com/content/331/7530/1431",1574.27,,1574.27,96.89874,96.89874,New Malawi estimate (2021),18.51354935,26.34828508,5.235442628,13.74163665,19.56152023,4,0.393518902,0.393518902,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,067,HIV/AIDS,Treatment ,Secondline ARVs for Pediatriacs,Secondline ARVs for Pediatriacs,Secondline ART for Pediatriacs,,,Primary,,,,,,,,,,,,,,,,,,,,,,Children 0-14 years with HIV," 118,639 ",30%,preval 1.5% DHA,35591.7,,,86%,DHA report on 95-95-95,86%,,,,,,,,,,48.44937,48.44937,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,068,HIV/AIDS,Treatment ,,Home-based highly active retroviral therapy (HAART),Home-based highly active retroviral therapy (HAART),,HIV/AIDS Program - Established Medically Complex,,Home-based highly active retroviral therapy (HAART),,Uganda,Marseille (2009); Appl Health Econ Health Policy,0,Home based highly active anti-retroviral therapy (HAART) added to a package of home based care (HBAC) and cotrimoxazole prophylaxis,Cotrimoxazole prophylaxis alone,,,,6.861,5541.19797,6.861,5607.692346,817.329,,,,,,100.00%,,,,,,,85.00%,90%,DHA report on 95-95-95,90%,,,,,647.585,Cost taken from CE study (cost of ARV drugs + other recurrent goods) - Marseille at al. (2010) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912402/,647.585,,647.585,Not available,647.585,Uganda estimate (2020),18.51354935,26.34828508,5.235442628,13.74163665,19.56152023,4,0.393518902,0.393518902,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Incomplete,Complete,Complete,New data available,,,,,,Cotrimoxazole prophylaxis alone,,,,,,,,,,,,,,,,,,,,,,,,,
,069,HIV/AIDS,Monitoring,Viral Load,Viral Load,Viral Load + CD4 count (Clinical monitoring and quarterly tests),,Laboratory - Serology,Tertiary,Viral load,,Uganda,Kahn (2011); BMJ,0,Clinical monitoring and quarterly CD4 counts and viral load measurement,Clinical monitoring and quarterly CD4 counts,,,,3.216,9168.58984,3.216,9278.612918,2885.141,,,Total number living with HIV,"3,577",100.00%,400.00%,Total number living with HIV," 1,045,011 ",150%,,1567516.5,100.00%,85.00%,95%,DHA report on 95-95-95,95%,,,,,56.113236,From Malawi HBP - multiplied by 4 for quarterly testing (comparable to Ying et al. (2015) study in Uganda),56.113236,14.028309,14.028309,13.7553,13.7553,New Malawi estimate (2021),0,0,0,0,0,0,0,0,1.219870115,6.609935057,2.170194828,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Clinical monitoring and quarterly CD4 counts,,,,,,,,,,,,,,,,,,,,,,,,,
,070,HIV/AIDS,Advanced HIV Testing and Treatment,CD4 Count,CD4 Test,CD4 count (Clinical monitoring and quarterly tests),,Laboratory - Serology,Primary,CD4 Test,,Uganda,Kahn (2011); BMJ,0,Clinical monitoring and quarterly CD4 counts (clinical/CD4),Clinical monitoring alone,,,,3.491,7470.47856,3.491,7560.124303,2165.604,,,Total number living with HIV,,,400.00%,Total number living with HIV," 1,045,011 ",75%,,783758.25,,85.00%,85%,DHA report on 95-95-95,85%,,,,,36,Ying et al. (2015) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509901/,36,57.0918446,57.0918446,4.12662,4.12662,New Malawi estimate (2021),0,0,0,0,0,0,0,0,1.219870115,6.609935057,2.170194828,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Clinical monitoring alone,,,,,,,,,,,,,,,,,,,,,,,,,
,071,HIV/AIDS,Advanced HIV Testing and Treatment,Adv HIV labs,Adv HIV labs,Adv HIV labs,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Total number living with HIV," 1,045,011 ",30%,,313503.3,,,,,,,,,,,,,,,2.234496,2.234496,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,072,HIV/AIDS,Advanced HIV Testing and Treatment,Management of opportunistic infections associated with HIV/AIDS,Management of opportunistic infections associated with HIV/AIDS,Management of opportunistic infections associated with HIV/AIDS,,,Secondary,Management of opportunistic infections associated with HIV/AIDS,,,,0,,,,,,,,,,,,,People in need of OI management,"2,579",100.00%,100.00%,Total number living with HIV," 1,045,011 ",15%,,156751.65,95.00%,60.00%,95%,DHA report on 95-95-95,95%,0,0,0,0,233,Hogan et al. (2005) - https://www.bmj.com/content/331/7530/1431,233,9.13643528,9.13643528,5.584668,5.584668,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,073,HIV/AIDS,Nutrition support,Nutrition supplements in first 6 months for HIV/AIDS cases ,Nutrition supplements in first 6 months for HIV/AIDS cases ,Nutrition supplements in first 6 months for HIV/AIDS cases ,,,Primary,Nutrition supplements in first 6 months for HIV/AIDS cases ,,,,0,,,,,,,,,,,,,Direct entry,484,100.00%,100.00%,New diagnosis of HIV," 100,000 ",100%,DHA,100000,100.00%,60.00%,95%,DHA report on 95-95-95,95%,0,0,0,0,33.77,Median price of supplements for 6 months taken from Koethe et al. (2014) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024113/,33.77,94.0688999,94.0688999,Not available,94.0688999,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,074,HIV/AIDS,Nutrition support,Nutritional care and support (HIV+ pregnant and lactating women),Nutritional care and support (HIV+ pregnant and lactating women),Nutritional care and support (HIV+ pregnant and lactating women),,,Primary,Nutritional care and support (HIV+ pregnant and lactating women),,,,0,,,,,,,,,,,,,Pregnant women,"6,760",12.90%,,Females pregnant/lactating HIV," 80,000 ",100%,DHA estimates,80000,62.00%,,95%,DHA report on 95-95-95,62%,,,,,,,0,0,0,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,075,HIV/AIDS,Interventions for marginalized populations,Interventions focused on female sex workers ,Interventions focused on female sex workers ,Interventions focused on female sex workers ,,,Community/Primary,Interventions focused on female sex workers ,,South Africa,Vickerman (2006); Sex Transm Dis,0,"The FSW intervention used a mobile clinic to provide monthly STI services in 12 of the 25 hotels where women practice sex
work. Services included syndromic management of symptomatic STIs, health education, safe-sex negotiation skills, and condom distribution. In addition, the women in 6 of the hotels received PPT with azithromycin (1 g), whereas the others received a vitamin pill. All women were asked to return to the clinic monthly. The STI clinic came to each hotel for approximately 3 days per month and was operated by a nurse and a community health worker (CHW). FSWs in the hotel were encouraged to attend the clinic irrespective of whether they had STI symptoms or not. The CHW provided women with condoms, information about STIs, and how to negotiate safer sex. The FSWs were then seen by a nurse who
treated their STI syndromes according to provincial guidelines 22 and gave them PPT or vitamins.",None,,,,0,0,0,0,,,,Sex workers,"25,207",0.50%,100.00%,Sex workers," 36,000 ",100%,UNAIDS KP Atlas estimate of FSW),36000,59.00%,75.00%,60%,Prior estimates,59%,,,,,88.78882612,From Malawi HBP,88.78882612,88.7888261,88.7888261,Not available,88.7888261,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,076,HIV/AIDS,Interventions for marginalized populations,Interventions focused on male sex workers ,Interventions focused on male sex workers ,Interventions focused on male sex workers ,,,Community/Primary,Interventions focused on male sex workers ,,India,Vassall (2014); Lancet Glob Health,0,"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",increase in condom use assumed,,,,6.87,372.07188,6.87,376.5367426,54.809,,,5% of female sex workers,,,100.00%,5% of female sex workers," 36,000 ",5%,UNAIDS KP Atlas estimate of FSW),1800,,75.00%,60%,Prior estimates,60%,,,,,88.78882612,From Malawi HBP,88.78882612,88.7888261,88.7888261,Not available,88.7888261,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetitive - there is another intervention for peer education of sex workers,,,,,increase in condom use assumed,,,,,,,,,,,,,,,,,,,,,,,,,
,077,HIV/AIDS,Interventions for marginalized populations,Interventions focused on men who have sex with men ,Interventions focused on men who have sex with men ,Interventions focused on men who have sex with men ,,Voluntary Counseling and Testing Program - For HIV-Positive,Community/Primary,Interventions focused on men who have sex with men ,,India,Vassall (2014); Lancet Glob Health,0,"Avahan HIV prevention programme- peer-led outreach, education and condom distribution, free treatment of sexually transmitted infections (STIs), free commodity supplies (condoms, STI drugs), and facilitation of community mobilization",increase in condom use assumed,,,,6.87,372.07188,6.87,376.5367426,54.809,,,Men who have sex with men (MSM),"38,962",0.20%,100.00%,Men who have sex with men (MSM)," 42,000 ",100%,UNAIDS KP Atlas estimate of FSW),42000,36.00%,75.00%,40%,Prior estimates,36%,,,,,118.3755378,From Malawi HBP,118.3755378,118.375538,118.375538,Not available,118.375538,Malawi estimate (2016),0,0,0,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,increase in condom use assumed,,,,,,,,,,,,,,,,,,,,,,,,,
,078,HIV/AIDS,Interventions for marginalized populations,,Peer education for sex workers,Peer education for sex workers,,Family Planning,,Peer education for sex workers,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,Peer education for sex workers (95%) - Training of selected sex workers by social workers to undertake peer education; provision of condoms,Nothing,0.029554214,0.123879937,Int $ (2000),0.029554214,0.123879937,15.7047438,29.81187346,1.898,Yes,2000 Int$,Sex workers,,,100.00%,Sex workers," 36,000 ",100%,UNAIDS KP Atlas estimate of FSW),36000,,71.00%,60%,Prior estimates,60%,,,,,0.000001,No drug costs,0.000001,,0.000001,Not available,0.000001,Uganda estimate (2020),0.151080074,0.755400368,2.725273328,18.79135941,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,079,HIV/AIDS,Interventions for marginalized populations,,Condom promotion among key populations (Female sex workers),Condom promotion among key populations (Female sex workers),Male condom,Family Planning,,Condom promotion among key populations (Female sex workers),added from Uganda HBP,Vietnam,Pham (2015); PLoS One,per capita,Condom promotion programme for female sex workers for HIV prevention,None,0.00087287,0.263927813,United States (2013); currency year assumed,0.00087287,0.263927813,0.463832185,155.8155026,335.931,Yes,2013 US$,,,,,," 36,000 ",100%,UNAIDS KP Atlas estimate of FSW),36000,,,60%,"Assumed to be the same as ""Peer education for sex workers"" based on input from Planning",60%,,,,,,,0,,0,5.0328,5.0328,New Malawi estimate (2021),0.151080074,0.755400368,2.725273328,18.79135941,0,0,0,0,0,0,0,,,,,,,,,,,Yes,Complete,Complete,Complete,Complete,New data available,,2015-01-01880-02,Condom promotion programme for female sex workers for HIV prevention,Condom promotion programme for female sex workers for HIV prevention,,None,Vietnam,302,335.5165202,0,0,0,12769300,0,0,0,0,Pham,2015,United States,2013,,,,,,,,,,
,080,HIV/AIDS,Interventions for marginalized populations,,Condom promotion among key populations (MSM),Condom promotion among key populations (MSM),Male condom,Family Planning,,Condom promotion among key populations (MSM),added from Uganda HBP,Vietnam,Pham (2015); PLoS One,per capita,Condom promotion programme for men who have sex with men for HIV prevention,None,0.000768678,0.079347829,United States (2013); currency year assumed,0.000768678,0.079347829,0.350113538,40.15260863,114.685,Yes,2013 US$,,,,,," 42,000 ",100%,UNAIDS KP Atlas estimate of FSW),42000,,,60%,"Assumed to be the same as ""Peer education for sex workers"" based on input from Planning",60%,,,,,,,0,,0,5.0328,5.0328,New Malawi estimate (2021),0.151080074,0.755400368,2.725273328,18.79135941,0,0,0,0,0,0,0,,,,,,,,,,,Yes,Complete,Complete,Complete,Complete,New data available,,2015-01-01880-03,Condom promotion programme for men who have sex with men for HIV prevention,Condom promotion programme for men who have sex with men for HIV prevention,,None,Vietnam,103,114.4311311,0,0,0,3838990,0,0,0,0,Pham,2015,United States,2013,,,,,,,,,,
,081,HIV/AIDS,Interventions for marginalized populations,,IDU: outreach,IDU: outreach,,Family Planning,,IDU: outreach,added from Uganda HBP,,WHO-CHOICE,0,,,,,,4.14,4.837107066,4.14,4.89515235,1.182,,,,,,100.00%,People who inject drugs (IDU)," 13,000 ",100%,Estimate from herion prevalence use,13000,,75.00%,25%,estimates from nearby countries https://www.hri.global/files/2018/12/10/Sub-SaharanAfrica-harm-reduction.pdf,25%,0,0,0,0,0.000001,Assume 0 drug costs,0.000001,,0.000001,Not available,0.000001,Uganda estimate (2020),0.151080074,0.755400368,2.725273328,18.79135941,0,0,0,0,0,0,0,,,,,,,,,,,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,082,HIV/AIDS,Interventions for marginalized populations,,IDU: needle exchange,IDU: needle exchange,,Family Planning,,IDU: needle exchange,added from Uganda HBP,Vietnam,Pham (2015); PLoS One,per capita,Needle and syringe programme for HIV prevention,None,0.000337028,0.494727458,United States (2013); currency year assumed,0.000337028,0.494727458,0.495947953,808.817744,1630.852,Yes,2013 US$,People who inject drugs (IDU),,,100.00%,People who inject drugs (IDU)," 13,000 ",100%,Estimate from herion prevalence use,13000,,75.00%,25%,estimates from nearby countries https://www.hri.global/files/2018/12/10/Sub-SaharanAfrica-harm-reduction.pdf,25%,0,19.18743454,0,0,,,19.18743454,,19.18743454,67.239792,67.239792,New Malawi estimate (2021),0.151080074,0.755400368,2.725273328,18.79135941,0,0,0,0,0,0,0,,,,,,,,,,,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,083,HIV/AIDS,Interventions for marginalized populations,,IDU: drug substitution,Methadone maintenance treatment (MMT) programme among injection drug users (IDUs),IDU: drug subsitution,Family Planning,,IDU: drug substitution,added from Uganda HBP,Vietnam,Tran(2012);IJRPP,0,Methadone maintenance treatment (MMT) programme among injection drug users (IDUs) +  ART,nothing,,,,0.759,434.484,0.759,439.697808,579.312,,,People who inject drugs (IDU),,,100.00%,People who inject drugs (IDU)," 13,000 ",100%,Estimate from herion prevalence use,13000,,75.00%,25%,estimates from nearby countries https://www.hri.global/files/2018/12/10/Sub-SaharanAfrica-harm-reduction.pdf,25%,0,0,0,0,211.76,based on the CE paper from Vietnam (cost per person in paper less annual ART cost),211.76,,211.76,227.201136,227.201136,New Malawi estimate (2021),0.151080074,0.755400368,2.725273328,18.79135941,0,0,0,0,0,0,0,,,,,,,,,,,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,084,HIV/AIDS,Prevention,Condoms,Condoms,Condoms,,,Community/Primary,Condoms,,International,Stover (2017); PLoS One,0,"Current trend in condom use (for family planning, HIV and STI prevention) continues through to 2030","Current condom use (for family planning, HIV and STI prevention), 10 condoms per per woman per year on average (47% of demand met)",,,,0.00228009,0.412989129,0.00228009,0.417944999,183.302,,,Eligible condom users,"87,510",100.00%,100.00%,Male 15-49 years," 4,363,012 ",100%,,4363012,70.00%,75.00%,70%,prior estimates DHA,70%,3.141393908,3.141393908,3.141393908,0,,,3.141393908,9.06762744,9.06762744,0.8586,0.8586,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repeated under RMNCH,,,,,"Current condom use (for family planning, HIV and STI prevention), 10 condoms per per woman per year on average (47% of demand met)",,,,,,,,,,,,,,,,,,,,,,,,,
,085,HIV/AIDS,Prevention,Male circumcision ,Male circumcision ,Male circumcision ,Male circumcision,Male Circumscisions,Primary,Male circumcision ,,Uganda,Uthman (2011); Value Health,0,Circumcision for prevention of heterosexual acquisition of HIV,ART without circumcision,,,,0.31,-94.52081,0.31,-95.65505972,-308.565,,,Direct entry,"3,071",100.00%,100.00%,Direct Entry (VMMC)," 165,000 ",100%,UNAIDS VMMC,165000,100.00%,40.00%,100%,Already accounted for,100%,10.30806027,10.30806027,10.30806027,10.30806027,,,10.30806027,114.629347,114.629347,3.042396,3.042396,New Malawi estimate (2021),0,9.989070767,7.073325219,0,11.98992772,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,ART without circumcision,,,,,,,,,,,,,,,,,,,,,,,,,
,086,HIV/AIDS,Prevention,PMTCT (NEED UPDATE),PMTCT,PMTCT,,HIV/AIDS Program - PMTCT,Primary,PMTCT,Note that option A was found to be more cost-effective than option B+ in Malawi,Uganda,Kuznik (2012); Bull World Health Organ,0,18-month antiretroviral therapy (ART) to prevent mother-to-child HIV transmission. A combination of zidovudine and lamivudine with either efavirenz or nevirapine,None,,,,8.58,334.278,8.58,338.289336,39.428,,,Women in need of PMTCT,194,100.00%,100.00%,Live births to females HIV," 80,000 ",100%,DHA estimates,80000,87.00%,99.00%,90%,DHA estimate,87%,0,0,21.95593003,21.95593003,,,21.95593003,36.1944777,36.1944777,15.860904,15.860904,New Malawi estimate (2021),7,1.024632696,0.949656017,8.500174907,2.525157416,1.4,1.5,1.5,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,2013-01-00915-01,"Antepartum twice-daily zidovudine (AZT) starting from 14 weeks of gestation and continued during pregnancy followed by single-dose nevirapine (sd-NVP) at labour onset and initiation of twice daily AZT+3TC for 7 days postpartum + daily NVP from birth for a minimum of 4 to 6 weeks, and until 1 week after all exposure to breast milk has ended for infants (Option A)","Option A: Antepartum twice-daily zidovudine (AZT) starting from as early as 14 weeks of gestation and continued during pregnancy. At onset of labour, single-dose nevirapine (sd-NVP) and initiation of twice daily AZT+3TC for 7 days postpartum and for infants daily NVP from birth for a minimum of 4 to 6 weeks, and until 1 week after all exposure to breast milk has ended",,None,Malawi,38,45.10225814,0,0,3672590,9500260,0,0,0,0,Fasawe,2013,United States,2010,,,,,,,,,,
,087,HIV/AIDS,Prevention,Cotrimoxazole for children in PMTCT,Cotrimoxazole for children,Cotrimoxazole for children in PMTCT,,,Primary,Cotrimoxazole for children,,,,0,,,,,,,,,,,,,Direct entry,988,100.00%,100.00%,Live births to females HIV," 80,000 ",100%,DHA estimates,80000,100.00%,56.00%,90%,DHA estimate,90%,0,0,9.737074529,9.737074529,,,9.737074529,5.49620632,5.49620632,Not available,5.49620632,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,088,HIV/AIDS,Prevention,PrEP,Pre-exposure prophylaxis for high-risk serodiscordant couples,Pre-exposure prophylaxis for high-risk serodiscordant couples,,Voluntary Counseling and Testing Program - For HIV-Positive,Primary,Pre-exposure prophylaxis for high-risk serodiscordant couples,,Uganda,Ying (2015); J Int AIDS Soc,0,Pre-exposure prophylaxis (PrEP) for high-risk serodiscordant couples and high-risk couples + antiretroviral therapy (ART) use (40%),Current coverage of ART only - 40% - (no PreP),,,,16.20162016,34091.80918,16.20162016,34500.91089,2129.473,,,Number of high-risk serodiscordant couples,,,100.00%,Number of high-risk serodiscordant couples," 90,000 ",100%,"NSP 2020-2025, annual target",90000,,90.00%,70%,DHA estimate,70%,0,0,0,0,101,Cost per serodiscordant couple from CE study - Ying et al. (2015) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509901/,101,,101,56.278452,56.278452,New Malawi estimate (2021),0,0,0,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Current coverage of ART only - 40% - (no PreP),,,,,,,,,,,,,,,,,,,,,,,,,
,089,HIV/AIDS,Prevention,PrEP,Pre-exposure prophylaxis for pregnant and breastfeeding women,Pre-exposure prophylaxis for pregnant and breastfeeding women,,HIV/AIDS Program - PMTCT,,Pre-exposure prophylaxis for pregnant and breastfeeding women,,Uganda,Price (2016); J Acquir Immune Defic Syndr,0,Antiretroviral pre-exposure prophylaxis (PrEP) administered to pregnant and breastfeeding women,None,,,,0.34,359.307,0.34,363.618684,1069.467,,,Women in need of PMTCT,,,100.00%,Women at high-risk," 60,000 ",100%,"NSP 2020-2025, annual target",60000,,99.00%,70%,DHA estimate,70%,0,0,0,0,101,Cost per serodiscordant couple from CE study - Ying et al. (2015) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509901/,101,,101,56.278452,56.278452,New Malawi estimate (2021),7,1.024632696,0.949656017,8.500174907,2.525157416,1.4,1.5,1.5,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,090,HIV/AIDS,Prevention,PEP,PEP,PEP,,,Primary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.460052,10.460052,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,Yes,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,091,HIV/AIDS,Prevention,,Cotrimoxazole preventive therapy for TB HIV+ patients,Cotrimoxazole preventive therapy for TB HIV+ patients,,TB Program - Follow-up Patient,,Cotrimoxazole preventive therapy for TB HIV+ patients,added from Uganda HBP,Uganda,Pitter (2007); J Acquir Immune Defic Syndr,0,Daily cotrimoxazole prophylaxis (all individuals),Nothing,,,,0.0686,16.07364,0.0686,16.26652368,237.121,,,Number of TB/HIV co-infected cases,,,500.00%,Number of TB/HIV co-infected cases," 12,648 ",100%,46.5% of all TB cases are TB/HIV co-infected,12648,100.00%,41.00%,90%,from DHA 95-95-95 goals,90%,,,,,9.31,Pitter (2007) - https://journals.lww.com/jaids/fulltext/2007/03010/Cost_Effectiveness_of_Cotrimoxazole_Prophylaxis.14.aspx,9.31,,9.31,Not available,9.31,Uganda estimate (2020),2.295789734,2.874845514,2.585317624,1.426052567,3.424899069,0.573947433,1.732058993,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,092,HIV/AIDS,Prevention,,Mass media,HIV Behaviour change intervention (Mass media),,No HRH time,,Mass media,added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"Television and radio episodes and inserts in key newspapers, repeated every two years (development and administration costs included; effectiveness scaled by proportion of population reporting weekly exposure to radio, television, or newspapers)",Nothing,0.00796371,0.028315414,Int $ (2000),0.00796371,0.028315414,0.008061269,0.01298039,1.610,Yes,2000 Int$,Total Population,,,100.00%,Total Population," 18,898,441 ",100%,,18898441,,71.00%,70%,,70%,,,,,1E-35,The Malawi HBP had a cost of $1.43 but these seems inaccurate given the way in which Hogan (2005) describes the intervention so this was changed to 0,1E-35,1.43451617,1.43451617,Not available,1.43451617,Malawi estimate (2016),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,093,HIV/AIDS,Prevention,,Youth focused interventions - In-school,HIV Behaviour change intervention (Schools - 10-18 years),,No HRH time,,Youth focused interventions - In-school,added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"School-based education targeted at youths aged 10-18 years; sessions provided during regular lessons to all students, to promote prevention of HIV and other sexually transmitted infections; includes training of selected teachers at each school",Nothing,0.000353943,0.136267931,Int $ (2000),0.000353943,0.136267931,0.003806363,0.663663316,174.356,Yes,2000 Int$,Teenagers (13-19 years),,,100.00%,Teenagers (14-17 years)," 1,778,839 ",100%,,1778839,,71.00%,70%,,70%,,,,,1E-35,The Malawi HBP had a cost of 23.5$ but these seems inaccurate given the way in which Hogan (2005) describes the intervention so this was changed to 0,1E-35,23.3517292,23.3517292,Not available,23.3517292,Malawi estimate (2016),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,094,HIV/AIDS,Prevention,,Blood safety,Blood safety,,Laboratory - Blood Transfusion Lab Analysis,,Blood safety,added from Uganda HBP,Peru,Aldridge (2009); BMC Public Health,per capita,Blood safety,None,0.004362356,0.353612769,United States (2008); currency year stated,0.004362356,0.353612769,0.441579691,43.02495015,97.434,Yes,2008 US$,Total Population,,,1.00%,Total Population," 18,898,441 ",1%,,188984.41,,100.00%,100%,,100%,,,,,6.765,Cost of HIV-Ab test in Ghana  from van Hulst et al. (2008); https://www.sciencedirect.com/science/article/pii/S1098301510605608,6.765,130.817196,130.817196,Not available,130.817196,Malawi estimate (2016),0,0,0,0,0,0,0,0,2.438879082,10.21943954,2.341681377,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,095,HIV/AIDS,Prevention,,Screen HIV+ cases for TB,Screen HIV+ cases for TB,,HIV/AIDS Program - Established Medically Complex,,Screen HIV+ cases for TB,added from Uganda HBP,Uganda,Shah (2014); AIDS,0,Xpert combined with LF-LAM for HIV-infected individuals with signs/symptoms of TB in Uganda,Nothing,,,,1.022729032,114.84493,1.022729032,116.2230692,113.640,,,Direct entry,352,100.00%,100.00%,Total HIV Population," 1,045,011 ",100%,DHA prevalence,1045011,95.00%,60.00%,90%,from DHA 95-95-95 goals,90%,11.96721489,11.96721489,11.96721489,11.96721489,,,11.96721489,15.1482091,15.1482091,Not available,15.1482091,Malawi estimate (2016),18.51354935,26.34828508,5.235442628,13.74163665,19.56152023,4,0.393518902,0.393518902,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,096,HIV/AIDS,Treatment of STIs,Treatment of gonorrhea,Treatment of gonorrhea,Treatment of gonorrhea,,STI,,Treatment of gonorrhea,added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"Treatment of sexually transmitted infections (Provided in primary care facilities, available to anyone who requests it; includes visits, drugs, counselling, advice on protection, and condom distribution if requested; effectiveness scaled by access and likelihood of using the services)",Nothing,0.012564965,0.405264366,Int $ (2000),0.012564965,0.405264366,8.759662256,127.9503092,14.607,Yes,2000 Int$,,,,0.00%,Adults 15-49 years," 9,162,016 ",0.300%,GBD STI,27440.23792,,70.00%,60%,Ng'ambi 2020 adult,60%,0,0,0.817759684,0.817759684,,,0.817759684,0.62440858,0.62440858,0.051708,0.051708,New Malawi estimate (2021),5,4.907896622,1.291582499,1.580052088,6.220468791,0.580052088,0.580052088,0.580052088,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,097,HIV/AIDS,Treatment of STIs,Treatment of chlamydia,Treatment of chlamydia,Treatment of chlamydia,,STI,,Treatment of chlamydia,added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"Treatment of sexually transmitted infections (Provided in primary care facilities, available to anyone who requests it; includes visits, drugs, counselling, advice on protection, and condom distribution if requested; effectiveness scaled by access and likelihood of using the services)",Nothing,0.012564965,0.405264366,Int $ (2000),0.012564965,0.405264366,5.247037692,76.64223519,14.607,Yes,2000 Int$,,,,0.00%,Adults 15-49 years," 9,162,016 ",1%,GBD STI,45810.08,,70.00%,60%,Ng'ambi 2020 adult,60%,0,0,3.558251894,3.558251894,,,3.558251894,3.96832107,3.96832107,0.289464,0.289464,New Malawi estimate (2021),5,4.907896622,1.291582499,1.580052088,6.220468791,0.580052088,0.580052088,0.580052088,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,098,HIV/AIDS,Treatment of STIs,Treatment of syphillis,Treatment of syphillis,Treatment of syphillis,,,,Treatment of syphillis,added from Uganda HBP,Zimbabwe,Hansen (2008); Cost Eff Resour Alloc,0,Syphilis treatment as an inpatient,None,,,,0,,0,,,,,,,,0.00%,Adults 15-49 years," 9,162,016 ",0%,GBD STI,8245.8144,,70.00%,60%,Ng'ambi 2020 adult,60%,0,0,4.374017042,4.374017042,,,4.374017042,,4.374017042,Not available,4.374017042,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - CE evidence not appropriate,2008-01-01767-26,Syphilis treatment as an inpatient,Syphilis treatment as an inpatient,,None,Zimbabwe,3725,18.63269884,0,0,0,0,0,0,0,0,Hansen,2008,Zimbabwe,1997,Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease,,,,,,,,,
,099,HIV/AIDS,Treatment of STIs,Treatment of Meningococcal meningitis,Treatment of Meningococcal meningitis,Treatment of Meningococcal meningitis,,,,Treatment of Meningococcal meningitis,added from Uganda HBP,Zimbabwe,Hansen (2008); Cost Eff Resour Alloc,0,Meningococcal meningitis treatment as an inpatient,None,,,,0,,0,,,,,Meningococcal meningitis cases,,,,Adults 15-49 years," 9,162,016 ",,,,,100.00%,100%,,100%,0,0,1.236612205,1.236612205,,,1.236612205,,1.236612205,Not available,1.236612205,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,100,HIV/AIDS,Treatment of STIs,Treatment of trichomoniasis,Treatment of trichomoniasis,Treatment of trichomoniasis,,STI,,Treatment of trichomoniasis,added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"Treatment of sexually transmitted infections (Provided in primary care facilities, available to anyone who requests it; includes visits, drugs, counselling, advice on protection, and condom distribution if requested; effectiveness scaled by access and likelihood of using the services)",Nothing,0.012564965,0.405264366,Int $ (2000),0.012564965,0.405264366,2.547105676,37.20496854,14.607,Yes,2000 Int$,,,,0.00%,Adults 15-49 years," 9,162,016 ",1%,GBD STI,94368.7648,,70.00%,60%,Ng'ambi 2020 adult,60%,0,0,0.438797879,0.438797879,,,0.438797879,0.59057669,0.59057669,0.0678,0.0678,New Malawi estimate (2021),5,4.907896622,1.291582499,1.580052088,6.220468791,0.580052088,0.580052088,0.580052088,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,101,HIV/AIDS,Treatment of STIs,Treatment of PID (Pelvic Inflammatory Disease),Treatment of PID (Pelvic Inflammatory Disease),Treatment of PID (Pelvic Inflammatory Disease),,STI,,Treatment of PID (Pelvic Inflammatory Disease),added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,"Treatment of sexually transmitted infections (Provided in primary care facilities, available to anyone who requests it; includes visits, drugs, counselling, advice on protection, and condom distribution if requested; effectiveness scaled by access and likelihood of using the services)",Nothing,0.012564965,0.405264366,Int $ (2000),0.012564965,0.405264366,10.0904571,147.3889138,14.607,Yes,2000 Int$,,,,25.25%,Adults 15-49 years," 9,162,016 ",0.260%,GBD STI,23821.2416,,70.00%,90%,Ng'ambi 2020 adult/increase with severity,90%,0,0,5.445082774,5.445082774,,,5.445082774,7.24750994,7.24750994,6.150588,6.150588,New Malawi estimate (2021),5,4.907896622,1.291582499,1.580052088,6.220468791,0.580052088,0.580052088,0.580052088,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,102,Malaria,Malaria Prevention,Larviciding,Larviciding,Larviciding,,,Community,Larviciding,,,,0,The Guinea Worm Eradication Programme,,,,,,,,,,,,Direct entry - number of districts,0,100.00%,20.00%,5 districts, 29 ,20%,,5.8,100.00%,41.00%,100%,,100%,0,0,0,0,1.44,Rahman et al. (2016),1.44,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - larviciding for Guinea worm disease not relevant to Malawi,2017-01-03769-03,The Guinea Worm Eradication Programme,"The Guinea Worm Eradication Programme - includes: 1) community-based education of residents about the disease and prevention, 2) filtration of drinking water through cloth and pipe filters, 3) treatment of contaminated stagnant water with ABATE larvicide (1986 - 2030)",,None,International,222,242.4131687,0,0,0,0,0,0,0,0,Fitzpatrick,2017,United States,2015,The cost-effectiveness of an eradication programme in the end game: Evidence from guinea worm disease,,,,,,,,,
,103,Malaria,Malaria Prevention,ITN distribution to pregnant women,ITN distribution to pregnant women,ITN distribution to pregnant women,,,Primary,ITN distribution to pregnant women,,"Congo, Rep.",Becker-Dreps (2009); Am J Trop Med Hyg,per capita,Long-lasting insecticide-treated bed nets (ITNs) + information on correct use and malaria transmission,None,1.75149E-05,0.0003016,United States (2005); currency year stated,1.75149E-05,0.0003016,0.000352889,0.008051537,22.816,Yes,2005 US$,Pregnant women,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100%,,949472,87.00%,70.00%,95%,ANC coverage,87%,0,2.991803722,2.991803722,0,,,2.991803722,6.47464228,6.47464228,0.8124,0.8124,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - CE evidence was only avaible for general ITN distribution,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,104,Malaria,Malaria Prevention,ITN distribution to New Born Babies,ITN distribution to New Born Babies,ITN distribution to New Born Babies,,,Primary,,,,,,,,,,,,,,,,,,,,,,Live births," 620,346 ",100%,,620346,,,98%,Facility birth coverage,98%,,,,,,,,,,0.8124,0.8124,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,105,Malaria,Malaria Prevention,Mass ITN Distribution,ITN distribution to pregnant women,Mass ITN Distribution,,Community-based intervention,Community,ITN distribution to pregnant women,,"Congo, Rep.",Becker-Dreps (2009); Am J Trop Med Hyg,per capita,Long-lasting insecticide-treated bed nets (ITNs) + information on correct use and malaria transmission,None,1.75149E-05,0.0003016,United States (2005); currency year stated,1.75149E-05,0.0003016,0.000352889,0.008051537,22.816,Yes,2005 US$,Pregnant women,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100%,,949472,87.00%,70.00%,95%,ANC coverage,87%,0,2.991803722,2.991803722,0,,,2.991803722,6.47464228,6.47464228,0.8124,0.8124,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,NA,NA,NA,NA,NA,remove - repetition (134),,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,106,Malaria,Malaria Prevention,Indoor residual spraying drugs,Indoor residual spraying drugs,Indoor residual spraying drugs,,,Community,Indoor residual spraying drugs,,,White et al 2011,0,Indoor residual spraying (IRS)Indoor residual spraying (IRS),,,,,0,,0,,,,,Number of households,"35,896",100.00%,30.00%,Number of households in high risk districts," 45,283 ",100%,Malaria program,45283,87.00%,70.00%,90%,,87%,0,0,0,0,0.86,Guyatt et al. (2002) https://pubmed.ncbi.nlm.nih.gov/12000774/,0.86,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,,,,,,,,,,,Yes,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,107,Malaria,Malaria Prevention,IPT (pregnant women),IPT (pregnant women),IPT (pregnant women),,Antenatal Care - Followup Visit,Community,IPT (pregnant women),,Uganda,Morel (2005); BMJ,per capita,Intermittent presumptive treatment with sulfadoxine-pyrimethamine in pregnancy for malaria 95% coverage,Standard/Usual Care,0.000103686,0.03646813,Int $ (2000),0.000103686,0.03646813,0.002089059,0.332753111,159.284,Yes,2000 Int$,Pregnant women,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100%,,949472,72.00%,41.00%,95%,ANC coverage,72%,0,0,0.059836074,0.059836074,,,0.059836074,0.15034046,0.15034046,0.15066,0.15066,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,2017-01-03764-05,3-IPT High (intermittent preventive treatment with sulfadoxine pyrimethamine),3-IPT High (intermittent preventive treatment with sulfadoxine pyrimethamine),,Standard/Usual Care,Malawi,2.35911,2.57603302,0,0,393772,5400,0,0,0,0,Choi,2017,United States,2015,,,,,,,,,,
,108,Malaria,Uncomplicated malaria treatment,"Uncomplicated (adult, <36 kg) ",Case management with artemisinin based combination therapy (80% coverage),Uncomplicated malaria treatment,,Over 5 Outpatient visit,Primary,Case management with artemisinin based combination therapy (80% coverage),,Uganda,Morel (2005); BMJ,per capita,Case management with artemisinin based combination therapy (80% coverage),Standard/Usual Care,0.008946675,0.343422086,Int $ (2000),0.008946675,0.343422086,0.044543849,0.774339067,17.384,Yes,2000 Int$,,,,100.00%,Total population >5," 16,009,457 ",24%,Malawi Malaria Indicator Survey 2017,3842269.68,59.00%,100.00%,80%,Ng'ambi 2020 adult,59%,,,,,2.543033164,Malaria treatment cost from OHT,2.543033164,,2.543033164,0.816624,0.816624,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,109,Malaria,Uncomplicated malaria treatment,"Uncomplicated (adult, >36 kg)",Case management with artemisinin based combination therapy (80% coverage),"Uncomplicated (adult, >36 kg)",,,Primary,Case management with artemisinin based combination therapy (80% coverage),,Uganda,Morel (2005); BMJ,per capita,Case management with artemisinin based combination therapy (80% coverage),Standard/Usual Care,0.008946675,0.343422086,Int $ (2000),0.008946675,0.343422086,#VALUE!,,,Yes,2000 Int$,,,,100.00%,,,,,,,100.00%,80%,Ng'ambi 2020 adult,80%,,,,,2.543033164,Malaria treatment cost from OHT,2.543033164,,2.543033164,0.816624,0.816624,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 108),,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,110,Malaria,Complicated malaria treatment ,,"Complicated (adults, injectable artesunate)",Complicated malaria treatment (adults),,,,"Complicated (adults, injectable artesunate)",added from Uganda HBP,,,0,,,,,,,,,,,,,People 5+,"149,970",2.80%,2.89%,Total malaria cases >5," 3,890,298 ",3%,Malawi Malaria Indicator Survey 2017,132270.132,100.00%,100.00%,100%,increase for severity,100%,36.19584602,36.19584602,36.19584602,36.19584602,,,36.19584602,36.195846,36.195846,0,0,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,111,Malaria,Uncomplicated malaria treatment,"Uncomplicated - 2nd line (adult, <36 kg)","Uncomplicated - 2nd line (adult, <36 kg)","Uncomplicated - 2nd line (adult, <36 kg)",,,Secondary,,,,,,,,,,,,,,,,,,People 5+,"140,159",11.50%,,Total malaria cases >5," 3,890,298 ",12%,Malawi Malaria Indicator Survey 2017,447384.27,7.00%,,100%,Assume already received treatment,7%,,,,,,,,0.43168452,0.43168452,0.828912,0.828912,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,112,Malaria,Uncomplicated malaria treatment,"Uncomplicated - 2nd line (adult, >36 kg)","Uncomplicated - 2nd line (adult, >36 kg)","Uncomplicated - 2nd line (adult, >36 kg)",,,Secondary,,,,,,,,,,,,,,,,,,People 5+,"140,159",11.50%,,Total malaria cases >5," 3,890,298 ",12%,Malawi Malaria Indicator Survey 2017,447384.27,3.00%,,100%,Assume already received treatment,3%,,,,,,,,0.86336905,0.86336905,0.707844,0.707844,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,113,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, <15 kg)",Uncomplicated malaria treatment (<5 years) - moderate to high transmission settings,"Uncomplicated (children, <15 kg)",,,Primary,Uncomplicated malaria treatment (<5 years) - moderate to high transmission settings,,Uganda,Pfeil (2015); Am J Trop Med Hyg,0,Dihydroartemisinin piperaquine for first line treatment of plasmodium falciparum malaria,Standard/Usual Care- Artemether-Lumefantrine for first line treatment,,,,,,,,,,,,,,,Children 0-59 months," 2,888,984 ",37%,https://www.sciencedirect.com/science/article/pii/S240584402030791X,1068924.08,,,80%,Ng'ambi 2020 adult/child,80%,,,,,,,0,,0,2.26938,2.26938,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetitive (see interventions 116 and 117),,,,,Standard/Usual Care- Artemether-Lumefantrine for first line treatment,,,,,,,,,,,,,,,,,,,,,,,,,
,114,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, <15 kg)",Combined antimalarial and antibacterial rectal formulation (< 5 years),"Uncomplicated (children, <15 kg)",,,Primary,Combined antimalarial and antibacterial rectal formulation (< 5 years),,Uganda,Buchanan (2010); PLoS One,0,Combined antimalarial and antibacterial rectal formulation added to usual practice,Standard/Usual Care,,,,,,,,,,,,,,,Children 0-59 months," 2,888,984 ",37%,https://www.sciencedirect.com/science/article/pii/S240584402030791X,1068924.08,,,80%,Ng'ambi 2020 adult/child,80%,,,,,,,0,,0,2.26938,2.26938,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetitive (see interventions 116 and 117),,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,115,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, <15 kg)",Rectal antimalarial treatment (<5 years),Rectal antimalarial treatment (<5 years),,,Primary,Rectal antimalarial treatment (<5 years),,Uganda,Buchanan (2010); PLoS One,0,Rectal antimalarial treatment added to usual practice,Standard/Usual Care,,,,,,,,,,,,,,,Children 0-59 months," 2,888,984 ",37%,https://www.sciencedirect.com/science/article/pii/S240584402030791X,1068924.08,,,80%,Ng'ambi 2020 adult/child,80%,,,,,,,0,,0,1.56,1.56,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,116,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, <15 kg)",Dihydroartemisinin piperaquine for first line treatment of plasmodium falciparum malaria - under 5,First line malaria treatment with Dihydroartemisinin piperaquin (Children),,Under 5 Outpatient Visit,Primary,Dihydroartemisinin piperaquine for first line treatment of plasmodium falciparum malaria - under 5,,Uganda,Pfeil (2015); Am J Trop Med Hyg,0,Dihydroartemisinin piperaquine for first line treatment of plasmodium falciparum malaria - under 5,Standard/Usual Care,,,,0.03,0.082275,0.03,0.0832623,2.775,,,,,,100.00%,Children 0-59 months," 2,888,984 ",37.00%,https://www.sciencedirect.com/science/article/pii/S240584402030791X,1068924.08,59.00%,100.00%,80%,Ng'ambi 2020 adult/child,59%,,,,,3.5,Pfeil (2015) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703290/,3.5,,3.5,2.26938,2.26938,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,117,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, <15 kg)",Home management of fevers using antimalarial (artesunate- amodiaquine AAQ) - under 5,Home management of fevers using antimalarial (artesunate- amodiaquine AAQ) (under 5),,Community-based intervention,Community,Home management of fevers using antimalarial (artesunate- amodiaquine AAQ) - under 5,,Ghana,Nonvignon (2012); Trop Med Int Health,per capita,Febrile children 2–59 months received artesunate–amodiaquine when taken to community health workers (CHWs) by their caregivers and diagnosed of having uncomplicated fever,Standard/Usual Care,0.168766287,11.51032292,United States (2009); currency year stated,0.168766287,11.51032292,26.26364351,2160.250407,82.253,Yes,2009 US$,,,,30.00%,Total Malaria infection children 0-59 months," 1,068,924 ",11.50%,Malawi Malaria Indicator Survey 2017,122926.26,,87.00%,80%,Ng'ambi 2020 adult/child,80%,,,,,2.543033164,Malaria treatment cost from OHT,2.543033164,,2.543033164,2.26938,2.26938,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,118,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, >15 kg)","Uncomplicated (children, >15 kg)","Uncomplicated (children, >15 kg)",,,Primary,,,,,,,,,,,,,,,,,,Children 0-4 years,"27,160",14.00%,,Children 5-14 years," 5,619,432 ",,,,41.00%,,80%,Ng'ambi 2020 adult/child,41%,,,,,,,,14.5601225,14.5601225,1.894368,1.894368,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,119,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, >15 kg)",Combined antimalarial and antibacterial rectal formulation added to usual practice (5 and over),Combined antimalarial and antibacterial rectal formulation for malaria treament,,,,Combined antimalarial and antibacterial rectal formulation added to usual practice (5 and over),The intervention should be updated to complicated/severe malaria,Uganda,Buchanan (2010); PLoS One,0,Combined antimalarial and antibacterial rectal formulation added to usual practice,Standard/Usual Care,,,,,,,,,,,,,,,Children 5-14 years," 5,619,432 ",24%,Malawi Malaria Indicator Survey 2017,1348663.68,,,,,,,,,,,,0,,0,1.894368,1.894368,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,120,Malaria,Uncomplicated malaria treatment,"Uncomplicated (children, >15 kg)",Rectal antimalarial treatment (5 and over years),Rectal antimalarial treatment (5 and over years),,,,Rectal antimalarial treatment (5 and over years),The intervention should be updated to complicated/severe malaria,Uganda,Buchanan (2010); PLoS One,0,Rectal antimalarial treatment added to usual practice,Standard/Usual Care,,,,,,,,,,,,,,,Children 5-14 years," 5,619,432 ",24%,Malawi Malaria Indicator Survey 2017,1348663.68,,,,,,,,,,,,0,,0,1.894368,1.894368,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,121,Malaria,Uncomplicated malaria treatment,"Uncomplicated - 2nd line (children, <15 kg)","Uncomplicated - 2nd line (children, <15 kg)","Uncomplicated - 2nd line (children, <15 kg)",,,,,,,,,,,,,,,,,,,,,Children 0-4 years,"27,160",14.00%,,Children 0-59 months x incidence 2nd line,,,,,2.00%,,100%,Assume already received treatment,2%,,,,,,,,0.10785639,0.10785639,2.161032,2.161032,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,122,Malaria,Uncomplicated malaria treatment,"Uncomplicated - 2nd line (children, >15 kg)","Uncomplicated - 2nd line (children, >15 kg)","Uncomplicated - 2nd line (children, >15 kg)",,,,,,,,,,,,,,,,,,,,,Children 0-4 years,"27,160",14.00%,,Children 0-59 months x incidence 2nd line,,,,,1.00%,,100%,Assume already received treatment,1%,,,,,,,,0.21584226,0.21584226,2.1606,2.1606,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,123,Malaria,Uncomplicated malaria treatment,Uncomplicated - First trimester pregnancy,Uncomplicated - First trimester pregnancy,Uncomplicated - First trimester pregnancy,,,,,,,,,,,,,,,,,,,,,,,,,Pregnant women x incidence * (1/3)," 949,472 ",,,,,,,,,,,,,,,,,,3.377964,3.377964,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,124,Malaria,Uncomplicated malaria treatment,Uncomplicated - Second trimester pregnancy,Uncomplicated - Second trimester pregnancy,Uncomplicated - Second trimester pregnancy,,,,,,,,,,,,,,,,,,,,,,,,,Pregnant women x incidence * (1/3)," 949,472 ",,,,,,,,,,,,,,,,,,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,"remove - this is already included in 108, 116, 117",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,125,Malaria,Complicated malaria treatment ,"Complicated (children, injectable artesunate)","Complicated (children, injectable artesunate)","Complicated (children, injectable artesunate)",,Under 5 Outpatient Visit,Secondary,"Complicated (children, injectable artesunate)",,Uganda,Lubell (2011); Bull World Health Organ,0,Parental artesunate,Standard/Usual Care- Quinine dihyrocholride,,,,0.7,3.576,0.7,3.618912,5.170,,,Children 0-4 years,"20,962",0.30%,0.39%,"Total Malaria cases, children 0-59 months"," 1,068,924 ",3.40%,Malawi Malaria Indicator Survey 2017,36343.416,100.00%,100.00%,100%,increase for severity,100%,12.88724775,12.88724775,12.88724775,12.88724775,,,12.88724775,12.8872478,12.8872478,7.086012,7.086012,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care- Quinine dihyrocholride,,,,,,,,,,,,,,,,,,,,,,,,,
,126,Malaria,Complicated malaria treatment ,Pregnant women - complicated,Pregnant women - complicated,Complicated malaria treatment (pregnant women),,,Secondary,,,,,,,,,,,,,,,,,,Pregnant women,"6,760",1.70%,,Pregnant women x incidence complicated," 949,472 ",,,,100.00%,,100%,increase for severity,100%,,,,,,,,28.4512549,28.4512549,2.38518,2.38518,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,127,Maternal/Newborn and Reproductive Health,ANC Package,Basic ANC,Basic ANC,Basic ANC,,Antenatal Care - First Visit,All,Basic ANC,,Afr-D,"Darmstadt, 2004; Lancet",per capita,Universal ANC (95%),None,0.004688804,0.220918544,Int $ (2000),0.004688804,0.220918544,0.094469989,2.015769196,21.338,Yes,2000 Int$,Pregnant women,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100.00%,,949472,63.00%,100.00%,95%,ANC coverage,63%,0,0,0,0,38.91117317,Malawi's OHT,38.91117317,38.9111732,38.9111732,19.4056164,19.4056164,New Malawi estimate (2021),7.5,1.5,3.456081238,10,0,3.5,0.073319933,0.25,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,128,Maternal/Newborn and Reproductive Health,ANC Package,Urinanalysis,Urinanalysis,Urinanalysis,,,All,,,,,,,,,,,,,,,,,,,,,,Pregnant women," 949,472 ",100%,,949472,,,95%,ANC coverage,95%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,129,Maternal/Newborn and Reproductive Health,ANC Package,Deworming (pregnant women),Deworming (pregnant women),Deworming (pregnant women),,,All,Deworming (pregnant women),,,,0,,,,,,,,,,,,,Pregnant women,"6,760",29.00%,29.00%,Pregnant women," 949,472 ",100%,,949472,100.00%,100.00%,95%,ANC coverage,95%,0,0,0.124658488,0.124658488,,,0.124658488,0,0,0.003264,0.003264,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,130,Maternal/Newborn and Reproductive Health,ANC Package,Tetanus toxoid (pregnant women),Tetanus toxoid (pregnant women),Tetanus toxoid (pregnant women),,EPI,All,Tetanus toxoid (pregnant women),,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Tetanus Toxoid,None,0.005486112,0.095564523,Int $ (2000),0.005486112,0.095564523,0.110534135,0.871977598,7.889,Yes,2000 Int$,Pregnant women,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100.00%,,949472,98.00%,85.00%,95%,ANC coverage,95%,0,0.21939894,0.21939894,0.21939894,,,0.21939894,0.396885,0.396885,1.666404,1.666404,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,131,Maternal/Newborn and Reproductive Health,ANC Package,,Daily iron and folic acid supplementation (pregnant women),Daily iron and folic acid supplementation (pregnant women),,Antenatal Care - Followup Visit,,Daily iron and folic acid supplementation (pregnant women),added from Uganda HBP,,WHO-CHOICE,0,,,,,,0.19,22.63009155,0.19,22.90165265,120.535,,,Pregnant women,"6,623",28.80%,100.00%,Pregnant women," 949,472 ",100.00%,,949472,84.00%,83.00%,95%,ANC coverage,84%,,,,,1.512,MSH International Medical Producets Price Guide (2015) - 180 tablets X $0.0084/tablet,1.512,0,0,1.307196,1.307196,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,132,Maternal/Newborn and Reproductive Health,ANC Package,Syphilis detection and treatment (pregnant women),Syphilis detection and treatment (pregnant women),Syphilis detection and treatment (pregnant women),,STI,All,Syphilis detection and treatment (pregnant women),,Uganda,Kuznik (2013); PLoS Med,0,Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,None,,,,0.098991704,0.822768609,0.098991704,0.832641832,8.411,,,Births,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100.00%,,949472,100.00%,59.00%,95%,ANC coverage,95%,0,0,0.480483678,0.480483678,,,0.480483678,0,0,4.6722,4.6722,New Malawi estimate (2021),5,4.907896622,1.291582499,1.580052088,6.220468791,0.580052088,0.580052088,0.580052088,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2013-01-00773-26,Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,Syphilis screening before third trimester + treat with three injections of benzathine penicillin if positive,,None,Malawi,6.14263,7.067605942,0,0,0,414013,0,0,0,0,Kuznik,2013,United States,2011,,,,,,,,,,
,133,Maternal/Newborn and Reproductive Health,ANC Package,Malaria Prevention IPT,"Intermittent preventive treatment in infants (IPTi) using 3 days of amodiaquine-artesunate (AQ3-AS3) against clinical malaria; at 2, 3, and 9 months.",Intermittent preventive treatment in infants (IPTi),,Under 5 Outpatient Visit,All,"Intermittent preventive treatment in infants (IPTi) using 3 days of amodiaquine-artesunate (AQ3-AS3) against clinical malaria; at 2, 3, and 9 months.",,Kenya,Conteh (2010); PLoS One,0,"Intermittent preventive treatment in infants (IPTi) using 3 days of amodiaquine-artesunate (AQ3-AS3) against clinical malaria; at 2, 3, and 9 months.",None,,,,0.158,1.533852,0.158,1.552258224,9.824,,,,,,100.00%,Pregnant women," 949,472 ",100.00%,,949472,,41.00%,95%,ANC coverage,95%,0,0,0,0,1.244,Conteh (2010) - Tufts Database,1.244,,1.244,0.15066,0.15066,New Malawi estimate (2021),7,5.283719796,0.880739061,7.49135629,10.4628284,3.5,2.5,3.332945747,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,134,Malaria,Prevention,Malaria Prevention ITN,Malaria Prevention ITN,Malaria Prevention ITN,Mass ITN Distribution,No HRH time,All,,The CE evidence is specifically for pregnant women,"Congo, Rep.","Becker-Dreps(2009);Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic Republic of the Congo",,Long-lasting insecticide-treated bed nets (ITNs) + information on correct use and malaria transmission,,,,,0.553121332,9.524562678,0.553121332,12.62004555,22.816,Yes,2005 US$,,,,,Total population,18898441,50.00%,One net per 2 household members. WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014. http://www.who.int/malaria/publications/world_malaria_report/en/.,9449220.5,,,60%,Ng'ambi 2020 adults,60%,,,,,,,,,,0.8124,0.8124,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Complete,Complete,Complete,Incomplete,,2009-01-01632-03,Long-lasting insecticide-treated bed nets (ITNs) + information on correct use and malaria transmission,Long-lasting insecticide-treated bed nets (ITNs) + information on correct use and malaria transmission,,None,"Congo, Rep.",17.34,22.97891828,0,0,0,0,0,0,0,0,Becker-Dreps,2009,United States,2005,"Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic Republic of the Congo",9897,170423,,0.553121332,9.524562678,2005 US$,17.22,,
,135,Maternal/Newborn and Reproductive Health,Modern Family Planning,Oral Contraception,Pill,Oral Contraception,,EPI,All,Pill,,Uganda,Babigumira (2012); PLoS One,0,Universal access to modern contraceptives,Standard/Usual Care- current contraceptive program,,,,0.37,-57.17016,0.37,-57.85620192,-156.368,,,Women of reproductive age (15-49),"4,682",100.00%,24.08%,Women of reproductive age (15-49)," 4,799,004 ",20.00%,proportion DHIS-2,959800.8,60.00%,73.00%,60%,,60%,,,,,6.05,Babigumira et al. (2012) - 9 month cycle,6.05,6.95740076,6.95740076,0,0,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care- current contraceptive program,,,,,,,,,,,,,,,,,,,,,,,,,
,136,Maternal/Newborn and Reproductive Health,Modern Family Planning,Male condom,Condoms,Male condom,,EPI,All,Condoms,,International,Stover (2017); PLoS One,0,"Current trend in condom use (for family planning, HIV and STI prevention) continues through to 2030","Current condom use (for family planning, HIV and STI prevention), 10 condoms per per woman per year on average (47% of demand met)",,,,0.00228009,0.412989129,0.00228009,0.417944999,183.302,,,Eligible condom users,"87,510",100.00%,100.00%,Men 15-49 years," 4,363,012 ",40.00%,,1745204.8,70.00%,75.00%,70%,,70%,3.141393908,3.141393908,3.141393908,0,,,3.141393908,9.06762744,9.06762744,5.0328,5.0328,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,"Current condom use (for family planning, HIV and STI prevention), 10 condoms per per woman per year on average (47% of demand met)",,,,,,,,,,,,,,,,,,,,,,,,,
,137,Maternal/Newborn and Reproductive Health,Modern Family Planning,Female Condom,Female Condom,Female Condom,,EPI,All,Female Condom,,Uganda,Mvundura (2015); Int J Womens Health,0,"Distributing 100,000 Woman’s Condoms",None,,,,0.015661833,2.81913,0.015661833,3.17715951,202.860,Yes,2012 US$,Direct entry,684,100.00%,,Women of reproductive age (15-49)," 4,799,004 ",0.01%,proportion DHIS-2,479.9004,60.00%,,60%,,60%,,,,,,,0,0,0,0.79776,0.79776,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2015-01-02003-05,Women's condom distribution,"Distributing 100,000 Woman’s Condoms",,None,Malawi,73,82.28961994,0,0,0,0,0,0,0,0,Mvundura,2015,United States,2012,Estimating the hypothetical dual health impact and cost-effectiveness of the Woman's Condom in selected sub-Saharan African countries,1566.183333,281913,per condom distributed,0.015661833,2.81913,2012 US$,180,,
,138,Maternal/Newborn and Reproductive Health,Modern Family Planning,Injectable Contraception,Injectable,Injectable Contraception,,Minor Surgical Procedures,All,Injectable,,Uganda,Babigumira (2012); PLoS One,0,Universal access to modern contraceptives,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,0.37,-57.17016,0.37,-57.85620192,-156.368,,,Women of reproductive age (15-49),"35,076",100.00%,30.96%,Women of reproductive age (15-49)," 4,799,004 ",30.00%,proportion DHIS-2,1439701.2,60.00%,73.00%,60%,,60%,,,,,5.42,Babigumira et al. (2012) - 9 month cycle,5.42,4.45588891,4.45588891,0.836736,0.836736,New Malawi estimate (2021),32,40,16,24,12,2.5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,,,,,,,,,,,,,,,,,,,,,,
,139,Maternal/Newborn and Reproductive Health,Modern Family Planning,IUD,IUD,IUD,,Major Surgical Procedures,All,IUD,,Uganda,Babigumira (2012); PLoS One,0,Universal access to modern contraceptives,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,0.37,-57.17016,0.37,-57.85620192,-156.368,,,Women of reproductive age (15-49),"1,657",100.00%,2.75%,Women of reproductive age (15-49)," 4,799,004 ",1.00%,proportion DHIS-2,47990.04,60.00%,73.00%,60%,,60%,,,,,1.66,Babigumira et al. (2012) - 9 month cycle,1.66,0.60048992,0.60048992,0.07626,0.07626,New Malawi estimate (2021),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,,,,,,,,,,,,,,,,,,,,,,
,140,Maternal/Newborn and Reproductive Health,Modern Family Planning,Implant,Implant,Implant,,Minor Surgical Procedures,All,Implant,,Uganda,Babigumira (2012); PLoS One,0,Universal access to modern contraceptives,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,0.37,-57.17016,0.37,-57.85620192,-156.368,,,Women of reproductive age (15-49),"11,380",100.00%,0.69%,Women of reproductive age (15-49)," 4,799,004 ",10.00%,proportion DHIS-2,479900.4,60.00%,73.00%,60%,,60%,,,,,34.6,Babigumira et al. (2012) - 9 month cycle,34.6,19.9482922,19.9482922,2.348076,2.348076,New Malawi estimate (2021),32,40,16,24,12,2.5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,,,,,,,,,,,,,,,,,,,,,,
,141,Maternal/Newborn and Reproductive Health,Modern Family Planning,Tubal Ligation,Female sterilization,Tubal Ligation,,Minor Surgical Procedures,,Female sterilization,,Uganda,Babigumira (2012); PLoS One,0,Universal access to modern contraceptives,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,0.37,-57.17016,0.37,-57.85620192,-156.368,,,Women of reproductive age (15-49),"11,668",100.00%,3.44%,Women of reproductive age (15-49)," 4,799,004 ",0.05%,proportion DHIS-2,2399.502,60.00%,73.00%,60%,,60%,,,,,4.95,Babigumira et al. (2012) - 9 month cycle,4.95,4.1900365,4.1900365,4.18782,4.18782,New Malawi estimate (2021),32,40,16,24,12,2.5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,,,,,,,,,,,,,,,,,,,,,,
,142,Maternal/Newborn and Reproductive Health,Modern Family Planning,Vastectomy ,Male sterilization,Vastectomy ,,Minor Surgical Procedures,All,Male sterilization,,Uganda,Babigumira (2012); PLoS One,0,Universal access to modern contraceptives,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,0.37,-57.17016,0.37,-57.85620192,-156.368,,,Men 15-49,432,100.00%,3.44%,Men 15-49," 4,363,012 ",0.001%,proportion DHIS-2,43.63012,60.00%,73.00%,60%,,60%,,,,,8.38,Seamans & Harner-Jay (2007) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1947949/,8.38,2.45541407,2.45541407,2.788572,2.788572,New Malawi estimate (2021),32,40,16,24,12,2.5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Current contraceptive program (CCP) - 31% women have access to modern contraceptives,,,,,,,,,,,,,,,,,,,,,,,,,
,143,Maternal/Newborn and Reproductive Health,Delivery Package,Antenatal corticosteroids for preterm labour,Antenatal corticosteroids for preterm labour,Antenatal corticosteroids for preterm labour,,Antenatal Care - Followup Visit,All,Antenatal corticosteroids for preterm labour,,,"Darmstadt et al, 2005; Lancet",0,Corticosteroids (50% coverage),,,,,1.26,55.36159865,1.26,56.02593783,44.465,,,Pregnant women,"6,760",18.00%,5.00%,Pregnant women," 949,472 ",15.70%,"GBD, preg 5% population WHO",149067.104,50.00%,20.00%,50%,RHU estimate,50%,0,0,0,3.390710885,,,3.390710885,7.8069257,7.8069257,6.3346176,6.3346176,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,144,Maternal/Newborn and Reproductive Health,Delivery Package,Antibiotics for pPRoM,Antibiotics for pPRoM,Antibiotics for pPRoM,,Antenatal Care - Followup Visit,All,Antibiotics for pPRoM,,,"Darmstadt et al, 2005; Lancet",0,Antibiotics for pPROM (95%),,,,,0.79,55.2899795,0.79,55.95345925,70.827,,,Pregnant women,"6,760",7.00%,4.67%,Pregnant women," 949,472 ",15.70%,GBD,149067.104,81.00%,55.00%,80%,RHU estimate,80%,0,0,0.893552045,0.893552045,,,0.893552045,1.92035801,1.92035801,6.9621744,6.9621744,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,145,Maternal/Newborn and Reproductive Health,Delivery Package,Induction of labour (beyond 41 weeks),Induction of labour (beyond 41 weeks),Induction of labour (beyond 41 weeks),,Normal Deliveries,secondary / tertiary,Induction of labour (beyond 41 weeks),,,WHO-CHOICE,0,,,,,,7.31,22.48700918,7.31,22.75685329,3.113,,,Pregnant women,"6,760",5.00%,5.00%,Pregnant women," 949,472 ",8.00%,World estimates,75957.76,5.00%,44.00%,5%,RHU estimate,5%,0,0,0.003490438,0.003490438,,,0.003490438,0.00277339,0.00277339,0.056988,0.056988,New Malawi estimate (2021),11.09394914,13.8709557,27.7419114,107.7924328,0,0,1.133005872,2.596928537,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,146,Maternal/Newborn and Reproductive Health,Delivery Package,Vaginal delivery - skilled attendance,Vaginal delivery - skilled attendance,Vaginal delivery - skilled attendance,,Normal Deliveries,All,Vaginal delivery - skilled attendance,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Normal delivery by a skilled attendant (95%),None,0.004955197,0.20351704,Int $ (2000),0.004955197,0.20351704,0.133116378,2.475985773,18.600,Yes,2000 Int$,Pregnant women,"6,761",84.50%,100.00%,Pregnant women," 949,472 ",75.00%,Proportions from DHIS-2,712104,94.00%,76.00%,95%,RHU skilled delivery estimate,94%,0,0,2.251432028,2.251432028,,,2.251432028,17.9514515,17.9514515,11.934672,11.934672,New Malawi estimate (2021),11.09394914,13.8709557,27.7419114,107.7924328,0,0,1.133005872,2.596928537,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,147,Maternal/Newborn and Reproductive Health,Delivery Package,Vaginal Delivery - with complication,Vaginal Delivery - with complication,Vaginal Delivery - with complication,,Complicated Deliveries,secondary / tertiary,Vaginal Delivery - with complication,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Normal delivery by a skilled attendant (95%),None,0.004955197,0.20351704,Int $ (2000),0.004955197,0.20351704,0.665581889,12.37992887,18.600,Yes,2000 Int$,Pregnant women,"6,756",14.90%,14.91%,Pregnant women," 949,472 ",15.00%,Proportions from DHIS-2,142420.8,94.00%,92.00%,95%,RHU skilled delivery estimate,94%,18.56925188,18.56925188,18.56925188,18.56925188,,,18.56925188,18.5692519,18.5692519,26.3805168,26.3805168,New Malawi estimate (2021),22.3721002,21.81242521,24.33795885,13.97805612,0,3.5,1.361142741,1.138857259,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,148,Maternal/Newborn and Reproductive Health,Delivery Package,Active management of the 3rd stage of labour,Active management of the 3rd stage of labour,Active management of the 3rd stage of labour,,Antenatal Care - Followup Visit,All,Active management of the 3rd stage of labour,,,WHO-CHOICE,0,,,,,,7.3,22.60701375,7.3,22.87829791,3.134,,,Pregnant women,"6,760",100.00%,100.00%,Pregnant women," 949,472 ",100.00%,,949472,88.00%,55.00%,95%,RHU skilled delivery estimate,88%,0,0,0.229371619,0.229371619,,,0.229371619,0,0,0.232548,0.232548,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,149,Maternal/Newborn and Reproductive Health,Delivery Package,Management of pre-eclampsia and eclampsia,Management of pre-eclampsia,Management of pre-eclampsia and eclampsia,,Complicated Deliveries,,Management of pre-eclampsia,Too broad,Nepal,Feldhaus (2016); Cost Eff Resour Alloc,0,Magnesium sulfate + calcium during antenatal care for pre-eclampsia/eclampsia,Standard/Usual Care- Magnesium sulfate only,,,,0.13,2.6676,0.13,2.6996112,20.766,,,Pregnant women,"6,760",2.20%,2.80%,Pregnant women," 949,472 ",1.40%,GBD,13292.608,97.00%,42.00%,95%,RHU skilled delivery estimate,95%,0,0,8.489741696,8.489741696,,,8.489741696,7.22206803,7.22206803,49.8740844,49.8740844,New Malawi estimate (2021),22.3721002,21.81242521,24.33795885,13.97805612,0,3.5,1.361142741,1.138857259,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care- Magnesium sulfate only,,,,,,,,,,,,,,,,,,,,,,,,,
,150,Maternal/Newborn and Reproductive Health,Delivery Package,Management of obstructed labour,Management of obstructed labour,Management of obstructed labour,,Complicated Deliveries,,Management of obstructed labour,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Tetanus toxoid + Normal delivery by a skilled attendant + Management of OL (95%) ,None,0.009556452,0.591084272,Int $ (2000),0.009556452,0.591084272,1.925433321,53.93342923,28.011,Yes,2000 Int$,Pregnant women,"6,760",10.00%,10.00%,Pregnant women," 949,472 ",10.00%,Proportions from DHIS-2,94947.2,100.00%,100.00%,95%,RHU skilled delivery estimate,95%,0,0,0,20.52661575,,,20.52661575,38.106985,38.106985,69.6587904,69.6587904,New Malawi estimate (2021),22.3721002,21.81242521,24.33795885,13.97805612,0,3.5,1.361142741,1.138857259,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,151,Maternal/Newborn and Reproductive Health,Delivery Package,Cesearian section with indication,Cesearian section with indication,Cesearian section with indication,,Caesarean Sections,secondary / tertiary,Cesearian section with indication,,Zambia,Roberts (2016); World J Surg,0,"Elective caesarian section, using Zambian life expectancy",None,,,,9.636363636,328.5955673,9.636363636,332.5387141,34.509,,,Pregnant women,"6,628",0.50%,0.51%,Pregnant women," 949,472 ",9.50%,Proportions from DHIS-2,90199.84,94.00%,92.00%,95%,RHU skilled delivery estimate,94%,62.90206779,62.90206779,62.90206779,62.90206779,,,62.90206779,62.9020678,62.9020678,63.07281,63.07281,New Malawi estimate (2021),25.05031601,32.88241634,34.67167214,43.52285532,0,7,9.671745627,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,152,Maternal/Newborn and Reproductive Health,Delivery Package,Cesearian Section with indication (with complication),Cesearian Section with indication (with complication),Cesearian Section with indication (with complication),,Caesarean Sections,secondary / tertiary,Cesearian Section with indication (with complication),,Zambia,Roberts (2016); World J Surg,0,"Emergency caesarian section, using Zambian life expectancy",None,,,,27.18877551,335.2912653,27.18877551,339.3147605,12.480,,,Pregnant women,"7,511",0.10%,0.09%,Pregnant women," 949,472 ",0.50%,Proportions from DHIS-2,4747.36,94.00%,92.00%,95%,RHU skilled delivery estimate,94%,108.3094596,108.3094596,108.3094596,108.3094596,,,108.3094596,108.30946,108.30946,35.594571,35.594571,New Malawi estimate (2021),25.05031601,32.88241634,34.67167214,43.52285532,0,7,9.671745627,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,153,Maternal/Newborn and Reproductive Health,Delivery Package,Treatment of postpartum hemorrhage,Treatment of postpartum hemorrhage,Treatment of postpartum hemorrhage,,,secondary / tertiary,Treatment of postpartum hemorrhage,,,,0,,,,,,,,,,,,,Pregnant women,"6,760",3.90%,9.80%,Pregnant women," 949,472 ",2%,Proportions from DHIS-2,23072.1696,76.00%,56.00%,95%,RHU skilled delivery estimate,76%,0,0,0,9.076633859,,,9.076633859,30.1370898,30.1370898,185.212824,185.212824,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,154,Maternal/Newborn and Reproductive Health,Delivery Package,Maternal sepsis case management,Maternal sepsis case management,Maternal sepsis case management,,Complicated Deliveries,secondary / tertiary,Maternal Sepsis case management,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Management of maternal sepsis (95%),None,0.001061828,0.132728504,Int $ (2000),0.001061828,0.132728504,1.19517897,67.65810043,56.609,Yes,2000 Int$,Pregnant women,"6,760",7.00%,100.00%,Pregnant women," 949,472 ",1.79%,GBD,16995.5488,88.00%,70.00%,95%,RHU skilled delivery estimate,88%,0,0,41.07212972,41.07212972,,,41.07212972,135.166121,135.166121,42.8835888,42.8835888,New Malawi estimate (2021),22.3721002,21.81242521,24.33795885,13.97805612,0,3.5,1.361142741,1.138857259,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,155,Maternal/Newborn and Reproductive Health,Delivery Package,Mastitis,Mastitis,Mastitis,,,secondary / tertiary,Mastitis,,,,0,,,,,,,,,,,,,Births,"4,489",0.50%,20.00%,Live births," 620,346 ",2%,"GBD, live births from census 2021",12406.92,94.00%,56.00%,70%,Ng'ambi 2020 adult fever,70%,0,0,1.595628652,1.595628652,,,1.595628652,2.29523508,2.29523508,4.619688,4.619688,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,156,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Clean practices and immediate essential newborn care (in facility),Clean practices and immediate essential newborn care (in facility),Clean practices and immediate essential newborn care (in facility),,Normal Deliveries,,Clean practices and immediate essential newborn care (in facility),,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Community newborn care package (95%),None,0.012564965,0.10972223,Int $ (2000),0.012564965,0.10972223,0.387472824,1.532326926,3.955,Yes,2000 Int$,,-,0.00%,100.00%,Live births," 620,346 ",100.00%,,620346,,76.00%,95%,RHU skilled delivery estimate,95%,1.366257033,0,0,0,,,1.366257033,1.97007007,1.97007007,3.337044,3.337044,New Malawi estimate (2021),11.09394914,13.8709557,27.7419114,107.7924328,0,0,1.133005872,2.596928537,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,157,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Newborn medications,Newborn medications,Newborn medications,,,,,,,,,,,,,,,,,,,,,,,,,," 620,346 ",,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - this intervention is not specific enough,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,158,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Neonatal resuscitation (institutional),Neonatal resuscitation (institutional),Neonatal resuscitation (institutional),,Complicated Deliveries,,Neonatal resuscitation (institutional),,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Emergency neonatal care (95%) ,None,0.005663083,0.339784971,Int $ (2000),0.005663083,0.339784971,0.949106733,25.78951348,27.172,Yes,2000 Int$,Births,"4,489",1.00%,10.00%,Live births," 620,346 ",18.40%,GBD Neonatal complications+prematurity,114143.664,100.00%,73.00%,95%,RHU skilled delivery estimate,95%,0,0,0.378213853,0.378213853,,,0.378213853,0,0,0,0,New Malawi estimate (2021),22.3721002,21.81242521,24.33795885,13.97805612,0,3.5,1.361142741,1.138857259,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,159,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Treatment of local infections (newborn),Treatment of local infections (newborn),Treatment of local infections (newborn),,,,Treatment of local infections (Newborn),,,,0,,,,,,,,,,,,,Births,"4,489",10.00%,100.00%,Live births," 620,346 ",,,,96.00%,100.00%,95%,RHU skilled delivery estimate,95%,0,0,0.6432378,0.882582098,,,0.882582098,1.45613029,1.45613029,6.482868,6.482868,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,160,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Newborn sepsis - full supportive care,Newborn sepsis - full supportive care,Newborn sepsis - full supportive care,,Inpatient Admissions (Ongoing Monitoring),,Newborn sepsis - Full supportive care,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Management of serious newborn infections (95%),None,0.003185484,0.212365607,Int $ (2000),0.003185484,0.212365607,7.016610493,211.8424322,30.192,Yes,2000 Int$,Births,"4,489",12.00%,100.00%,Live births," 620,346 ",1.40%,GBD Neonatal sepsis,8684.844,97.00%,70.00%,95%,RHU skilled delivery estimate,95%,0,0,0,1.95863417,,,1.95863417,16.4766976,16.4766976,27.864042,27.864042,New Malawi estimate (2021),3.415304021,7.390547654,10.58460448,18.49074541,2.959718983,0.592159643,2.440657709,1.92840814,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,161,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Newborn sepsis - full supportive care,Community-based management of newborn complications,Newborn sepsis - full supportive care,,,,Community-based management of newborn complications,added from Uganda HBP,Zambia,Sabin (2012); PLoS One,0,Training for traditional birth attendants (TBAs) on resuscitation and treatment of sepsis,Standard/Usual Care- no special training and supplies,,,,0,0,0,0,,,,,,,100.00%,Live births," 620,346 ",18%,GBD Neonatal sepsis,114143.664,,76.00%,95%,due to severity,95%,,,,,29.90656864,"Cost of ""Pre-referal management of labor complications"" from the Uganda OHT",29.90656864,,29.90656864,27.864042,27.864042,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence not against null + repeated,,,,,Standard/Usual Care- no special training and supplies,,,,,,,,,,,,,,,,,,,,,,,,,
,162,Maternal/Newborn and Reproductive Health,Perinatal newborn care,Newborn sepsis - injectable antibiotics,Newborn sepsis - injectable antibiotics,Newborn sepsis - injectable antibiotics,,,,Newborn sepsis - Injectable antibiotics,,,,0,Inject-able antibiotics for newborn sepsis,,,,,,,,,,,,Births,"4,489",9.00%,10.00%,Live births," 620,346 ",1%,GBD Neonatal sepsis,8684.844,97.00%,70.00%,95%,RHU skilled delivery estimate,95%,0,0,1.236612205,1.236612205,,,1.236612205,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - CE evidence not against null,2019-01-04988-08,Inject-able antibiotics for newborn sepsis,"Newborn sepsis—inject-able antibiotics: Administration of IV/IM antibiotics for neonatal sepsis, meningitis, or pneumonia",,None,Ethiopia,17,17.52156252,0,0,0,910000,0,0,0,0,Memirie,2019,United States,2018,A cost-effectiveness analysis of maternal and neonatal health interventions in Ethiopia,52000,910000,,,,,17,,
,163,Maternal/Newborn and Reproductive Health,Other,Safe abortion services,Safe abortion services,Safe abortion services,,Caesarean Sections,,Safe abortion services,,,WHO-CHOICE,0,,,,,,0.06,29.08264468,0.06,29.43163641,490.527,,,,,,100.00%,Pregnant women," 949,472 ",0.49%,GBD maternal,4652.4128,,3.00%,60%,"Estimate from Ng'ambi 2020 and account for stimga, higher if bleeding",60%,0,0,1.258452372,1.258452372,,,1.258452372,1.14641686,1.14641686,0.265704,0.265704,New Malawi estimate (2021),25.05031601,32.88241634,34.67167214,43.52285532,0,7,9.671745627,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,164,Maternal/Newborn and Reproductive Health,Other,Post-abortion case management,Post-abortion case management,Post-abortion case management,,Inpatient Admissions (Ongoing Monitoring),,Post-abortion case management,,,WHO-CHOICE,0,,,,,,0.05,28.69955318,0.05,29.04394782,580.879,,,Abortions,"1,393",47.10%,5.00%,Pregnant women," 949,472 ",0.49%,GBD maternal,4652.4128,100.00%,100.00%,60%,"Estimate from Ng'ambi 2020 and account for stimga, higher if bleeding",60%,0,0,0,15.56067034,,,15.56067034,32.2742607,32.2742607,106.4848272,106.4848272,New Malawi estimate (2021),3.415304021,7.390547654,10.58460448,18.49074541,2.959718983,0.592159643,2.440657709,1.92840814,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,165,Maternal/Newborn and Reproductive Health,Other,Ectopic case management,Ectopic case management,Ectopic case management,,Inpatient Admissions (Ongoing Monitoring),secondary / tertiary,Ectopic case management,,,WHO-CHOICE,0,,,,,,0.02,27.13487828,0.02,27.46049682,1373.025,,,Pregnant women,"6,760",2.40%,1.00%,Pregnant women," 949,472 ",0.08%,GBD maternal,759.5776,100.00%,100.00%,60%,"Estimate from Ng'ambi 2020 and account for stimga, higher if bleeding",60%,0,0,27.39056144,27.39056144,,,27.39056144,80.0007846,80.0007846,76.758996,76.758996,New Malawi estimate (2021),3.415304021,7.390547654,10.58460448,18.49074541,2.959718983,0.592159643,2.440657709,1.92840814,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,166,Maternal/Newborn and Reproductive Health,Other,Hysterectomy,Hysterectomy,Hysterectomy,,,secondary / tertiary,Hysterectomy,,,,0,,,,,,,,,,,,,Female (47 years),-,0.00%,11.63%,Women direct entry," 3,498 ",100%,RHU estimates,3498,,100.00%,100%,This is due to need usually for cervical cancer or post delivery,100%,,,,,86.09547124,Malawi OHT (Not that the cost of medicines and materials for a uterine evacuation as per this paper is only $6 - https://www.sciencedirect.com/science/article/pii/S0039606015001415?via%3Dihub),86.09547124,100.903927,100.903927,16.344504,16.344504,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,167,Maternal/Newborn and Reproductive Health,Other,Treatment of Antepartum hemorrhage,Treatment of Antepartum hemorrhage,Treatment of Antepartum hemorrhage,,,,Treatment of antepartum hemorrhage,,,,0,,,,,,,,,,,,,,-,0.00%,,Pregnant women," 949,472 ",,,,,,,,,,,,,,,0,,0,Not available,0,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,324,0,1,9,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,168,Maternal/Newborn and Reproductive Health,Delivery Package,Kangaroo mother care,Kangaroo mother care,Kangaroo mother care,,Antenatal Care - Followup Visit,,Kangaroo mother care,added from Uganda HBP,,WHO-CHOICE,0,,,,,,1.83,22.48700918,1.83,22.75685329,12.435,,,Pregnant women,"6,760",13.00%,20.00%,Live births," 620,346 ",15.70%,GBD neonatal,97394.322,82.00%,60.00%,95%,RHU skilled delivery estimate,82%,0,0,0,0,1E-35,No drugs and commodities cost,1E-35,,1E-35,Not available,1E-35,Uganda estimate (2020),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,169,Maternal/Newborn and Reproductive Health,Delivery Package,Support for breastfeeding mothers,Support for breastfeeding mothers,Support for breastfeeding mothers,,Antenatal Care - Followup Visit,,Support for breastfeeding mothers,added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Adam (2005); BMJ,per capita,Support for breastfeeding mothers (95%),None,0.01061828,0.113261657,Int $ (2000),0.01061828,0.113261657,0.327441823,1.581756827,4.831,Yes,2000 Int$,,,,100.00%,Live births," 620,346 ",100.00%,,620346,,76.00%,95%,RHU skilled delivery estimate,95%,,,,,1E-35,No drugs and commodities cost,1E-35,,1E-35,Not available,1E-35,Uganda estimate (2020),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,170,Maternal/Newborn and Reproductive Health,,Prenatal distribution of misoprostol (for PPH prevention),Prenatal distribution of misoprostol (for PPH prevention),Prenatal distribution of misoprostol (for PPH prevention),,Antenatal Care - Followup Visit,,Prenatal distribution of misoprostol (for PPH prevention),added from Uganda HBP,Uganda,Lubinga et al. (2016),0,Prenatal community distribution of misoprostol to pregnant mothers as a strategy to increase access to uterotonics for prevention of PPH,nothing,,,,0.08,0.386208,0.08,0.390842496,4.886,,,,,,100.00%,pregnant women," 949,472 ",100.00%,,949472,,100.00%,95%,RHU ANC coverage,95%,,,,,0.3576,Lubinga et al. (2015),0.3576,,0.3576,0.91176,0.91176,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,171,"Mental, Neurological and Substance use disorders",Screening and Diagnosis,Screening and diagnosis for Common Mental Disorders (CMDs) and Substance Use Disorders (SUDs),Screening and diagnosis for Common Mental Disorders (CMDs) and Substance Use Disorders (SUDs),Screening and diagnosis for Common Mental Disorders (CMDs) and Substance Use Disorders (SUDs),,,Primary,,,,,,,,,,,,,,,,,,,,,,Total population," 18,898,441 ",10000%,,1889844100,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,172,"Mental, Neurological and Substance use disorders",Treatment,Anxiety,Anxiety,Treatment of anxiety,,,primary,Anxiety,,,,0,,,,,,,,,,,,,Total population,"179,478",5.00%,100.00%,Total population," 18,898,441 ",4%,GBD NCD,669004.8114,3.00%,10.00%,3%,Mental health team estimate,3%,,,,,,,0,0,0,7.213512,7.213512,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,15,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,173,"Mental, Neurological and Substance use disorders",Treatment,Treatment of depression,Treatment of depression,Treatment of depression,,Mental Health OPD,primary,Treatment of depression,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,Episodic treatment with newer antidepressants (TCAs) (50% coverage),None,0.000681,0.58,Int $ (2005),0.000681,0.58,0.022236856,9.70781375,436.564,Yes,2005 Int$,Population with depressive disorders,"179,478",5.00%,100.00%,Total population," 18,898,441 ",3.10%,GBD NCD,585851.671,3.00%,10.00%,3%,Mental health team estimate,3%,,,,,6.252198176,Malawi HBP,6.252198176,6.25219818,6.25219818,4.722738,4.722738,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,15,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,174,"Mental, Neurological and Substance use disorders",Treatment,Treatment of Postpartum Depression,Treatment of Postpartum Depression,Treatment of Postpartum Depression,,,Community/Primary,,,,,,,,,,,,,,,,,,,,,,Pregnant women," 949,472 ",4%,GBD NCD,35130.464,,,3%,Mental health team estimate,3%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,175,"Mental, Neurological and Substance use disorders",Treatment,Treatment of acute psychotic disorders,Treatment of acute psychotic disorders,Treatment of acute psychotic disorders,,Mental Health Clinic Visit,Primary,Treatment of acute psychotic disorders,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,"Older anti-psychotic drug + psychosocial intervention  (80% coverage), community model",None,0.000332,0.91,Int $ (2005),0.000332,0.91,0.067213428,94.43359514,1404.981,Yes,2005 Int$,Total population,"179,478",1.00%,0.60%,Total population," 18,898,441 ",0.50%,GBD NCD,94492.205,2.00%,10.00%,3%,Mental health team estimate,2%,,,,,18.06311231,Malawi HBP,18.06311231,18.0631123,18.0631123,11.7731796,11.7731796,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,176,"Mental, Neurological and Substance use disorders",Treatment,Treatment of bipolar disorder,Treatment of bipolar disorder,Treatment of bipolar disorder,,Mental Health Clinic Visit,Secondary,Treatment of bipolar disorder,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,"Lithium (older mood stabiliser) alone (50% coverage), community model",None,0.000347,0.62,Int $ (2005),0.000347,0.62,0.07025018,64.33937251,915.861,Yes,2005 Int$,Total population,"179,478",1.00%,100.00%,Total population," 18,898,441 ",0.50%,GBD NCD,94492.205,3.00%,10.00%,3%,Mental health team estimate,3%,,,,,63.01892416,Malawi HBP,63.01892416,63.0189242,63.0189242,53.6694804,53.6694804,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,177,"Mental, Neurological and Substance use disorders",Treatment,Rapid Tranquilization ,Rapid Tranquilization ,Rapid Tranquilization ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.41052,0.41052,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,178,"Mental, Neurological and Substance use disorders",Treatment,Anti-epileptic medication,Anti-epileptic medication,Anti-epileptic medication,,Mental Health OPD,Primary,Anti-epileptic medication,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,Older antiepileptic drug in primary care (50% coverage),None,0.00136,0.36,Int $ (2005),0.00136,0.36,0.043020643,5.837241458,135.685,Yes,2005 Int$,Population with epilepsy,"179,478",2.80%,100.00%,Total population," 18,898,441 ",3.20%,STEPS 2017,604750.112,5.00%,10.00%,60%,MH and Ng'ambi 2020 adult Other,5%,,,,,7.955677023,Malawi HBP,7.955677023,7.95567702,7.95567702,9.917094,9.917094,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,15,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,179,"Mental, Neurological and Substance use disorders",Treatment,Treatment of schizophrenia,Treatment of schizophrenia,Treatment of schizophrenia,,Mental Health Clinic Visit,Secondary,Treatment of schizophrenia,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,"Older anti-psychotic drug + psychosocial intervention  (80% coverage), community model",None,0.000332,0.91,Int $ (2005),0.000332,0.91,0.168033571,236.0839878,1404.981,Yes,2005 Int$,Population suffering from schizophrenia,"179,478",0.20%,100.00%,Total population," 18,898,441 ",0.20%,GBD NCD,37796.882,2.00%,10.00%,3%,Mental health team estimate,2%,,,,,18.06311231,Malawi HBP,18.06311231,18.0631123,18.0631123,81.2329104,81.2329104,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,180,"Mental, Neurological and Substance use disorders",Treatment,Treatment of extrapyramidal side effects of neuroleptic drugs,Treatment of extrapyramidal side effects of neuroleptic drugs,Treatment of extrapyramidal side effects of neuroleptic drugs,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,181,"Mental, Neurological and Substance use disorders",Treatment,Substance use disorder - alcohol,Substance use disorder - alcohol,Substance use disorder - alcohol,,Mental Health Clinic Visit,Secondary,Substance use disorder - alcohol,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,Brief advice on alcohol use in primary care including education and psychosocial counselling (30% coverage),None,0.000461,0.38,Int $ (2005),0.000461,0.38,0.040228228,16.99733145,422.522,Yes,2005 Int$,Total population,"179,478",6.00%,1.00%,Total population," 18,898,441 ",1.16%,GBD NCD,219221.9156,1.00%,30.00%,3%,Mental health team estimate,1%,,,,,0.035938809,Malawi HBP - Diazepam and Themine,0.035938809,0.03593881,0.03593881,1.397532,1.397532,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,182,"Mental, Neurological and Substance use disorders",Treatment,Substance use disorder - cannabis,Substance use disorder - cannabis,Substance use disorder - cannabis,,,Teritary,Substance use disorder - cannabis,,,,0,,,,,,,,,,,,,Total population,"179,478",1.00%,,Total population," 18,898,441 ",0%,GBD NCD,47246.1025,1.00%,,3%,Mental health team estimate,1%,,,,,,,0,11.9351757,11.9351757,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,183,"Mental, Neurological and Substance use disorders",Treatment,Substance use disorder - opioid,Substance use disorder - opioid,Substance use disorder - opioid,,,,,,,,,,,,,,,,,,,,,,,,,Total population," 18,898,441 ",0%,GBD NCD,11339.0646,,,,,,,,,,,,,,,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,184,"Mental, Neurological and Substance use disorders",Treatment,Substance use disorder - heroin,Substance use disorder - heroin,Substance use disorder - heroin,,,,,,,,,,,,,,,,,,,,,,,,,Total population," 18,898,441 ",0%,GBD NCD,13228.9087,,,,,,,,,,,,,,,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,185,"Mental, Neurological and Substance use disorders",Treatment,Smoking cessation,Smoking Cessation interventions,Prevention and treatment of exacerbations through smoking cessation,,Mental Health Clinic Visit,,Smoking Cessation interventions,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Stanciole (2012); BMJ,per capita,Prevention and treatment of exacerbations through smoking cessation,None,0.00002,0.391792,Int $ (2005),0.00002,0.391792,0.000180759,1.815067068,10041.365,Yes,2005 Int$,,,,60.59%,Total population," 18,898,441 ",11.20%,STEPS 2017,2116625.392,,15.00%,1%,Estimate,1%,0,0,0,0,,,0,,0,0,0,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,186,"Mental, Neurological and Substance use disorders",Treatment,Brief Intervention for Substance Use,Brief Intervention for Substance Use,Brief Intervention for Substance Use,,,Primary,,,,,,,,,,,,,,,,,,,,,,Total population," 18,898,441 ",7%,SUM use disorders,1322890.87,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,187,"Mental, Neurological and Substance use disorders",Treatment,"Psychotherapy (PST, CBT)","Basic psychosocial support, advice, and follow-up",Maintenance psychosocial treatment (including antidepressants),Treatment of depression,Mental Health Clinic Visit,Secondary,"Basic psychosocial support, advice, and follow-up",,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Chisholm (2012); BMJ,per capita,Maintenance psychosocial treatment plus newer antidepressants (50% coverage),None,0.001526,2.02,Int $ (2005),0.001526,2.02,0.010297961,6.987394219,678.522,Yes,2005 Int$,Population with mental health disorders,-,0.00%,100.00%,Total population," 18,898,441 ",15.00%,GBD mental health,2834766.15,,10.00%,10%,Mental health team estimate,10%,0,0,7.225455305,7.225455305,,,7.225455305,,7.225455305,4.722738,4.722738,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,25,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,188,"Mental, Neurological and Substance use disorders",Treatment,Electroconvulsive Therapy,Electroconvulsive Therapy,Electroconvulsive Therapy,,,Teritary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,189,Neglected Tropical Disease,Diagnosis,Schistosomiasis diagnosis through urine and stools microscopy,Schistosomiasis diagnosis through urine and stools microscopy,Schistosomiasis diagnosis through urine and stools microscopy,,,Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.015848,1.015848,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,190,Neglected Tropical Disease,Treatment,Onchocerciasis mass drug administration,Onchocerciasis mass drug administration,Onchocerciasis mass drug administration,,,Primary,Onchocerciasis mass drug administration,,,"Coffeng et al, 2013.  ICER implied from total cost $47.9m and DALYs averted 2.13m in 2015, table 2",0,Ivermectin mass treatment,,,,,0,,0,,,,,,,,9.68%,Population in high risk areas," 2,237,526 ",100%,NTD direct entry,2237526,,80.00%,100%,If done as mass administration,100%,0,0,0,0,3.6829,Malawi HBP,3.6829,4.31640709,4.31640709,0,0,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,191,Neglected Tropical Disease,Treatment,Schistosomiasis mass drug administration,Schistosomiasis Mass drug administration (adults),Schistosomiasis mass drug administration (adults),,Community-based intervention,Primary,Schistosomiasis Mass drug administration (adults),,Cote d'Ivoire,Lo (2015); Lancet Glob Health,0,Annual mass drug administration for protection against schistosomiasis and/or soil-transmitted helminthiasis (praziquantel and albendazole),None,,,,0.121465,14.840118,0.121465,15.01819942,123.642,,,,,,25.23%,Population in high risk areas," 7,522,447 ",100.00%,NTD direct entry,7522447,100.00%,80.00%,100%,If done as mass administration,100%,0.359016447,0.359016447,0.359016447,0.359016447,,,0.359016447,,0.359016447,0.991296,0.991296,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,192,Neglected Tropical Disease,Treatment,Schistosomiasis mass drug administration,STH mass drug administration in school children,Schistosomiasis mass drug administration (school children),Schistosomiasis Mass drug administration (adults),Community-based intervention,,STH mass drug administration in school children,added from Uganda HBP,Cote d'Ivoire,Lo (2015); Lancet Glob Health,0,Annual mass drug administration for protection against schistosomiasis and/or soil-transmitted helminthiasis (praziquantel and albendazole),None,,,,0.148205,1.842588,0.148205,1.864699056,12.582,,,,,,44.06%,Direct entry from NTD," 2,847,188 ",100.00%,NTD direct entry,2847188,100.00%,80.00%,100%,If done as mass administration,100%,0,0,0,0,0.359016447,Assumed to be the same as the cost of drug administration for adults - Uganda OHT,0.359016447,,0.359016447,0.991296,0.991296,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,193,Neglected Tropical Disease,Treatment,Schistosomiasis treatment,Schistosomiasis treatment,Schistosomiasis treatment,,,Primary,,,,,,,,,,,,,,,,,,,,,,Total population x incidence," 18,898,441 ",3%,GBD NTD,510257.907,,,60%,,60%,,,,,,,,,,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,194,Neglected Tropical Disease,Treatment,LF hydrocele surgery,LF hydrocele surgery,LF hydrocele surgery,,,Secondary,LF hydrocele surgery,,,,0,,,,,,,,,,,,,Direct entry,18,100.00%,5.00%,Direct entry from NTD," 649,214 ",100%,,649214,100.00%,5.00%,100%,Due to severity,100%,0,0,0,39.48183645,,,39.48183645,0,0,1.732296,1.732296,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,195,Neglected Tropical Disease,Treatment,Lymphoedema management,LF lymphoedema management,Lymphoedema management,,,Primary,LF lymphoedema management,,,,0,,,,,,,,,,,,,,,,5.00%,Direct entry from NTD," 669,292 ",100%,,669292,,5.00%,60%,Ng'ambi 2020 adults,60%,114.6283667,114.6283667,114.6283667,114.6283667,,,114.6283667,,114.6283667,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,196,Neglected Tropical Disease,Treatment,Lymphoedema management,LF mass drug administration,Lymphoedema management,,,Primary,LF mass drug administration,,,"Remme et al, DCPN2 2006, Table 22.2",0,Control through mass drug administration,,,,,0,,0,,,,,,,,35.79%,Direct entry from NTD," 669,292 ",100%,,669292,,80.00%,100%,If done as mass administration,100%,0.117951861,0.117951861,0.117951861,0.117951861,,,0.117951861,,0.117951861,0,0,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,197,Non-Communicable Disease and Injury,Screening and Diagnosis for NCD,Screening and diagnosis for NCD,Screening and diagnosis for NCD,Screening and diagnosis for NCD,,,Secondary,,Too broad,,,,,,,,,,,,,,,,,,,,Total population," 18,898,441 ",100%,,18898441,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,198,Non-Communicable Disease and Injury,Treatment and Management NCD,Hypertension,Hypertension,Hypertension,,Over 5 Outpatient visit,Secondary,Hypertension,,Ethiopia,Tolla (2016); Cost Eff Resour Alloc,per capita,Primary prevention of ischemic heart disease and stroke: anti-hypertension treatment for systolic blood pressure >160 mmHg,None,0.001019802,0.075598185,United States (2012); currency year stated,0.001019802,0.075598185,0.012373794,1.033766146,83.545,Yes,2012 US$,Adults 40+,"28,554",32.90%,,Adults 18+ x prevalence," 9,672,513 ",16.30%,STEPS 2017,1576619.619,48.00%,,50%,NCD unit,48%,,,,,,,0,0,0,9.3710124,9.3710124,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,199,Non-Communicable Disease and Injury,Treatment and Management NCD,Monitoring treatment for hypertension,community-based management of hypertension,Community monitoring of hypertension,Hypertension,Community-based intervention,,community-based management of hypertension,,South Africa,Gaziano (2014); BMC Public Health,0,"Community health workers (CHW) visit patients twice yearly to increase hypertension adherence by monitoring blood pressure, teaching them about healthy lifestyle choices and encouraging follow-up visits",Standard/Usual Care,,,,0.0205,7.30784,0.0205,7.39553408,360.758,,,Hypertensive adults,,,100.00%,Adults 18+ x prevalence," 9,672,513 ",16.30%,STEPS 2017,1576619.619,48.00%,50.00%,50%,NCD unit,48%,,,,,0.000001,No drug costs,0.000001,,0.000001,9.3710124,9.3710124,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,200,Non-Communicable Disease and Injury,Treatment and Management NCD,Diabetes Type I,Diabetes Type I,Diabetes Type I,,,Secondary,Diabetes Type I,,,,0,,,,,,,,,,,,,Adults 40+,"28,554",0.90%,,Adults 15+ x prevalence," 10,989,159 ",1%,GBD NCD/STEPS 2017,98902.431,48.00%,,50%,NCD unit,48%,,,,,,,0,593.851605,593.851605,248.248428,248.248428,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,201,Non-Communicable Disease and Injury,Treatment and Management NCD,Diabetes Type II,Diabetes Type II,Diabetes Type II,,,Secondary,Diabetes Type II,,,,0,,,,,,,,,,,,,Adults 40+,"28,554",5.60%,,Adults 18+ x prevalence," 9,672,513 ",2%,GBD NCD/STEPS 2017,187646.7522,48.00%,,50%,NCD unit,48%,,,,,,,0,96.8298652,96.8298652,105.136692,105.136692,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,202,Non-Communicable Disease and Injury,Treatment and Management NCD,Systems inputs for diabetes,Diabetes Type I,Diabetes Type I,,,,Diabetes Type I,,,,0,,,,,,,,,,,,,Adults 40+,"28,554",0.90%,,Adults 15+ x prevalence," 10,989,159 ",1%,GBD NCD/STEPS 2017,98902.431,48.00%,,50%,NCD unit,48%,,,,,,,0,593.851605,593.851605,248.248428,248.248428,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,203,Non-Communicable Disease and Injury,Treatment and Management NCD,Systems inputs for diabetes,Diabetes Type II,Diabetes Type II,,,,Diabetes Type II,,,,0,,,,,,,,,,,,,Adults 40+,"28,554",5.60%,,Adults 18+ x prevalence," 9,672,513 ",2%,GBD NCD/STEPS 2017,187646.7522,48.00%,,50%,NCD unit,48%,,,,,,,0,96.8298652,96.8298652,105.136692,105.136692,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,204,Non-Communicable Disease and Injury,Treatment and Management NCD,High cholesterol,Prevention and treatment of cardiovascular disease,Prevention and treatment of cardiovascular disease,,Over 5 Outpatient visit,Secondary,Prevention and treatment of cardiovascular disease,,Uganda,Ortegón (2012); BMJ,0,Preventive multidrug treatment for >35% risk of CVD event + multidrug treatment of acute myocardial infarction & post-acute ischemic heart disease & stroke + diuretics & exercise for coronary heart failure,None,,,,0.005265,0.282993748,0.005265,0.286389673,54.395,,,,,,100.00%,Adults 18+ x prevalence," 9,672,513 ",16.30%,STEPS 2017,1576619.619,,5.00%,50%,NCD unit,50%,,,,,30.22351153,"Cost taken from Uganda OHT (each component of cost is weighted by the prevalence of the specific condition from GBD data, IHME 2013,2014)",30.22351153,,30.22351153,234.210276,234.210276,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,205,Non-Communicable Disease and Injury,Treatment and Management NCD,Ischemic heart disease,Ischemic heart disease,Ischemic heart disease,,,Secondary,,,,,,,,,,,,,,,,,,Adults 40+,"28,554",5.00%,,Adults 18+ x prevalence," 9,672,513 ",1%,GBD NCD,84150.8631,23.00%,,25%,NCD unit,23%,,,,,,,,0.10414588,0.10414588,233.764344,233.764344,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,206,Non-Communicable Disease and Injury,Treatment and Management NCD,Sickle Cell Anemia,Sickle Cell Anemia,Sickle Cell Anemia,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Total population x prevalence," 18,898,441 ",0%,GBD NCD,3779.6882,,,,,,,,,,,,,,,77.067768,77.067768,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,207,Non-Communicable Disease and Injury,Treatment and Management NCD,Treatment for those with cerebrovascular disease and post-stroke,Treatment for those with cerebrovascular disease and post-stroke,Treatment for those with cerebrovascular disease and post-stroke,,,Secondary,Treatment for those with cerebrovascular disease and post-stroke,,,,0,,,,,,,,,,,,,Total population,,0.10%,100.00%,Adults 18+ x prevalence," 9,672,513 ",1%,GBD NCD,87052.617,,5.00%,50%,NCD unit,50%,0,0,44.14007485,44.14007485,,,44.14007485,0,0,257.50917,257.50917,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,208,Non-Communicable Disease and Injury,Treatment and Management NCD,Treatment of cases with rheumatic heart disease ,Treatment of cases with rheumatic heart disease ,Treatment of cases with rheumatic heart disease ,,,Secondary,Treatment of cases with rheumatic heart disease ,,,,0,,,,,,,,,,,,,People 5-19,,3.40%,6.40%,Total population x prevalence," 18,898,441 ",3%,"https://pubmed.ncbi.nlm.nih.gov/27029239/#:~:text=Results%3A%20The%20prevalence%20of%20latent,RHD%20and%202.7%25%20borderline%20RHD.",642546.994,,10.00%,15%,"https://pubmed.ncbi.nlm.nih.gov/27029239/#:~:text=Results%3A%20The%20prevalence%20of%20latent,RHD%20and%202.7%25%20borderline%20RHD.",15%,0,0,7.778689678,7.778689678,,,7.778689678,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,209,Non-Communicable Disease and Injury,Diagnosis and Management of Injuries,Treatment of Injuries (Blunt Trauma - Soft Tissue Injury),Treatment of Injuries (Blunt Trauma - Soft Tissue Injury),Treatment of Injuries (Blunt Trauma - Soft Tissue Injury),,,Secondary,Treatment of Injuries (Blunt Trauma - Soft Tissue Injury),,,,0,,,,,,,,,,,,,Total population,"179,478",0.00%,,Total population x incidence," 18,898,441 ",13%,GBD NCD,2475695.771,100.00%,,,,100%,,,,,,,0,36.4625451,36.4625451,56.019816,56.019816,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,210,Non-Communicable Disease and Injury,Diagnosis and Management of Injuries,Treatment of injuries (Fracture and dislocation),Treatment of injuries (Fracture and dislocation - reduction),Treatment of injuries (Fracture reduction),,Accidents and Emergencies,Secondary,Treatment of injuries (Fracture and dislocation - reduction),,Zambia,Roberts (2016); World J Surg,0,"Fracture/dislocation reduction, using Zambian life expectancy",None,,,,1.611650485,177.2579495,1.611650485,179.3850449,111.305,,,Total Population,,,0.90%,Total population x incidence," 18,898,441 ",0.90%,GBD NCD,170085.969,100.00%,90.00%,90%,due to severity,90%,,,,,5.2,"Cost of medications, and procedure related supplies from Malawi based study (Diab et a., 2019) - https://link.springer.com/article/10.1007/s00268-018-4750-3#appendices
Note that implants were not considered",5.2,,5.2,134.701188,134.701188,New Malawi estimate (2021),1.483516395,11.75712978,8.469782734,29.59540365,23.81342133,3.5,2.099289698,2.099289698,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,211,Non-Communicable Disease and Injury,Diagnosis and Management of Injuries,Treatment of injuries (Fracture and dislocation),Treatment of injuries (Fracture and dislocation - fixation),Treatment of injuries (Fracture fixation),,Accidents and Emergencies,Secondary,Treatment of injuries (Fracture and dislocation - fixation),,Zambia,Roberts (2016); World J Surg,0,"Fracture/dislocation fixation, using Zambian life expectancy",None,,,,1.206896552,452.7949034,1.206896552,458.2284423,379.675,,,Total population,,,0.10%,Total population x incidence," 18,898,441 ",0.10%,GBD NCD,18898.441,100.00%,90.00%,90%,due to severity,90%,,,,,24.90524288,"Cost of traction/nailing from Kamau et al. (2014) - Kenya (Note that only the costs of commodities were included) - https://www.ajol.info/index.php/eaoj/article/view/104541
Data extracted from systematic review - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623315/",24.90524288,,24.90524288,Not available,24.90524288,Uganda estimate (2020),1.483516395,11.75712978,8.469782734,29.59540365,23.81342133,3.5,2.099289698,2.099289698,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,212,Non-Communicable Disease and Injury,Diagnosis and Management of Injuries,Rehabilitation from injuries,Rehabilitation from injuries,Rehabilitation from injuries,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Total population x incidence," 18,898,441 ",1%,GBD NCD,188984.41,,,70%,due to severity,70%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,213,Non-Communicable Disease and Injury,Screening for oncologic processes,Screening: Mammography,Breast Cancer (mammography + treatment),Screening: Mammography,,Mammography,Teritary,Breast Cancer (mammography + treatment),,Uganda,Ginsberg (2012); BMJ,0,"Optimal  programme- treatment of stages I-IV cancer, plus biannual mammographic screening for 50-70 years",None,,,,0.000501,0.497521266,0.000501,0.503491521,1004.973,,,Women 50-70,,,100.00%,Females 40+," 1,746,757 ",0.07%,GBD NCD,1222.7299,,50.00%,50%,NCD unit,50%,,,,,397.7373403,"Cost of screening, treatment and post-treatment surveillance from Uganda OHT; Weighted average of treatment costs taken across stages of cancer based on distribution for Ghana in Zelle et al. (2012) - https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3156.2012.03021.x",397.7373403,,397.7373403,0.876672,0.876672,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,214,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Breast Cancer (clinical examination + treatment),0,,,,Breast Cancer (clinical examination + treatment),added from Uganda HBP,Ghana,Zelle (2012); Trop Med Int Health,0,"Biennial clinical breast examination (CBE) screening + Treatment of breast cancer, stages I-IV",None,,,,3.532058493,5467.594722,3.532058493,5533.205859,1566.567,,,Women 40-69,,,100.00%,Females with breast cancer," 1,254 ",100%,from 217,1254,,50.00%,50%,NCD unit,50%,,,,,392.5116564,"Cost of screening (zero cost for CBE), treatment and post-treatment surveillance from Uganda OHT; Weighted average of treatment costs taken across stages of cancer based on distribution for Ghana in Zelle et al. (2012) - https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3156.2012.03021.x",392.5116564,,392.5116564,Not available,392.5116564,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - only 213 retained because we are not estimating examination cost,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,215,Non-Communicable Disease and Injury,Screening for oncologic processes,Screening: Cervical Cancer,Cervical cancer screening,Screening: Cervical Cancer,,,Primary,Cervical cancer screening,,Uganda,Ginsberg (2012); BMJ,0,Smear test for detection of cervical cancer every five years for ages 20-65 + HPV vaccine from age 12 + cancer treatment,None,,,,0.000934,0.328637901,0.000934,0.332581555,356.083,,,,,,33.00%,Females 25-49," 3,728,679 ",33%,every 3 years,1230464.07,,70.00%,50%,NCD unit,50%,0,0,0.376967269,0.376967269,,,0.376967269,,0.376967269,3.537432,3.537432,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - the CE evidence is on a compound intervention,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,216,Non-Communicable Disease and Injury,Treatment for oncologic processes,Breast Cancer (first line),Breast Cancer (first line),Breast Cancer (first line),,Over 5 Outpatient visit,Teritary,Breast Cancer (first line),,Ghana,Zelle (2012); Trop Med Int Health,0,Basic palliative care (BPC) for breast cancer,None,,,,0.38556701,7418.083893,0.38556701,7507.100899,19470.288,,,Women with breast canccer (prevalence),"5,157",0.00%,100.00%,Females with breast cancer," 1,254 ",100.00%,from 217,1254,100.00%,10.00%,100%,Once discovered severe so all treat,100%,235.7097549,235.7097549,235.7097549,235.7097549,,,235.7097549,245.78777,245.78777,3100.121292,3100.121292,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2012-01-01073-08,"Treatment of breast cancer, stages I-IV","Treatment of breast cancer, stages I-IV",,None,Ghana,3219,3883.30502,0,0,0,12183300,0,0,0,0,Zelle,2012,United States,2009,,,,,,,,,,
,217,Non-Communicable Disease and Injury,Treatment for oncologic processes,Hormal Theray,Hormal Theray,Hormonal Therapy,,,,,,,,,,,,,,,,,,,,,,,,,Females with breast cancer," 1,254 ",100%,from 217,1254,,,100%,Once discovered severe so all treat,100%,,,,,,,,,,15.0081408,15.0081408,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,218,Non-Communicable Disease and Injury,Treatment for oncologic processes,HER2,HER2,HER2,,,,,,,,,,,,,,,,,,,,,,,,,Females with breast cancer," 1,254 ",100%,from 217,1254,,,100%,Once discovered severe so all treat,100%,,,,,,,,,,0,0,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,219,Non-Communicable Disease and Injury,Treatment for oncologic processes,Cervical cancer (first line),Cervical cancer (first line),Cervical cancer (first line),,Radiotherapy,,Cervical cancer (first line),,Uganda,Ginsberg (2012); BMJ,0,"Treatment of invasive cervical cancer by surgery, chemotherapy, and/or radiotherapy",None,,,,0.000606,0.109545967,0.000606,0.110860518,182.938,,,Women with cervical cancer (incidence),"51,570",0.00%,100.00%,Females 25-49," 3,728,679 ",0.15%,,5593.0185,100.00%,50.00%,70%,RHU unit,70%,,,,,1154.283251,"Assumed to be the average across cost categories in the Uganda OHT (Cryotherapy, LEEP, stage 1- 4 treatment)",1154.283251,207.644544,207.644544,916.46454,916.46454,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,220,Non-Communicable Disease and Injury,Treatment for oncologic processes,Cervical cancer (first line),Testing of pre-cancerous cells (vinegar),Cervical cancer screening,,STI,,Testing of pre-cancerous cells (vinegar),added from Uganda HBP,Uganda,Campos (2017); Int J Gynaecol Obstet,0,Cervical screening with either HPV testing or visual inspection with acetic acid VIA,None,,,,0.060287081,4.193794258,0.060287081,4.244119789,70.398,,,,-,0.00%,33.00%,Females 25-49," 3,728,679 ",33.00%,every 3 years,1230464.07,,1.00%,50%,NCD unit,50%,2.990098393,2.990098393,2.990098393,2.990098393,,,2.990098393,,2.990098393,916.46454,916.46454,New Malawi estimate (2021),5,4.907896622,1.291582499,1.580052088,6.220468791,0.580052088,0.580052088,0.580052088,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,221,Non-Communicable Disease and Injury,Treatment for oncologic processes,Kaposi sarcoma - first line,Kaposi sarcoma - first line,Kaposi sarcoma - first line,,,,Kaposi sarcoma - first line,,,,0,,,,,,,,,,,,,Total population,"179,478",0.00%,,Direct entry from DHA," 165,000 ",100%,DHA,165000,100.00%,,100%,DHA/severity,100%,,,,,,,0,268.708946,268.708946,364.76514,364.76514,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,222,Non-Communicable Disease and Injury,Treatment for oncologic processes,Kaposi sarcoma - second line,Kaposi sarcoma - second line,Kaposi sarcoma - second line,,,,Kaposi sarcoma - second line,,,,0,,,,,,,,,,,,,Total population,,0.00%,,PLHIV x 2nd line treatment," 165,000 ",5%,DHA,8250,,,100%,DHA/severity,100%,,,,,,,0,302.288784,302.288784,0,0,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,223,Non-Communicable Disease and Injury,Treatment for oncologic processes,"Lymphomas, nonhodgkins","Lymphomas, nonhodgkins","Lymphomas, nonhodgkins",,,,"Lymphomas, nonhodgkins",,,,0,,,,,,,,,,,,,Total population,"179,478",0.00%,,Total population," 18,989,441 ",0%,GBD NCD,,100.00%,,100%,Severity,100%,,,,,,,0,131.761297,131.761297,90.261708,90.261708,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,224,Non-Communicable Disease and Injury,Treatment for oncologic processes,Hodgkin's lymphoma,Hodgkin's lymphoma,Hodgkin's lymphoma,,,,Hodgkin's lymphoma,,,,0,,,,,,,,,,,,,Total population,"179,478",0.00%,,Total population," 18,989,441 ",0%,GBD NCD,17090.4969,100.00%,,100%,Severity,100%,,,,,,,0,1197.98887,1197.98887,688.545384,688.545384,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,225,Non-Communicable Disease and Injury,Treatment for oncologic processes,Head and neck cancer (esophageal),Head and neck cancer (esophageal),Head and neck cancer (esophageal),,,,Head and neck cancer (esophageal),,,,0,,,,,,,,,,,,,Adults 15+,"103,357",0.00%,,Total population," 18,989,441 ",0%,GBD NCD,28484.1615,100.00%,,100%,Severity,100%,,,,,,,0,139.603604,139.603604,50650.68947,50650.68947,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,226,Non-Communicable Disease and Injury,Treatment for oncologic processes,"GIT, intestine cancer","GIT, intestine cancer","GIT, intestine cancer",,Major Surgical Procedures,,"GIT, Intestine cancer",,Uganda,Ginsberg (2012); BMJ,0,Annual faecal occult blood test + sigmoidoscopy every 5 years (with surgical removal of polyps) + cancer treatment,None,,,,0.001153,0.502085681,0.001153,0.50811071,440.686,,,Total population,"179,478",0.00%,100.00%,Total population," 18,989,441 ",0.02%,GBD NCD,3797.8882,100.00%,10.00%,100%,Severity,100%,,,,,6.227501361,"Cost is the sum of FOBT screening, sigmoidopscopy screening, median cancer treatment cost and post-treatment surveillance cost from the Uganda OHT. Note that sigmoidoscopy cost has been divided by 5 since it is expected to be carrie out once in 5 years, median colorectal cancer treatment has been scaled to account of prevalence based on GBD data (1,111 cases in 2012) among the screened population.",6.227501361,55.2955091,55.2955091,Not available,55.2955091,Malawi estimate (2016),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,227,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Colorectoral cancer (screening + treatment),Colorectoral cancer (screening + treatment),,Major Surgical Procedures,,Colorectoral cancer (screening + treatment),added from Uganda HBP,Uganda,Ginsberg (2012); BMJ,0,Colonoscopy at age 50 (with surgical removal of polyps)+ cancer treatment,None,,,,0.001115,0.296686994,0.001115,0.300247237,269.280,,,Total Population (50 years),,,100.00%,Total population," 18,989,441 ",0.01%,GBD NCD,1898.9441,100.00%,10.00%,100%,Severity,100%,,,,,5.325572265,,5.325572265,,5.325572265,Not available,5.325572265,Uganda estimate (2020),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,228,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Colorectoral cancer (treatment),Colorectoral cancer (treatment),,Major Surgical Procedures,,Colorectoral cancer (treatment),added from Uganda HBP,Uganda,Ginsberg (2012); BMJ,0,"Cancer treatment by surgery, chemotherapy, and/or radiotherapy",None,,,,0.000792,0.123239213,0.000792,0.124718083,157.472,,,People with colorectoral cancer (incidence),,,100.00%,People with colorectoral cancer," 18,989,441 ",0.01%,GBD NCD,1898.9441,100.00%,100.00%,100%,Severity,100%,,,,,680.53562,,680.53562,,680.53562,Not available,680.53562,Uganda estimate (2020),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,229,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Emergency inguinal hernia repair,Emergency inguinal hernia repair,Ingunial hernia repair,Major Surgical Procedures,,Emergency inguinal hernia repair,added from Uganda HBP,Zambia,Roberts (2016); World J Surg,0,"Emergency inguinal hernia repair, using Zambian life expectancy",None,,,,35.83333333,265.8561,35.83333333,269.0463732,7.508,,,Total population,,,0.00%,Total population x strangulated incidence," 18,898,441 ",1.75%,GBD NCD,330722.7175,,90.00%,100%,Severity,100%,,,,,91.53,"Interoperative and post operative variable costs (excluding personnel) taken from Ghana study - Shillcutt et al., 2010 - https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/archsurg.2010.208",91.53,,91.53,38.686251,38.686251,New Malawi estimate (2021),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,230,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Elective inguinal hernia repair,Elective inguinal hernia repair,Ingunial hernia repair,Major Surgical Procedures,,Elective inguinal hernia repair,added from Uganda HBP,Zambia,Roberts (2016); World J Surg,0,"Elective inguinal hernia repair, using Zambian life expectancy",None,,,,6.125,163.9626975,6.125,165.9302499,27.091,,,Total population,,,0.00%,Total population," 18,989,441 ",3.65%,GBD NCD,693114.5965,,50.00%,50%,,50%,,,,,91.53,"Interoperative and post operative variable costs (excluding personnel) taken from Ghana study - Shillcutt et al., 2010 - https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/archsurg.2010.208",91.53,,91.53,38.686251,38.686251,New Malawi estimate (2021),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,231,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Retinopathy Screening and photocoagulation for diabetics,Retinopathy Screening and photocoagulation for diabetics,,Tomography,,Retinopathy Screening and photocoagulation for diabetics,added from Uganda HBP,Uganda,Ortegón (2012); BMJ,0,Retinopathy screening + photocoagulation + intensive glycaemic control,None,,,,0.001529,1.446919645,0.001529,1.464282681,957.673,,,People with diabetes,"1,590",100.00%,100.00%,People with diabetes (calc from above)," 286,936 ",100.00%,,286936,10.00%,10.00%,50%,if in treatment would be good uptake,10%,0,0,1.03316257,1.03316257,,,1.03316257,,1.03316257,Not available,1.03316257,Uganda estimate (2020),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,"Check with MOH whether this should be dropped from analysis. Comment from Emi - ""This is also mostly equipment and health care worker time; not sure how to include""",,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,232,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Prevention of cardiovascular disease,Prevention of cardiovascular disease,,Over 5 Outpatient visit,,Prevention of cardiovascular disease,added from Uganda HBP,Uganda,Ortegón (2012); BMJ,0,Preventive multidrug treatment for >35% risk of cardiovascular event,None,,,,0.003163,0.150625704,0.003163,0.152433213,48.193,,,,,,100.00%,People with hypertension (calc from above)," 1,576,620 ",100.00%,,1576620,,5.00%,5%,,5%,0,27.39771683,27.39771683,27.39771683,,,27.39771683,,27.39771683,3.405612,3.405612,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,233,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Amputation,Amputation,,Major Surgical Procedures,,Amputation,added from Uganda HBP,Zambia,Roberts (2016); World J Surg,0,"Amputation, using Zambian life expectancy",None,,,,21.26086957,637.5906348,21.26086957,645.2417224,30.349,,,Total population,,,0.00%,," 18,989,441 ",0.003%,GBD,569.68323,,90.00%,90%,Severity,90%,,,,,778.2155,"Costs included : Analgesia (IV and oral), Antibiosis (IV and oral), lab tests, impaging studies, cost of crutches
Source - Thompson et al. (2019) diabetes-related lower limb amputations at a single district hospital in KwaZulu-Natal - https://www.tandfonline.com/doi/full/10.1080/16089677.2020.1782007",778.2155,,778.2155,150.928248,150.928248,New Malawi estimate (2021),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,234,Non-Communicable Disease and Injury,Treatment for oncologic processes,,Fistula,Fistula repair surgery,,Major Surgical Procedures,,Fistula,added from Uganda HBP,Uganda,Epiu (2018); Health Policy Plan,0,Fistula repair surgery,None,,,,7.02,402.6126,7.02,407.4439512,58.040,,,Women of reproductive age (15-49),,,0.10%,Women of reproductive age (15-49)," 4,799,004 ",0.14%,GBD maternal,6718.6056,,26.00%,50%,,50%,,,,,48.705,Epiu et al (2018) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263022/ - only medicines and consumables costs were considered,48.705,,48.705,59.170986,59.170986,New Malawi estimate (2021),180,180,72,108,0,5,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,235,Nutrition,Diagnosis/nutrition assessment,Diagnosis/ assessment,Diagnosis/ assessment,Diagnosis/ assessment,,,Primary,,This is too broad,,,,,,,,,,,,,,,,,,,,"Children 0-15, pregnant/lactating women",,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,236,Nutrition,Prevention of vitamin A defficiency in children,Vitamin A supplementation in infants and children 6-59 months,Vitamin A supplementation in infants and children 6-59 months,Vitamin A supplementation in infants and children 6-59 months,,Antenatal Care - Followup Visit,Primary,Child Days Plus (CDP): month-long outreach activity distributing vitamin A capsules to preschool children,,Uganda,Fiedler (2014); Food Nutr Bull,0,Child Days Plus (CDP): month-long outreach activity distributing vitamin A capsules to preschool children and deworms children 6 months-14 years old,None,,,,0.009747506,0.711624178,0.009747506,0.720163668,73.882,,2010 US$,Children 0-4 years,"23,245",58.80%,100.00%,Children 0-59 months," 2,888,984 ",100.00%,,2888984,94.00%,50.00%,94%,EPI program,94%,0.099726791,0.099726791,0.099726791,0.099726791,,,0.099726791,0,0,0.072744,0.072744,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,237,Nutrition,treatment of intestinal worms/Deworming,Deworming (children),Deworming (children),Vitamin A supplementation in infants and children 6-59 months + Deworming,,Antenatal Care - Followup Visit,Primary,Child Days Plus (CDP): month-long outreach activity distributing vitamin A capsules to preschool children and deworms children 6 months-14 years old,CE evidence is only available on compund intervention - treat this as a substitute for 236),Uganda,Fiedler (2014); Food Nutr Bull,0,Child Days Plus (CDP): month-long outreach activity distributing vitamin A capsules to preschool children and deworms children 6 months-14 years old,None,,,,0.007986483,1.373675008,0.007986483,1.390159108,174.064,,2010 US$,Children 0-14 years,"76,121",100.00%,100.00%,Children 0-14 years," 7,909,282 ",100.00%,,7909282,77.00%,90.00%,90%,,77%,0,0,0,0,0.022,Fiedler et al. (2014) - https://journals.sagepub.com/doi/pdf/10.1177/156482651403500111,0.022,0.05537116,0.05537116,0.006528,0.006528,New Malawi estimate (2021),0.291423118,0.291423118,3.130165832,9.229970856,0.708576882,3.5,0.287426935,0.287426935,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,238,Nutrition,Treatment in adults/Nutrition care support and treatment,Management of moderate acute malnutrition (pregnant and lactating women),Management of moderate acute malnutrition (pregnant and lactating women),Management of moderate acute malnutrition (pregnant and lactating women),,,Primary,Management of moderate acute malnutrition (pregnant and lactating women),,,,0,,,,,,,,,,,,,Pregnant women,"6,760",9.00%,100.00%,Pregnant women," 949,472 ",,,,62.00%,95.00%,60%,Estimate from Ng'ambi 2020/program,60%,,,,,43.9690434,Uganda OHT,43.9690434,44.0926408,44.0926408,38.532864,38.532864,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,239,Nutrition,Treatment in adults/Nutrition care support and treatment,Management of severe acute malnutrition (pregnant and lactating women),Management of moderate acute malnutrition (pregnant and lactating women),Management of severe acute malnutrition (pregnant and lactating women),,,Secondary,Management of moderate acute malnutrition (pregnant and lactating women),,,,0,,,,,,,,,,,,,Pregnant women,"6,760",9.00%,100.00%,Pregnant women," 949,472 ",,,,62.00%,95.00%,60%,Estimate from Ng'ambi 2020/program,60%,,,,,43.9690434,Uganda OHT,43.9690434,44.0926408,44.0926408,Not available,44.0926408,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,240,Nutrition,Treatment in adults/Nutrition care support and treatment,"Nutrition care, support and treatment program for Adolescents and adults","Nutrition care, support and treatment program for Adolescents and adults","Nutrition care, support and treatment program for Adolescents and adults",,,Primary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,52.037184,52.037184,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,241,Nutrition,Treatment in children/community management of acute malnutrition,Management of moderate acute malnutrition (children),Community-based management of moderate acute malnutrition (children),Community-based management of moderate acute malnutrition (children),,Community-based intervention,Community,Community-based management of moderate acute malnutrition (children),,Malawi,Wilford (2012); Health Policy Plan,0,Community-based management of acute malnutrition,None,,,,3.9,208.77156,3.9,211.2768187,54.174,,,,,,20.00%,Children 0-14 x cum incidence MAM," 7,909,282 ",2.70%,DHS/GBD child,213550.614,,35.00%,60%,Estimate from Ng'ambi 2020/program,60%,43.9690434,43.9690434,43.9690434,43.9690434,,,43.9690434,,43.9690434,79.2,79.2,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,30,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,242,Nutrition,Treatment in children/community management of acute malnutrition,Management of moderate acute malnutrition (children),Management of moderate acute malnutrition (children),Management of moderate acute malnutrition (children),,,Secondary,,,,,,,,,,,,,,,,,,Children 1-59 months,"25,313",2.40%,,Children 0-14 x cum incidence MAM," 7,909,282 ",3%,DHS/GBD child,213550.614,86.00%,,60%,Estimate from Ng'ambi 2020/program,60%,,,,,,,,0,0,79.2,79.2,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,243,Nutrition,Treatment in children/community management of acute malnutrition,Management of severe malnutrition (children),Management of severe malnutrition (children) - inpatient,Management of severe malnutrition (children),Management of severe malnutrition (children) - inpatient,Treatment of U5 Severe Malnutirion,Secondary,Management of severe malnutrition (children) - inpatient,,Bangladesh,Puett (2013); Health Policy Plan,0,Inpatient treatment for severe acute malnutrition,None,,,,2.38857,609.44,2.38857,616.75328,258.210,,,Children 6-59 months,,,4.90%,Children 0-14 x cum incidence SAM," 7,909,282 ",0.60%,DHS/GBD child,47455.692,,35.00%,90%,Higher for severity,90%,51.8977702,51.8977702,51.8977702,94.51512017,,,94.51512017,,94.51512017,9.169056,9.169056,New Malawi estimate (2021),0.343283153,0.91117089,0.514216254,7.656716847,3.827649949,0.057213859,0.071340205,0.25429041,0,0,0,0,0,0,0,0,210,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,244,Nutrition,Treatment in children/community management of acute malnutrition,Management of severe malnutrition (children),Community-based management of severe malnutrition (children),Management of severe malnutrition (children),,,Community,Community-based management of severe malnutrition (children),,Malawi,Wilford (2012); Health Policy Plan,0,Community-based management of acute malnutrition,None,,,,3.9,208.77156,3.9,211.2768187,54.174,,,,,,20.00%,Children 0-14 x cum incidence SAM," 7,909,282 ",1%,DHS/GBD child,47455.692,,35.00%,60%,Estimate from Ng'ambi 2020/program,60%,,,,,130.27,Malawi HBP,130.27,,130.27,Not available,130.27,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,40,0,0,0,0,Yes,NA,NA,NA,NA,NA,remove - repetition,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,245,Nutrition,Micronutrient supplementation,Micronutrient supplementation,Vitamin A supplementation in infants and children 6-59 months,Vitamin-A supplementation,Vitamin A supplementation in infants and children 6-59 months,Over 5 Outpatient visit,Primary,Vitamin A supplementation in infants and children 6-59 months,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Edejer et al. (2005),per capita,Vitamin A supplementation (95%),None,0.001698925,0.442428348,Int $ (2000),0.001698925,0.442428348,0.011249753,1.32674849,117.936,Yes,2000 Int$,Children 6-59 months,"23,245",58.80%,100.00%,Children 0-59 months," 2,888,984 ",100.00%,,2888984,94.00%,50.00%,94%,EPI program,94%,0.099726791,0.099726791,0.099726791,0.099726791,,,0.099726791,0,0,0.072744,0.072744,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,246,Nutrition,Micronutrient supplementation,Micronutrient supplementation,Calcium supplementation,Micronutrient supplementation,,,,Calcium Supplementation,added from Uganda HBP,Tanzania,Robberstad (2007); Cost Eff Resour Alloc,0,Calcium antagonist (Cab),None,,,,0.4,581.196,0.4,588.170352,1470.426,,,,,,100.00%,Children 0-59 months," 2,888,984 ",100%,,2888984,,20.00%,20%,Unsure,20%,10.7704934,10.7704934,10.7704934,10.7704934,,,10.7704934,,10.7704934,Not available,10.7704934,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - the CE evidence is incorrect. No evidence available for calcium supplementation,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,247,Nutrition,GMP,Growth Monitoring,Growth Monitoring,Growth Monitoring,,,Primary,Growth Monitoring,,,,0,,,,,,,,,,,,,,-,0.00%,,Children 6-59 months,,100%,,,,,,,,,,,,,,0,,0,Not available,0,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,248,Nutrition,Micronutrient supplementation,Micronutrient supplementation,Zinc supplementation,Zinc supplementation,,Over 5 Outpatient visit,Primary,Zinc supplementation,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Edejer et al. (2005),per capita,Zinc  supplementation (95%),None,0.000548611,0.067249109,Int $ (2000),0.000548611,0.067249109,0.003632733,0.20166577,55.514,Yes,2000 Int$,,,,100.00%,Children 0-59 months," 2,888,984 ",100.00%,,2888984,,100.00%,94%,EPI program,94%,14.56011145,14.56011145,0,0,,,14.56011145,,14.56011145,0.0108,0.0108,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,249,Nutrition,Micronutrient supplementation,Micronutrient supplementation,Child Days Plus (CDP): month-long outreach activity distributing vitamin A capsules to preschool children and deworms children 6 months-14 years old,Micronutrient supplementation,,,Primary,,,Uganda,Fiedler (2014); Food Nutr Bull,,Child Days Plus (CDP): month-long outreach activity distributing vitamin A capsules to preschool children and deworms children 6 months-14 years old,None,,,,0.01,0.71,0.009747506,0.720163668,73.882,,2010 US$,Children 0-4 years,,,100.00%,Children 0-59 months," 2,888,984 ",100%,,2888984,,95.00%,70%,,70%,,,,,0.022,CE paper - Fiedler et al. (2014) - https://journals.sagepub.com/doi/pdf/10.1177/156482651403500111,0.022,,0.022,Not available,0.022,Uganda estimate (2020),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - repetitive (see intervention 236),,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,250,Nutrition,Micronutrient supplementation,Micronutrient supplementation,Community management of nutrition in under-5 - micronutrient powder,Iron supplementation,,Over 5 Outpatient visit,Community,Community management of nutrition in under-5 - micronutrient powder,added from Uganda HBP,Uganda,Pasricha et al. (2020),0,Provision of a 6-month course of iron-containing daily MNPs to children aged 6 months,Nothing,,,,0.0028,10.6821,0.0028,10.8102852,3860.816,,,Children 0-4 years,,,100.00%,Children 0-59 months," 2,888,984 ",100.00%,,2888984,,95.00%,70%,,70%,,,,,9.9,"Cost of a course of MNPs for Uganda assumed by the CE paper(Pasricha et al., 2020) - see supplementary material, pg 28",9.9,,9.9,5.184,5.184,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,251,Nutrition,Screening/Active case finding,Mass nutrition screening,Provision of supplementary food and nutrition counselling with growth monitoring,Provision of supplementary food and nutrition counselling with growth monitoring,,Over 5 Outpatient visit,Primary,Provision of supplementary food and nutrition counselling with growth monitoring,,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Edejer et al. (2005),per capita,Provision of supplementary food and nutrition counselling with growth monitoring (95%),None,0.000141577,5.900224444,Int $ (2000),0.000141577,5.900224444,0.000937479,17.69351786,18873.500,Yes,2000 Int$,,,,100.00%,Children 0-59 months," 2,888,984 ",100.00%,,2888984,,50.00%,50%,,50%,,,,,42.00536382,CE paper - Edejer et al. (2005) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1285096/,42.00536382,,42.00536382,Not available,42.00536382,Uganda estimate (2020),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,252,Nutrition,Cooking demostrations and feed prepations for Treatment of malnutriton,Food preparation,Food preparation,Food preparation,,,Primary/ Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,253,Nutrition,Monitoring and evaluation Tools,Procurement of CMAM /NCST equipment,Procurement of CMAM /NCST equipment,Procurement of CMAM /NCST equipment,,,Primary/secondary/tertiary,,Not a health intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - this is not a service delivery intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,254,Nutrition,Nutrition waste management,waste disposal,Solid Wastes Disposal,Solid Wastes Disposal,,,Primary/secondary,Solid Wastes Disposal,See intervention 234,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0,,0,Not available,0,Uganda estimate (2020),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,255,Nutrition,Infection prevention in Nutritition Rehabilaitation Units,Procuremant of Protective equipment,Procuremant of Protective equipment,Procuremant of Protective equipment,,,Primary/ Secondary,,Not a health intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - this is not a service delivery intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,256,Nutrition,Clinical Ditetics,Management of and Procurement of anteral and parenteral nutrition equipment,Management of and Procurement of anteral and parenteral nutrition equipment,Management of and Procurement of anteral and parenteral nutrition equipment,,,Secondary,,Not a health intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - this is not a service delivery intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,257,Nutrition,Fortification,Vitamin-A fortification (sugar) and Zinc fortification (wheat),Vitamin-A fortification (sugar) and Zinc fortification (wheat),Vitamin-A fortification (sugar) and Zinc fortification (wheat),,No HRH time,,Vitamin-A fortification (sugar) and Zinc fortification (wheat),added from Uganda HBP,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Edejer et al. (2005),per capita,Vitamin A fortification and Zinc fortification (95%),None,0.002123656,0.040703408,Int $ (2000),0.002123656,0.040703408,0.014062191,0.122060861,8.680,Yes,2000 Int$,Children 0-4 years,,,100.00%,Children 0-59 months," 2,888,984 ",100.00%,,2888984,,95.00%,95%,,95%,,,,,0.021683918,CE paper - Edejer et al. (2005) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1285096/,0.021683918,,0.021683918,0.0384,0.0384,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,258,Nutrition,Fortification,Iron fortification,Iron fortification,Iron fortification,,,,Iron fortification,added from Uganda HBP,Afr-D,Baltussen et al. (2004),per capita,Iron fortification 80-95%,None,0.001919573,0.038698822,Int $ (2000),0.001919573,0.038698822,0.001933777,0.017655351,9.130,Yes,2000 Int$,Total population,,,100.00%,Total Population," 18,989,441 ",100%,,18989441,,60.00%,95%,,95%,,,,,0.046981823,CE paper - Batussen et al. (2004) - https://academic.oup.com/jn/article/134/10/2678/4688367 - Note that costs are actually for Arf-D region,0.046981823,,0.046981823,0.1248,0.1248,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,"remove - more comprehensive intervention added below (Fortification of sugar, oil, maize meal and wheat)",,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,259,Oral Health,Tooth extraction,Management of severe tooth pain - tooth extraction,Management of severe tooth pain - tooth extraction,Management of severe tooth pain - tooth extraction,,,Community/Primary,Management of severe tooth pain - tooth extraction,,,,0,,,,,,,,,,,,,People 4+,"170,326",5.60%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,0.589356,0.589356,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,260,Oral Health,conservative treatment(tooth fillings),Management of mild tooth pain - tooth filling,Management of mild tooth pain - tooth filling,Management of mild tooth pain - tooth filling,,,Secondary,Management of mild tooth pain - tooth filling,,,,0,,,,,,,,,,,,,People 4+,"177,552",3.10%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,0.93702,0.93702,New Malawi estimate (2021),,,,,,,,,,,,0,30,30,15,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,261,Oral Health,conservative treatment(tooth fillings),Atraumatic restorative treatment (ART) ,Atraumatic restorative treatment (ART) ,Atraumatic restorative treatment (ART) ,,,Community,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,262,Oral Health,conservative treatment(tooth fillings),Root canal therapy,Root canal therapy,Root canal therapy,,,Teritary,Root canal therapy,,,,0,,,,,,,,,,,,,People 9+,"138,883",5.60%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,13.031208,13.031208,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,263,Oral Health,management of maxillofacial fractures,Intermaxillary Fixation,Intermaxillary Fixation,Intermaxillary Fixation,,,Secondary,Intermaxillary Fixation,,,,0,,,,,,,,,,,,,People 12+,"135,324",0.40%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,47.344824,47.344824,New Malawi estimate (2021),,,,,,,,,,,,0,60,30,15,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,264,Oral Health,management of maxillofacial fractures,Bone plating,Bone plating,Bone plating,,,Teritary,Bone plating,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.40%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,47.344824,47.344824,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,265,Oral Health,management of maxillofacial fractures,Intraoseous wiring,Intraoseous wiring,Intraoseous wiring,,,Teritary,Intraoseous wiring,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.40%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,47.344824,47.344824,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,266,Oral Health,management of dental alveolar fractures,Tooth splinting,Tooth splinting,Tooth splinting,,,Secondary,Tooth Splinting,,,,0,,,,,,,,,,,,,People 4+,"187,996",0.40%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,47.390052,47.390052,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,267,Oral Health,management of cyst of the jaws,Enucleation and marsupulization of dental cysts,Enucleation and marsupulization of dental cysts,Enucleation and marsupulization of dental cysts,,,Teritary,Enucleation and marsupulization of dental cysts,,,,0,,,,,,,,,,,,,Total population,"211,151",0.40%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,0.167208,0.167208,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,268,Oral Health,management of facial tumours,Excision and incisional biopsy of dental tumors,Excision and incisional biopsy of dental tumors,Excision and incisional biopsy of dental tumors,,,Teritary,Excision and incisional biopsy of dental tumors,,,,0,,,,,,,,,,,,,Total population,"211,151",0.40%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,0.12198,0.12198,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,269,Oral Health,management of facial infections,Incision and drainage of dental abscess,Incision and drainage of dental abscess,Incision and drainage of dental abscess,,,Secondary,Incision and drainage of dental abscess,,,,0,,,,,,,,,,,,,Total population,"211,151",0.40%,,Total Population >5," 16,009,457 ",,,,100.00%,,,,100%,,,,,,,0,0,0,1.842516,1.842516,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,270,Oral Health,management of edentulousness,Denture,Denture,Denture,,,Teritary,Denture,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.00%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,4.20504,4.20504,New Malawi estimate (2021),,,,,,,,,,,,0,54,0,18,0,0,0.8,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,271,Oral Health,management of edentulousness,Tooth implants,Tooth implants,Tooth implants,,,Teritary,Tooth Implants,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.00%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,0.031524,0.031524,New Malawi estimate (2021),,,,,,,,,,,,0,90,0,100,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,272,Oral Health,management of edentulousness,Tooth crown and bridge,Tooth crown and bridge,Tooth crown and bridge,,,Teritary,Tooth crown and bridge,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.00%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,24.335352,24.335352,New Malawi estimate (2021),,,,,,,,,,,,0,54,0,18,0,0,0.8,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,273,Oral Health,management of maloclusion,Orthodontic appliances,Orthodontic appliances,Orthodontic appliances,,,Teritary,Orthodontic appliances,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.00%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,6.882012,6.882012,New Malawi estimate (2021),,,,,,,,,,,,0,54,0,18,0,0,0.8,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,274,Oral Health,management of maloclusion,fixed orthodontic Appiance,Orthodontic appliances,fixed orthodontic Appiance,,,Teritary,Orthodontic appliances,,,,0,,,,,,,,,,,,,Adults 18+,"109,606",0.00%,,Total Population 18+," 9,674,513 ",,,,100.00%,,,,100%,,,,,,,0,0,0,0,0,New Malawi estimate (2021),,,,,,,,,,,,0,54,0,18,0,0,0.8,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,275,Oral Health,prevention of dental caries,Topical tooth fluoride application,Topical tooth fluoride application,Topical tooth fluoride application,,,Community/Primary,Topical tooth fluoride application,,,,0,,,,,,,,,,,,,,,,,Total Population >5," 16,009,457 ",,,,,,,,,,,,,,,0,0,0,0.090456,0.090456,New Malawi estimate (2021),,,,,,,,,,,,0,30,30,15,0,0,0,0,0,0,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,276,Respiratory disease including COVID-19,Screening and Diagnosis,Pulse oximetry,Pulse oximetry,Pulse oximetry for pneumonia among children,,,Community/Primary/Secondary/Tertiary,,"This intervention is on top of pneumoia diagnosis, i.e. if pneumonia diagnosis is not included in the package, the data for this intervention does not hold",,,,Pulse oximetry with integrated management of childhood illness,,,,,,,,,,,,,,,,Total Population," 16,009,457 ",,,,,,,,,,,,,,,,,,0.323544,0.323544,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - equipment-based intervention,2015-01-02313-09,Pulse oximetry with integrated management of childhood illness,Pulse oximetry in addition to World Health Organization (WHO) guidelines for integrated management of childhood illness (IMCI) to diagnose pneumonia cases as severe or non-severe,,Other,Uganda,11.73,13.03181716,0,0,0,0,0,0,0,0,Floyd,2015,United States,2013,Evaluating the impact of pulse oximetry on childhood pneumonia mortality in resource-poor settings,,,,,,,,,
,277,Respiratory disease including COVID-19,Screening and Diagnosis,PFT,PFT,PFT,,,Community/Primary/Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population with asthma symptoms,,,,,,,,,,,,,,,,,,,0.323544,0.323544,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,278,Respiratory disease including COVID-19,Screening and Diagnosis,Xray,Xray,Xray,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population with asthma symptoms,,,,,,,,,,,,,,,,,,,0.323544,0.323544,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,279,Respiratory disease including COVID-19,Treatment,Asthma,Asthma: Inhaled short acting beta agonist for intermittent asthma,Asthma: Inhaled short acting beta agonist for intermittent asthma,,Over 5 Outpatient visit,Primary/Secondary,Asthma: Inhaled short acting beta agonist for intermittent asthma,,Uganda,Stanciole (2012); BMJ,per capita,Inhaled bronchodilator,None,0.000058,0.749047,Int $ (2005),0.000058,0.749047,0.001505398,9.965511572,6619.851,Yes,2005 Int$,People with asthma,,,16.00%,Total Population x prevalence asthma," 18,898,441 ",3.90%,https://thorax.bmj.com/content/62/9/758,737039.199,,36.00%,50%,NCD unit,50%,0,0,18.01813792,18.01813792,,,18.01813792,,18.01813792,54.552,54.552,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,280,Respiratory disease including COVID-19,Treatment,COPD,COPD - Inhaled salbutamol,COPD - Inhaled salbutamol,,Over 5 Outpatient visit,Primary/Secondary,COPD - Inhaled salbutamol,,Uganda,Stanciole (2012); BMJ,per capita,Inhaled bronchodilator,None,0.000058,0.749047,Int $ (2005),0.000058,0.749047,0.00124916,8.269254283,6619.851,Yes,2005 Int$,People living with COPD,,,100.00%,Total Population x prevalence COPD," 18,898,441 ",4.70%,https://pubmed.ncbi.nlm.nih.gov/30141966/,888226.727,,11.00%,50%,NCD unit,50%,0,0,18.01813792,18.01813792,,,18.01813792,,18.01813792,54.552,54.552,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,281,Respiratory disease including COVID-19,Treatment,Asthma/COPD exacerbation ,Asthma/COPD exacerbation ,Asthma/COPD exacerbation ,,,Secondary,,,,,,,,,,,,,,,,,,,,,,People living asthma/COPD x incidence exacerbation,,,,,,,90%,Severity,90%,,,,,,,,,,10.61952,10.61952,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,282,Respiratory disease including COVID-19,Treatment,Asthma/COPD exacerbation ,COPD - influenza vaccine,COPD - influenza vaccine,,Over 5 Outpatient visit,,COPD - influenza vaccine,,Uganda,Stanciole (2012); BMJ,per capita,Prevention and treatment of exacerbations through influenza vaccine,None,0.000004,0.048631,Int $ (2005),0.000004,0.048631,8.6149E-05,0.536872098,6231.899,Yes,2005 Int$,,,,,People living with COPD," 888,226 ",100.00%,per above,888226,,,50%,NCD unit,50%,,,,,,,0,,0,10.61952,10.61952,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,283,Respiratory disease including COVID-19,Treatment,Asthma/COPD severe exacerbation ,COPD - treatment of severe exacerbations,COPD - treatment of severe exacerbations,,Over 5 Outpatient visit,,COPD - treatment of severe exacerbations,,Uganda,Stanciole (2012); BMJ,per capita,Treatment of severe exacerbations,None,0.000007,0.117325,Int $ (2005),0.000007,0.117325,0.00125634,10.79361567,8591.316,Yes,2005 Int$,People living with COPD,,,12.00%,People living with COPD," 888,226 ",12.00%,Estimated,106587.12,,5.00%,90%,Severity,90%,0,0,0.437002797,0.437002797,,,0.437002797,,0.437002797,7.526892,7.526892,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,284,Respiratory disease including COVID-19,Treatment,Asthma/COPD severe exacerbation ,COPD - oxygen therapy and drugs,COPD - oxygen therapy and drugs,Severe/moderate COVID-19 disease treatment,Inpatient Admissions (Ongoing Monitoring),,COPD - oxygen therapy and drugs,,Uganda,Stanciole (2012); BMJ,per capita,Oxygen therapy + drugs,None,0.00001,0.376521,Int $ (2005),0.00001,0.376521,0.001794772,34.63901954,19299.958,Yes,2005 Int$,People living with COPD,,,12.00%,People living with COPD," 888,226 ",12.00%,Estimated,106587.12,,5.00%,90%,Severity,90%,0,0,43.22558018,43.22558018,,,43.22558018,,43.22558018,18.419808,18.419808,New Malawi estimate (2021),3.415304021,7.390547654,10.58460448,18.49074541,2.959718983,0.592159643,2.440657709,1.92840814,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,285,Respiratory disease including COVID-19,Screening and Diagnosis for Pneumonia/COVID-19,Screening and diagnosis,Screening and diagnosis,Screening and diagnosis,,,Community/Primary/Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",10000%,,1889844100,,,50%,,50%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,286,Respiratory disease including COVID-19,Screening and Diagnosis for Pneumonia/COVID-19,Laboratory,Laboratory,Laboratory,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population x pneumonia/COVID incidence (est 0.32%)," 6,186,500 ",100%,,6186500,,,50%,,50%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,287,Respiratory disease including COVID-19,Screening and Diagnosis for Pneumonia/COVID-19,Xray,Xray,Xray,,,Secondary/Tertiary,,,,,,,,,,,,,,,,,,,,,,Total Population x pneumonia/COVID incidence (est 0.32%)," 6,186,500 ",100%,,6186500,,,50%,,50%,,,,,,,,,,0.323544,0.323544,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,288,Respiratory disease including COVID-19,Treatment,Pneumonia ,Pneumonia ,Pneumonia ,,,,,,,,,,,,,,,,,,,,,,,,,Total Population x pneumonia incidence," 450,000 ",100%,,450000,,,90%,Severity,90%,,,,,,,,,,7.118148,7.118148,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,289,Respiratory disease including COVID-19,Treatment,Severe/moderate COVID-19 disease treatment,Severe/moderate COVID-19 disease treatment,Severe/moderate COVID-19 disease treatment,,,,,,,,,,,,,,,,,,,,,,,,,Total Population x hospitalization COVID (0.0238%)," 450,000 ",100%,,450000,,,90%,Severity,90%,,,,,,,,,,18.419808,18.419808,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,290,Respiratory disease including COVID-19,Treatment,Asthma,Asthma: Low dose inhaled beclometasone + SABA,Asthma: Low dose inhaled beclometasone + SABA,,Over 5 Outpatient visit,,Asthma: Low dose inhaled beclometasone + SABA,,Uganda,Stanciole (2012); BMJ,per capita,Low dose inhaled corticosteroids + long acting beta agonists,None,0.000045,0.245346,Int $ (2005),0.000045,0.245346,0.003946822,11.03014278,2794.690,Yes,2005 Int$,People with asthma,,,32.00%,People living with asthma," 727,039 ",30.00%,https://pubmed.ncbi.nlm.nih.gov/33479040/#&gid=article-figures&pid=figure-3-uid-2,218111.7,,36.00%,50%,NCD unit,50%,0,0,48.81277363,48.81277363,,,48.81277363,,48.81277363,Not available,48.81277363,Uganda estimate (2020),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,291,Respiratory disease including COVID-19,Treatment,Asthma,Asthma: Low dose inhaled beclometasone,Asthma: Low dose inhaled beclometasone,,Over 5 Outpatient visit,,Asthma: Low dose inhaled beclometasone,,Uganda,Stanciole (2012); BMJ,per capita,Low dose inhaled corticosteroids,None,0.000025,0.066982,Int $ (2005),0.000025,0.066982,0.002162929,2.970485948,1373.363,Yes,2005 Int$,People with asthma,,,32.00%,People living with asthma," 737,039 ",30.00%,https://pubmed.ncbi.nlm.nih.gov/33479040/#&gid=article-figures&pid=figure-3-uid-2,221111.7,,36.00%,50%,NCD unit,50%,,,,,,,0,,0,Not available,0,Uganda estimate (2020),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,292,"Eye, Ear and Skin",NA,Scabies ,Scabies and other skin diseases,Scabies ,,,,Scabies and other skin diseases,,Zimbabwe,Hansen (2008); Cost Eff Resour Alloc,0,Scabies treatment as an outpatient,None,,,,0,,0,,,,,Total population,"179,478",4.50%,4.50%,Total population," 18,898,441 ",4%,GBD,755937.64,89.00%,89.00%,90%,Severity/discomfort,89%,4.07402644,4.07402644,4.07402644,4.07402644,,,4.07402644,4.07402644,4.07402644,1.31166,1.31166,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence not appropriate,2008-01-01767-62,Scabies treatment as an outpatient,Scabies treatment as an outpatient,,None,Zimbabwe,1074,5.372219747,0,0,0,0,0,0,0,0,Hansen,2008,Zimbabwe,1997,Setting priorities for the health care sector in Zimbabwe using cost-effectiveness analysis and estimates of the burden of disease,,,,,,,,,
,293,"Eye, Ear and Skin",NA,Other skind conditions?,Other skind conditions? TO ADD,Other skin conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,294,Tuberculosis,Testing and Diagnostics,IGRA/Skin Test,IGRA/Skin Test,IGRA/Skin Test,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Suspected TB cases," 650,000 ",100%,NTP estimates,650000,,,100%,NTP,100%,,,,,,,,,,0.531768,0.531768,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,295,Tuberculosis,Testing and Diagnostics,HTS for TB patients (add into HTS testing),HIV Testing Services,HTS for TB patients (add into HTS testing),,,Primary,HIV Testing Services,Duplicate of HIV testing services,"Afr-E region (Botswana, Burundi, Central African Republic, Congo, Côte d'Ivoire, Democratic Republic Of The Congo, Eritrea, Ethiopi
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia, Zimbabwe )",Hogan et al. (2005),per capita,Voluntary counselling and testing (95%) - Performed in primary care clinics for anyone requesting the services; includes training of health workers; based on rapid test; number of tests over five year period assumed to be twice average annual prevalence,Nothing,0.008848567,0.718503637,Int $ (2000),0.008848567,0.718503637,6.441122055,236.8614603,36.773,Yes,2000 Int$,Direct entry,"44,285",100.00%,100.00%,TB cases," 26,280 ",100%,"based on 2019 TB incidence, https://extranet.who.int/tme/generateCSV.asp?ds=estimates",26280,100.00%,75.00%,100%,DHA,100%,0,0,0,0,14.38800924,from Malawi HBP,14.38800924,14.3880092,14.3880092,7.824,7.824,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - CE evidence is only for HTS for HIV patients not TB cases,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,296,Tuberculosis,Testing and Diagnostics,Microscopy Test,Microscopy Test,Microscopy Test,,,Primary,Microscopy Test,,,,0,,,,,,,,,,,,,Direct entry,"6,824",100.00%,2000.00%,Suspected TB cases," 650,000 ",100%,NTP estimates,650000,100.00%,84.00%,100%,DHA,100%,0.305727437,0.305727437,0.305727437,0.305727437,,,0.305727437,0,0,0.042744,0.042744,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,297,Tuberculosis,Testing and Diagnostics,Ultrasound,Ultrasound,Ultrasound,,,Primary/Secondary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.170976,0.170976,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,298,Tuberculosis,Testing and Diagnostics,GeneXpert test,Xpert test (Full),(Full) Xpert for all patients with presumptive tuberculosis,,Laboratory - TB Microscopy,Primary,Xpert test (Full),,Ethiopia,Tesfaye (2017); BMC Infect Dis,per capita,Xpert for all patients with presumptive tuberculosis (Full-Xpert),Standard/Usual Care- Ziehl-Neelsen microscopy using three sputum samples provided within two days (ZN-Spot-Morning-Spot),8.13446E-05,0.01035995,United States (2015); currency year assumed,8.13446E-05,0.01035995,0.002394029,0.332951423,139.076,Yes,2015 US$,TB/HIV coinfected cases+Extrapulmonary cases+ contacts of MDR/XDR cases (assuming 20 people contacted per person)+relapsed cases+new TB cases,,,1000.00%,Suspected TB cases," 650,000 ",100.00%,NTP estimates,650000,,90.00%,90%,NTP,90%,11.52343067,11.52343067,11.52343067,11.52343067,,,11.52343067,,11.52343067,9.990696,9.990696,New Malawi estimate (2021),0,0,0,0,0,0,0,0,2.400501286,11.40025064,3.199248071,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care- Ziehl-Neelsen microscopy using three sputum samples provided within two days (ZN-Spot-Morning-Spot),,,,,,,,,,,,,,,,,,,,,,,,,
,299,Tuberculosis,Testing and Diagnostics,GeneXpert test,Xpert test (targeted),"Targeted Xpert for patients with presumptive tuberculosis (Smear negative, HIV positive, retreatment, contacts of MDR-TB cases)",,Laboratory - TB Microscopy,Primary,Xpert test (targeted),,Ethiopia,Tesfaye (2017); BMC Infect Dis,per capita,"Targeted Xpert for patients with presumptive tuberculosis who are smear negative in addition to patients who are HIV positive, known contact of multidrug-resistant tuberculosis patients, and retreatment cases (Targeted-Xpert-ZN-Negative-Spot-Morning-Spot)",Standard/Usual Care- Ziehl-Neelsen microscopy using three sputum samples provided within two days (ZN-Spot-Morning-Spot),4.21489E-05,0.008482154,United States (2015); currency year assumed,4.21489E-05,0.008482154,0.002480946,0.545204406,219.757,Yes,2015 US$,TB/HIV coinfected cases+Extrapulmonary cases+ contacts of MDR/XDR cases (assuming 20 people contacted per person)+ relapsed cases,,,1000.00%,Suspected TB cases," 650,000 ",50.00%,NTP estimates,325000,,90.00%,90%,NTP,90%,11.52343067,11.52343067,11.52343067,11.52343067,,,11.52343067,,11.52343067,9.990696,9.990696,New Malawi estimate (2021),0,0,0,0,0,0,0,0,2.400501286,11.40025064,3.199248071,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care- Ziehl-Neelsen microscopy using three sputum samples provided within two days (ZN-Spot-Morning-Spot),,,,,,,,,,,,,,,,,,,,,,,,,
,300,Tuberculosis,Testing and Diagnostics,Urine LAM ,Urine LAM ,Urine LAM ,,,Primary,,,,,,,,,,,,,,,,,,,,,,Suspected HIV+ TB cases," 80,000 ",100%,DHA/NTP estimates on use,80000,,,80%,NTP,80%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,301,Tuberculosis,Testing and Diagnostics,Diagnosis Microscopy Test,Diagnosis Microscopy Test,Diagnosis Microscopy Test,,,Secondary,,Duplicate of microscopy test,,,,,,,,,,,,,,,,,,,,Suspected TB cases," 650,000 ",100%,NTP estimates,650000,,,90%,NTP,90%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - duplicate of microscopy test,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,302,Tuberculosis,Testing and Diagnostics,Chest X-ray,Chest X-ray,Chest X-ray,,,Secondary,,,,,,,,,,,,,,,,,,,,,,Suspected TB cases," 650,000 ",100%,NTP estimates,650000,,,80%,NTP,80%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,303,Tuberculosis,Testing and Diagnostics,Mycobacterium Growth Indicator tube (MGIT) ,Mycobacterium Growth Indicator tube (MGIT) ,Mycobacterium Growth Indicator tube (MGIT) ,,,Tertiary,,,,,,,,,,,,,,,,,,,,,,Suspected TB cases x MDR/XDR," 650,000 ",10%,NTP estimates,65000,,,100%,NTP,100%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,304,Tuberculosis,Testing and Diagnostics,LPA test,LPA test,LPA test,,,Tertiary,,,,,,,,,,,,,,,,,,,,,,Suspected TB cases x MDR/XDR," 650,000 ",10%,NTP estimates,65000,,,100%,NTP,100%,,,,,,,,,,0.042744,0.042744,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,305,Tuberculosis,Active TB Case finding,MDU (at primary and community),MDU (at primary and community),MDU (at primary and community),,,Community/Primary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,306,Tuberculosis,Active TB Case finding,House to house TB screening,Active TB screening,House to house TB screening,,,Community/Primary,,,,,,,,,,,,,,,,,,,,,,Total Population," 18,898,441 ",,,,,,100%,NTP,100%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,307,Tuberculosis,Preventive Treatment,"TB Preventative Therapy
HIV positive adults; all children 5-years and below in contact with TB patients",Isonized Preventive Therapy for HIV+ people,Isonized Preventive Therapy for HIV+ people,,TB Program - New Patient,Community/Primary,Isonized Preventive Therapy for HIV+ people,,Uganda,Johnson (2018); Clin Infect Dis,0,Regimen of 9 months of daily isoniazid (isoniazid preventive therapy),None,,,,10.843,11.971554,10.843,12.11521265,1.117,,,Total number living with HIV,,,100.00%,PLHIV," 1,045,011 ",100.00%,DHA prevalence,1045011,,85.00%,92%,Per DHA 95-95-95,92%,11.26952626,11.26952626,11.26952626,11.26952626,,,11.26952626,,11.26952626,14.4,14.4,New Malawi estimate (2021),6.029002225,7.187113784,7.890335338,6.804605751,5.149501524,0,2.869737167,4.247754799,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,308,Tuberculosis,Preventive Treatment,"TB Preventative Therapy
HIV positive adults; all children 5-years and below in contact with TB patients",Isonized Preventive Therapy for children in contact with TB patients,Isonized Preventive Therapy for children in contact with TB patients,,TB Program - New Patient,,Isonized Preventive Therapy for children in contact with TB patients,,Malawi,Jo et al. (2021); The Lancet https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30451-X/fulltext#seccesectitle0021,0,Contact investigation with TB treatment and provision of short-course isoniazid preventive therapy (children under 15),No IPT,,,,0.470733537,48.864,0.470733537,49.450368,105.050,,,Estimated number of child contacts under 15 years of age eligible for TB preventive treatment,-,0.00%,100.00%,Estimated number of child contacts under 15 years of age eligible for TB preventive treatment," 12,392 ",100.00%,67% of all TB cases are pulmonary; each pulmonary case has four household contacts: 17% of whichh are children of 5 years and below who may not submit sputum specimens (subtracted from denominator) and will require TB Preventive Therapy (TPT),12392,,85.00%,60%,NTP,60%,,,,,2.2,Jo et al (2021) - per patient cost of IPT,2.2,10.4624068,10.4624068,14.4,14.4,New Malawi estimate (2021),6.029002225,7.187113784,7.890335338,6.804605751,5.149501524,0,2.869737167,4.247754799,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,No IPT,,,,,,,,,,,,,,,,,,,,,,,,,
,309,Tuberculosis,Preventive Treatment,"TB Preventative Therapy
HIV positive adults; all children 5-years and below in contact with TB patients",Isonized Preventive Therapy for HIV+ pregnant women,Isonized Preventive Therapy for HIV+ pregnant women,Isonized Preventive Therapy for HIV+ people,TB Program - New Patient,,Isonized Preventive Therapy for HIV+ pregnant women,,India,Kapoor (2016); Int J Tuberc Lung Dis,0,Isoniazid preventive therapy (IPT) therapy for all HIV+ pregnant women regardless of CD4 count,Standard/Usual Care,,,,20.287,24.3324,20.287,24.6243888,1.214,,,Women in need of PMTCT,,,100.00%,Women in need of PMTCT," 80,000 ",100.00%,DHA estimate,80000,,85.00%,92%,Per DHA 95-95-95,92%,11.26952626,11.26952626,11.26952626,11.26952626,,,11.26952626,,11.26952626,14.4,14.4,New Malawi estimate (2021),6.029002225,7.187113784,7.890335338,6.804605751,5.149501524,0,2.869737167,4.247754799,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,Standard/Usual Care,,,,,,,,,,,,,,,,,,,,,,,,,
,310,Tuberculosis,First line treatment,First line treatment for new TB cases for adults,First line treatment of smear positive cases (95% coverage),First line treatment of smear positive cases (95% coverage),,TB Program - New Patient,Community/Primary,First line treatment of smear positive cases (95% coverage),,,Baltussen (2005); BMJ,0,Minimal DOTS,Nothing,,,,72.25806452,325.4850199,72.25806452,329.3908402,4.559,,,Number of new and previously treated non-MDR cases,,,100.00%,New and previously treated cases," 26,280 ",100.00%,"based on 2019 TB incidence, https://extranet.who.int/tme/generateCSV.asp?ds=estimates",26280,79.00%,85.00%,80%,NTP,79%,37.32255198,37.32255198,37.32255198,37.32255198,,,37.32255198,,37.32255198,17.609796,17.609796,New Malawi estimate (2021),6.029002225,7.187113784,7.890335338,6.804605751,5.149501524,0,2.869737167,4.247754799,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,311,Tuberculosis,First line treatment,First line treatment for new TB cases for adults,"Full DOTS (smear-positive, smear negative and Extrapulmonary cases)","Full DOTS (smear-positive, smear negative and Extrapulmonary cases)",,TB Program - New Patient,,"Full DOTS (smear-positive, smear negative and Extrapulmonary cases)",,,Baltussen (2005); BMJ,per capita,Minimal DOTS,Nothing,0.083884415,1.083418538,Int $ (2000),0.083884415,1.083418538,61.06183708,357.1590789,5.849,Yes,2000 Int$,New and previously treated cases,,,100.00%,New and previously treated cases," 26,280 ",100.00%,"based on 2019 TB incidence, https://extranet.who.int/tme/generateCSV.asp?ds=estimates",26280,60.00%,33.00%,80%,NTP,60%,,,,,622.1463717,"Baltussen (2005) - https://www.ncbi.nlm.nih.gov/pmc/articles/PM C1309642/ - Main paper table 2 and appendix table 4 - only drug and diagnostic costs are considered - weighted average of cost for smear positive, smear negative cases",622.1463717,,622.1463717,Not available,622.1463717,Uganda estimate (2020),6.029002225,7.187113784,7.890335338,6.804605751,5.149501524,0,2.869737167,4.247754799,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,312,Tuberculosis,First line treatment,First line treatment for new TB cases for adults,"Full combination DOTS  (smear-positive, smear negative, extrapulmonary cases, MDR cases)","Full combination DOTS  (smear-positive, smear negative, extrapulmonary cases, MDR cases)",,,,"Full combination DOTS  (smear-positive, smear negative, extrapulmonary cases, MDR cases)",,,Baltussen (2005); BMJ,per capita,Minimal DOTS,Nothing,0.085654128,1.308526081,Int $ (2000),0.085654128,1.308526081,#VALUE!,,,Yes,2000 Int$,New and previously treated cases + MDR/XDR cases,,,100.00%,New and previously treated cases + MDR/XDR cases," 27,046 ",,row 315 + 766 for MDR/XDR estimated cases,,,33.00%,80%,NTP,80%,,,,,4375.994123,"Baltussen (2005) - https://www.ncbi.nlm.nih.gov/pmc/articles/PM C1309642/ - Main paper table 2 and appendix table 4 - only drug and diagnostic costs are considered - weighted average of cost for smear positive, smear negative,MDR cases",4375.994123,,4375.994123,Not available,4375.994123,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,#VALUE!,Incomplete,Complete,Incomplete,New data available,,,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,313,Tuberculosis,First line treatment,First line treatment for retreatment TB cases for adults,First line treatment for retreatment TB cases for adults,First line treatment for retreatment TB cases for adults,,,Community/Primary,,,,,,,,,,,,,,,,,,Total population,"179,478",0.20%,,TB incidence x retreatment," 26,280 ",3%,At least 3% of all TB cases are retreatment cases,788.4,12.00%,,80%,,12%,,,,,,,,175.352465,175.352465,76.313928,76.313928,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,314,Tuberculosis,First line treatment,First line treatment for new TB cases for children,First line treatment for new TB cases for children,First line treatment for new TB cases for children,,,Community/Primary,,,,,,,,,,,,,,,,,,Total population,"179,478",0.20%,,TB incidence 0-14," 26,280 ",10%,10% of all TB cases are children 0 to 14 years,2628,9.00%,,70%,,9%,,,,,,,,30.293708,30.293708,96.914616,96.914616,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,315,Tuberculosis,First line treatment,First line treatment for retreatment TB cases for children,First line treatment for retreatment TB cases for children,First line treatment for retreatment TB cases for children,,,Community/Primary,,,,,,,,,,,,,,,,,,Total population,"179,478",0.20%,,TB incidence 0-14 x retreatment," 2,628 ",3%,At least 3% of all TB cases are retreatment cases,78.84,1.00%,,70%,,1%,,,,,,,,136.419999,136.419999,0.438048,0.438048,New Malawi estimate (2021),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,316,Tuberculosis,MDR treatment,MDR notification among new patients,MDR notification among new patients,MDR notification among new patients,,,Secondary,MDR notification among new patients,,,,0,,,,,,,,,,,,,"Number of new TB cases, excluding relapse",152,0.50%,,"Number of new TB cases, excluding relapse", 500 ,100%,Estimates NTP,500,60.00%,,80%,NTP,60%,,,,,,,0,4138.2673,4138.2673,Not available,4138.2673,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,317,Tuberculosis,MDR treatment,MDR notification among previously treated patients,MDR notification among previously treated patients,MDR notification among previously treated patients,,,Secondary,MDR notification among previously treated patients,,,,0,,,,,,,,,,,,,"Previously treated, including relapse",19,4.80%,,"Previously treated, including relapse", 166 ,100%,Estimates NTP,166,60.00%,,80%,NTP,60%,,,,,,,0,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,318,Tuberculosis,MDR treatment,Case management of MDR-TB Cases,Case management of MDR cases,Case management of MDR-TB Cases,,,Community/Primary,Case management of MDR cases,,Philippines,Tupasi (2006); PLoS Med,per capita,DOTS-Plus project- chronic cases of MDR-TB referred from public or private facilities and cases with a diagnosis of MDR-TB during treatment with the first-line retreatment regimen,Nothing,4.90742E-06,0.00074328,United States (2002); currency year stated,4.90742E-06,0.00074328,0.122556962,26.71149528,217.952,Yes,2002 US$,Direct entry,1,100.00%,1000.00%,TB MDR cum incidenence, 766 ,100%,Estimates NTP,766,100.00%,74.00%,80%,NTP,80%,2102.240749,2102.240749,2102.240749,2102.240749,,,2102.240749,556.875011,556.875011,420.038388,420.038388,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,NA,NA,NA,NA,NA,remove - repetition (311),,,,,Nothing,,,,,,,,,,,,,,,,,,,,,,,,,
,319,Tuberculosis,Care and Support,Support for TB patients,Care and support for TB HIV+ patients,Support for TB patients,,,Community/Primary,Care and support for TB HIV+ patients,,,,0,,,,,,,,,,,,,Number of TB/HIV co-infected cases,88,100.00%,100.00%,PLHIV co-infected TB,,,,,100.00%,90.00%,92%,Per DHA 95-95-95,92%,0,0,0,0,,,0,0,0,Not available,0,Malawi estimate (2016),,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Complete,Incomplete,New data available,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,320,Tuberculosis,"Monitoring, Evaluation, and Supervision",Integrated Supervision,Integrated Supervision,Integrated Supervision,,,Community/Primary,,Not a health intervention,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,Incomplete,Incomplete,Incomplete,Incomplete,Incomplete,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,321,Tuberculosis,,LED test,LED test,LED test,,Laboratory - POC,,LED test,added from Uganda HBP,Ethiopia,Tesfaye (2017); BMC Infect Dis,per capita,Light-emitting diode (LED) fluorescence microscopy using two sputum samples provided within two days (FN-Spot-Morning),Standard/Usual Care- Ziehl-Neelsen microscopy using three sputum samples provided within two days (ZN-Spot-Morning-Spot),1.55873E-05,-0.000470446,United States (2015); currency year assumed,1.55873E-05,-0.000470446,0.000458744,-0.015119349,-32.958,Yes,2015 US$,Direct entry,"3,412",100.00%,,Suspected TB cases," 650,000 ",100%,NTP estimates,650000,100.00%,,,,100%,,,,,,,0,0,0,Not available,0,Malawi estimate (2016),0,1,0.819906439,4.180093561,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Incomplete,Complete,Complete,New data available,,,,,,Standard/Usual Care- Ziehl-Neelsen microscopy using three sputum samples provided within two days (ZN-Spot-Morning-Spot),,,,,,,,,,,,,,,,,,,,,,,,,
,322,Vaccine Preventable Disease,Essential Vaccines Package,Rotavirus vaccine,Rotavirus vaccine,Rotavirus vaccine,,EPI,,Rotavirus vaccine,,Uganda,Kim (2011); BMC Infect Dis,0,Rotavirus vaccine at Int $25 per vaccinated child (70% coverage),None,,,,0.187969925,11.41103821,0.187969925,11.54797067,61.435,,,Children < 1,"4,395",100.00%,100.00%,Children <12 months," 599,135 ",100.00%,Vaccination,599135,98.00%,90.00%,98%,Based on coverage estimates,98%,0,4.647268448,4.647268448,4.647268448,,,4.647268448,15.1477285,15.1477285,0.4416,0.4416,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,323,Vaccine Preventable Disease,Essential Vaccines Package,Polio vaccine,Polio vaccine,Polio vaccine,,EPI,,Polio vaccine,,Global,Khan (2008),0,Introduction of Inactivated Polio Vaccine (IPV),Oral Polio vaccine,,,,0.000499002,1.018,0.000499002,1.030216,2064.553,,,Children < 1,"4,395",100.00%,100.00%,Children <12 months," 599,135 ",100.00%,Vaccination,599135,96.00%,90.00%,96%,Based on coverage estimates,96%,0.53852467,0.53852467,0.53852467,0.53852467,,,0.53852467,0.79032263,0.79032263,0.990624,0.990624,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,Oral Polio vaccine,,,,,,,,,,,,,,,,,,,,,,,,,
,324,Vaccine Preventable Disease,Essential Vaccines Package,BCG vaccine,BCG vaccine,BCG vaccine,,EPI,,BCG vaccine,,Indonesia,Machlaurin (2020); Vaccines,0,Universal BCG vaccination,None,,,,0.114612245,13.0643405,0.114612245,13.22111258,115.355,,,Children < 1,"4,395",100.00%,100.00%,Children <12 months," 599,135 ",100.00%,Vaccination,599135,100.00%,90.00%,100%,Based on coverage estimates,100%,0,0.566946805,0.566946805,0.566946805,,,0.566946805,0.22990623,0.22990623,0.190716,0.190716,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,325,Vaccine Preventable Disease,Essential Vaccines Package,Pneumococcal vaccine,Pneumococcal vaccine,Pneumococcal vaccine,,EPI,,Pneumococcal vaccine,,Uganda,Sinha (2007); Lancet,0,Pneumococcal conjugate vaccination,None,,,,3.5,261.6853354,3.5,264.8255594,75.664,,,Children < 1,"4,395",100.00%,100.00%,Children <12 months," 599,135 ",100.00%,Vaccination,599135,97.00%,90.00%,97%,Based on coverage estimates,97%,0,9.288054655,9.288054655,9.288054655,,,9.288054655,17.8043591,17.8043591,2.94306,2.94306,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,326,Vaccine Preventable Disease,Essential Vaccines Package,HPV vaccine,HPV vaccine,HPV vaccine,,EPI,,HPV vaccine,,Uganda,Campos (2017); Int J Gynaecol Obstet,0,Human papillomavirus (HPV) vaccination,None,,,,0.032423208,6.353614334,0.032423208,6.429857706,198.310,,,Females 9-13 years,"11,377",100.00%,100.00%,Females 9-13 years (sub 10-14 years)," 1,207,173 ",100.00%,Vaccination,1207173,73.00%,80.00%,70%,Based on coverage estimates,70%,0,9.084113368,9.084113368,0,,,9.084113368,14.5528823,14.5528823,1.10346,1.10346,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,327,Vaccine Preventable Disease,Essential Vaccines Package,Measles rubella vaccine,Measles rubella vaccine,Measles rubella vaccine,,,,Measles rubella vaccine,There are no cost-effectiveness studies with health impact measured in DALYs for MR; only studies for measles vaccine - see sytematic review - https://onlinelibrary.wiley.com/doi/10.1111/risa.12331,Benin,Kaucley (2015); Cost Eff Resour Alloc,0,Supplementary immunization activity for measles vaccine every 3 years,None,,,,0,0,0,0,,,,,"4,395",100.00%,100.00%,Children 0-24 months (add <1 and (1-4)/4)," 1,171,597 ",100%,Vaccination,1171597,97.00%,90.00%,97%,Based on coverage estimates,97%,0,0.707062946,0.707062946,0.707062946,,,0.707062946,2.58232219,2.58232219,1.750836,1.750836,New Malawi estimate (2021),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,328,Vaccine Preventable Disease,Essential Vaccines Package,Pentavalent (DPT-Hep-Hib),DPT-Heb-Hib / Pentavalent vaccine,Pentavalent (DPT-Hep-Hib),,EPI,,DPT-Heb-Hib / Pentavalent vaccine,,Kenya,Akumu (2007); Bull World Health Organ,per capita,"Haemophilus influenzae type b (Hib) vaccine included in pentavalent vaccine with DPT (diphtheria, pertussis and tetanus) and hepatitis B vaccine",None,0.175572503,6.590450335,United States (2004); currency year stated,0.175572503,6.590450335,5.605905325,288.2869055,51.426,Yes,2004 US$,Children < 1,"4,395",100.00%,100.00%,Children <12 months," 599,135 ",100.00%,Vaccination,599135,98.00%,90.00%,98%,Based on coverage estimates,98%,0,1.838463387,1.838463387,0,,,1.838463387,1.98844842,1.98844842,4.18146,4.18146,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,329,Vaccine Preventable Disease,,Measles vaccine,Measles vaccine,Measles vaccine,Measles rubella vaccine,EPI,,Measles vaccine,added from Uganda HBP,Benin,Kaucley (2015); Cost Eff Resour Alloc,0,Routine immunization for measles at 9 months + supplementary immunization activity every 3 years to children aged 0-5 years,None,,,,0.005648478,0.017358249,0.005648478,0.017566548,3.110,,,,,,100.00%,Children 0-24 months (add <1 and (1-4)/4)," 1,171,597 ",100.00%,Vaccination,1171597,97.00%,90.00%,98%,Based on coverage estimates,97%,0,0.707062946,0.707062946,0.707062946,,,0.707062946,,0.707062946,1.750836,1.750836,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,Yes,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,330,Vaccine Preventable Disease,,BCG revaccination,BCG revaccination,BCG revaccination,,,,BCG revaccination,added from Uganda HBP,South Africa,Dye (2013); J R Soc Interface,0,Bacille Calmette Guerin revaccination,None,,,,0,0,0,0,,,,Adolescents,,,100.00%,Youth 6-13 years," 4,011,408 ",100%,Vaccination,4011408,,90.00%,80%,Based on coverage estimates,80%,0,0.566946805,0.566946805,0.566946805,,,0.566946805,,0.566946805,Not available,0.566946805,Uganda estimate (2020),,,,,,,,,,,,0,0,0,0,0,0,0,0,0,0,No,Incomplete,Complete,Complete,Incomplete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,331,Vaccine Preventable Disease,,Oral cholera vaccine,Oral cholera vaccine,Oral cholera vaccine,,EPI,,Oral cholera vaccine,added from Uganda HBP,Mozambique,Jeuland (2009); Value Health,0,School-based program targeting all 1-14 year olds for Oral cholra vaccination,None,,,,0.001859277,2.478429157,0.001859277,2.508170307,1349.003,,,School children (1-14 years),,,100.00%,School children (0-14 years)," 7,909,282 ",100.00%,Vaccination,7909282,,53.00%,50%,Based on coverage estimates,50%,,,,,2.7126,Jeuland (2009),2.7126,,2.7126,1.2576,1.2576,New Malawi estimate (2021),0.010008818,0.010008818,2.023100526,2.290407064,0.04,0.04,0.04,1.6,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,,,,,None,,,,,,,,,,,,,,,,,,,,,,,,,
,332,Non-Communicable Disease and Injury,,Sickle cell screening,,Sickle cell screening,,,,,,,,,Sickle cell disease screening using isoelectric focusing (IEF),,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence inaapropriate,2016-01-02819-27,Sickle cell disease screening using isoelectric focusing (IEF),"Sickle cell disease screening using isoelectric focusing (IEF).  If positive: insecticide-treated mosquito bed nets, folic acid supplementation, prophylactic antimalarial and penicillin therapy, and vaccinations against bacterial
infections",,None,Malawi,435,475.5625887,0.0277,0,0,8411580,0,0,0,0,Kuznik,2016,United States,2014,Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis,,,,,,,,,
,333,Child Health,Malaria,Home management of fevers using antimalarial (artesunate- amodiaquine AAQ),ICCM Malaria treament  (infants),Home management of fevers using antimalarial (artesunate- amodiaquine AAQ),"Uncomplicated (children, <15 kg)",Community-based intervention,Community,,,Ghana,Nonvignon(2012);Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian District,,Home management of fevers using antimalarial (artesunate- amodiaquine AAQ),,,,,0.168823047,11.5795728,0.168823047,13.9649648,82.720,Yes,2009 US$,,,,,Children 0-59 months,2888984,37.00%,https://www.sciencedirect.com/science/article/pii/S240584402030791X,1068924.08,59.00%,,80.00%,Ng'ambi 2020 adult/child,59%,,,,,,,,,,2.26938,2.26938,New Malawi estimate (2021),0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Complete,Complete,Complete,Incomplete,,2012-01-01106-01,Home management of fevers using antimalarial (artesunate- amodiaquine AAQ),Home management of fevers using antimalarial (artesunate- amodiaquine AAQ),,Standard care,Ghana,90.25,108.8748922,0,0,0,0,0,0,0,0,Nonvignon,2012,United States,2009,Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian District,,,,0.168823047,11.5795728,2009 US$,68.59,,
,334,Child Health,,Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),,Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),,Community-based intervention,,,,Ghana,Nonvignon(2012);Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian District,,Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),,,,,0.161814902,14.4150864,0.161814902,17.3845942,107.435,Yes,2009 US$,,,,,children 2–59 months,,,,,59.00%,,,,59%,,,,,,,,,,Not available,,N/A,0,0,0,0,0,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Incomplete,Incomplete,Complete,Incomplete,,2012-01-01106-02,Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),Home management of fevers using combined treatment of antimalarials and antibiotics (artesunate- amodiaquine plus amoxicillin AAQ+AMX),,Standard care,Ghana,114.21,137.7795173,0,0,0,0,0,0,0,0,Nonvignon,2012,United States,2009,Is home management of fevers a cost-effective way of reducing under-five mortality in Africa? The case of a rural Ghanaian District,,,,0.161814902,14.4150864,2009 US$,89.0838,,
,335,Non-Communicable Disease and Injury,Treatment for oncologic processes,"Biennial clinical breast examination (CBE) screening + Treatment of breast cancer, stages I-IV",,"Biennial clinical breast examination (CBE) screening + Treatment of breast cancer, stages I-IV",,,,,,,,,"Biennial clinical breast examination (CBE) screening + Treatment of breast cancer, stages I-IV",,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence inaapropriate,2012-01-01073-11,"Biennial clinical breast examination (CBE) screening + Treatment of breast cancer, stages I-IV","Biennial clinical breast examination (CBE) screening + Treatment of breast cancer, stages I-IV",,None,Ghana,1299,1567.074626,0,0,0,16311000,0,0,0,0,Zelle,2012,United States,2009,"Costs, effects and cost-effectiveness of breast cancer control in Ghana",,,,,,,,,
,336,Child Health,,Pulse oximetry with integrated management of childhood illness,,Pulse oximetry with integrated management of childhood illness,,,,,,,,,Pulse oximetry with integrated management of childhood illness,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound program,2015-01-02313-09,Pulse oximetry with integrated management of childhood illness,Pulse oximetry in addition to World Health Organization (WHO) guidelines for integrated management of childhood illness (IMCI) to diagnose pneumonia cases as severe or non-severe,,Other,Uganda,11.73,13.03181716,0,0,0,0,0,0,0,0,Floyd,2015,United States,2013,Evaluating the impact of pulse oximetry on childhood pneumonia mortality in resource-poor settings,,,,,,,,,
,337,Neglected Tropical Disease,,"Integrated neglected tropical disease program: preventative chemotherapy for Schistosomiasis, Ascariasis, Hookworm, Trichuriasis, and Lymphatic filariasis",,"Integrated neglected tropical disease program: preventative chemotherapy for Schistosomiasis, Ascariasis, Hookworm, Trichuriasis, and Lymphatic filariasis",,,,,,,,,Integrated neglected tropical disease program ,,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound program,2018-01-04725-01,Integrated neglected tropical disease program ,"Integrated neglected tropical disease program: preventative chemotherapy for Schistosomiasis, Ascariasis, Hookworm, Trichuriasis, and Lymphatic filariasis",,None,Madagascar,125,138.8727319,0,0,0,0,0,0,0,0,De Neve,2018,United States,2013,"Health, financial, and education gains of investing in preventive chemotherapy for schistosomiasis, soil-transmitted helminthiases, and lymphatic filariasis in  Madagascar: A modeling study",,,,,,,,,
,338,"Eye, Ear and Skin",,Annual screening all primary and secondary school children for uncorrected refractive error,,Annual screening all primary and secondary school children for uncorrected refractive error,,,,,,,,per capita,Annual screening all primary and secondary school children for uncorrected refractive error,,,,,0.001306,0.25,#VALUE!,,,Yes,2005 Int$,,,,,Primary/Secondary school children,,100%,,,,,80%,"Based on CE paper (Baltussen et al, 2012)",80%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,#VALUE!,#REF!,Incomplete,Incomplete,Incomplete,,2012-01-01157-07,Annual screening all primary and secondary school children for uncorrected refractive error,Annual screening all primary and secondary school children for uncorrected refractive error  (80% coverage),,None,Multiple Countries,190,251.7874552,0.001306,0,0,0,0,0,0,0,Baltussen,2012,United States,2005,Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study,,,per capita,0.001306,0.25,2005 Int$,190,,
,339,HIV/AIDS,,"Initiating combination antiretroviral thrapy (cART) early, consisting of zidovudine, lamivudine and either efavirenz or nevirapine",,"Initiating combination antiretroviral thrapy (cART) early, consisting of zidovudine, lamivudine and either efavirenz or nevirapine",,,,,,,,,"Initiating Combination antiretroviral therapy (cART) early, consisting of zidovudine, lamivudine and either efavirenz or nevirapine",,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence not against null,2012-01-01055-01,"Initiating Combination antiretroviral therapy (cART) early, consisting of zidovudine, lamivudine and either efavirenz or nevirapine","Initiating combination antiretroviral thrapy (cART) early, consisting of zidovudine, lamivudine and either efavirenz or nevirapine",,Other,Uganda,260,299.1515922,1.98,0,0,0,0,0,0,0,Sempa,2012,United States,2011,Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda,,,,,,,,,
,340,Child Health,,"Child Health Weeks (CHWs)- semi annual, campaign-style, facility- and outreach-based events for provision of measles vaccination, vitamin A and deworming",,"Child Health Weeks (CHWs)- semi annual, campaign-style, facility- and outreach-based events for provision of measles vaccination, vitamin A and deworming",,,,,,,,,"Child Health Weeks (CHWs)- semi annual, campaign-style, facility- and outreach-based events for provision of measles vaccination, vitamin A and deworming",,,,,0.010124399,2.369109422,0.010124399,2.812132884,277.758,Yes,2010 US$,Children 6-59 months,,,,Children 6-59 months,,,,,,,,,,,,,,,"Combined cost of deworming, vitamin-A supp., and measles vaccination",,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound intervention,2014-01-00988-01,"Child Health Weeks (CHWs)- semi annual, campaign-style, facility- and outreach-based events for provision of measles vaccination, vitamin A and deworming","Child Health Weeks (CHWs)- semi annual, campaign-style, facility- and outreach-based events for provision of measles vaccination, vitamin A and deworming",,None,Zambia,234,277.734958,0,0,0,0,0,0,0,0,Fiedler,2014,United States,2010,"Child Health Week in Zambia: costs, efficiency, coverage and a reassessment of need",25660.33037,6004517.306,,0.010124399,2.369109422,2010 US $,234,,
,341,Non-Communicable Disease and Injury,,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (women 45-59)",,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (women 45-59)",,,,,,,,,"adding diabetes, hypertension, and high cholesterol screening & treatment to hiv/aids treatment",,,,,,,,0,,,,Women (45-59) on ART,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound intervention,2020-01-05327-02,"adding diabetes, hypertension, and high cholesterol screening & treatment to hiv/aids treatment","screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics",,Standard care,Uganda,3255,3436.805667,0,43424000,0,43424000,0,0,0,0,Sando,2020,United States,2017,Cost-effectiveness analysis of integrating screening and treatment of selected  non-communicable diseases into HIV/AIDS treatment in Uganda,,,,,,,,Not considered since compound intervention,
,342,Non-Communicable Disease and Injury,,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (Women 60-69)",,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (Women 60-69)",,,,,,,,,"adding diabetes, hypertension, and high cholesterol screening and treatment to hiv/aids treatment",,,,,,,,0,,,,Women (60-69) on ART,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound intervention,2020-01-05327-03,"adding diabetes, hypertension, and high cholesterol screening and treatment to hiv/aids treatment","screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics",,Standard care,Uganda,1445,1525.709428,0,10541000,0,10541000,0,0,0,0,Sando,2020,United States,2017,Cost-effectiveness analysis of integrating screening and treatment of selected  non-communicable diseases into HIV/AIDS treatment in Uganda,,,,,,,,Not considered since compound intervention,
,343,Non-Communicable Disease and Injury,,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (men 45-59)",,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (men 45-59)",,,,,,,,,"adding diabetes, hypertension, and high cholesterol screening & treatment to hiv/aids treatment",,,,,,,,0,,,,Men (45-59) on ART,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound intervention,2020-01-05327-05,"adding diabetes, hypertension, and high cholesterol screening & treatment to hiv/aids treatment","screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics",,Standard care,Uganda,1915,2021.960938,0,18566000,0,18566000,0,0,0,0,Sando,2020,United States,2017,Cost-effectiveness analysis of integrating screening and treatment of selected  non-communicable diseases into HIV/AIDS treatment in Uganda,,,,,,,,Not considered since compound intervention,
,344,Non-Communicable Disease and Injury,,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (men 60-69)",,"annual screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics (men 60-69)",,,,,,,,,"adding diabetes, hypertension, and high cholesterol screening & treatment to hiv/aids treatment",,,,,,,,0,,,,Men (60-69) on ART,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - compound intervention,2020-01-05327-06,"adding diabetes, hypertension, and high cholesterol screening & treatment to hiv/aids treatment","screening for and treating diabetes, hypertension, and high cholesterol at public hiv clinics",,Standard care,Uganda,1400,1478.195986,0,2386000,0,2386000,0,0,0,0,Sando,2020,United States,2017,Cost-effectiveness analysis of integrating screening and treatment of selected  non-communicable diseases into HIV/AIDS treatment in Uganda,,,,,,,,Not considered since compound intervention,
,345,Community Health,,Rehabilitation of urban wastewater treatment plants,,Rehabilitation of urban wastewater treatment plants,,,,,,,,,Basic rehabilitation of five urban wastewater treatment plants,,,,,,,0,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence inaapropriate,2011-01-03325-01,Basic rehabilitation of five urban wastewater treatment plants,"Basic rehabilitation of five urban wastewater treatment plants, without work on sewer and household connections",,None,Ghana,41,49.28519807,0,0,0,166000,0,0,0,0,Drechsel,2011,United States,2008,Cost-effectiveness of options for reducing health risks in areas where food crops are irrigated with treated or untreated wastewater,,,,,,,,,
,346,Community Health,,On- and off-farm interventions to reduce microbial risk for consumers of irrigates vegetables,,On- and off-farm interventions to reduce microbial risk for consumers of irrigates vegetables,,,,,"On-farm interventions comprised of improved irrigation practices, including cessation of irrigation, drip irrigation and improved (low-splash) overhead irrigation. As the actual intervention or set of interventions may vary from site to site based on existing practices, and local constraints and opportunities, an average pathogen-reduction level was assumed.

• 
Off-farm interventions focusing on vegetable-washing practices in kitchens, based on the recommendations of Amoah et al. (2007b, 2011).",,,,Farm- and post-harvest options (50% adoption rate on-farm + 50% adoption rate post-harvest),,,,,,,0,0,,,,,,,,,,,,,,,50%,Assumed for CE evidence drawn from Drechsel et al. (2011),50%,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,remove - CE evidence inaapropriate,2011-01-03325-11,Farm- and post-harvest options (50% adoption rate on-farm + 50% adoption rate post-harvest),Farm- and post-harvest options (50% adoption rate on-farm + 50% adoption rate post-harvest),,None,Ghana,59,70.9226021,0,0,0,1100000,0,0,0,0,Drechsel,2011,United States,2008,Cost-effectiveness of options for reducing health risks in areas where food crops are irrigated with treated or untreated wastewater,,,,,,,,,
,347,Nutrition,,Management of moderate acute malnutrition (children) with ready-to-use supplementary foods (RUSF),,Management of moderate acute malnutrition (children) with ready-to-use supplementary foods (RUSF),,Over 5 Outpatient visit,,,Note that this intervention would involve provision of RUSF on top of MAM treatment (intervention 247),Mali,Isanaka(2019);,,MAM treatment with ready-to-use supplementary foods (RUSF; PlumpySup),None,,,,52.05,0.15,52.05,0.1518,0.003,,,,,,,Children 0-14 x cum incidence MAM,7909282,2.70%,DHS/GBD child,213550.614,86.00%,,60.00%,Estimate from Ng'ambi 2020/program,60%,,,,,,,,,,288,288,New Malawi estimate (2021),1.238950168,9.034712305,1.849883622,13.86759714,18.16322923,0.457252627,2.5480796,6.049689834,0,0,0,,,,,,,,,,,Yes,Complete,Complete,Complete,Complete,Incomplete,,2019-01-04973-01,Ready-to-use supplementary foods,Community-based screening for acute malnutrition every 2 months and treatment of moderately acute malnourished kids with ready-to-use supplementary foods (RUSF; PlumpySup),,None,Mali,347,378.90707,0,0,0,0,0,0,0,0,Isanaka,2019,United States,2015,,,,,,,,,,
,348,Nutrition,,Sugar fortification with vitamin-A,,Sugar fortification with vitamin-A,,No HRH time,,,,Zambia,Fiedler(2013);Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,,Fortification of sugar with vitamin A,,,,,0.001065696,0.126812334,0.001065696,0.162827036,152.789,Yes,2006 US$,Total population,,,,," 18,898,441 ",100.00%,Fielder et al (2013),18898441,,,60%,"Assumed to be the same as in Zambia in the paper (Fiedler et al, 2013) - based on consumption of various items",60%,,,,,0.13,Fiedler et al (2013); https://journals.sagepub.com/doi/pdf/10.1177/156482651303400413,0.13,,0.13,Not available,0.13,Uganda estimate (2020),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2013-01-00663-01,Fortification of sugar with vitamin A,Fortification of sugar with vitamin A; 60% coverage (Scenario 1). Prevalence-based measures,,None,Zambia,119,152.7703819,0,0,0,873065,0,0,0,0,Fiedler,2013,United States,2006,Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,7337,873065,,0.001065696,0.126812334,2006 US$,119,,
,349,Nutrition,,Vegetable oil fortification eith vitamin A,,Vegetable oil fortification with vitamin A,,No HRH time,,,,Zambia,Fiedler(2013);Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,,Fortification of oil with vitamin A,,,,,0.002527524,0.035682689,0.002527524,0.045816573,18.127,Yes,2006 US$,Total population,,,,," 18,898,441 ",100.00%,Fielder et al (2013),18898441,,,59%,"Assumed to be the same as in Zambia in the paper (Fiedler et al, 2013) - based on consumption of various items",59%,,,,,0.04,Fiedler et al (2013); https://journals.sagepub.com/doi/pdf/10.1177/156482651303400413,0.04,,0.04,Not available,0.04,Uganda estimate (2020),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2013-01-00663-02,Fortification of oil with vitamin A,Fortification of oil with vitamin A; 59% coverage (Scenario 2). Prevalence-based measures,,None,Zambia,14,17.97298611,0,0,0,242400,0,0,0,0,Fiedler,2013,United States,2006,Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,17170,242400,,0.002527524,0.035682689,2006 US$,14,,
,350,Nutrition,,"Maize fortification with vitamin A, iron and zinc",,"Maize fortification with vitamin A, iron and zinc",,No HRH time,,,,Zambia,Fiedler(2013);Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,,"Fortification of maize (roller & breakfast meal) with iron, vitamin A, and zinc",,,,,0.002169515,0.869618158,0.002169515,1.116589715,514.672,Yes,2006 US$,Total population,,,,," 18,898,441 ",100.00%,Fielder et al (2013),18898441,,,23%,"Assumed to be the same as in Zambia in the paper (Fiedler et al, 2013) - based on consumption of various items",23%,,,,,0.87,Fiedler et al (2013); https://journals.sagepub.com/doi/pdf/10.1177/156482651303400413,0.87,,0.87,Not available,0.87,Uganda estimate (2020),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2013-01-00663-03,"Fortification of maize (roller & breakfast meal) with iron, vitamin A, and zinc","Fortification of maize (roller & breakfast meal) with iron, vitamin A, and zinc; 23% coverage (Scenario 3). Prevalence-based measures",,None,Zambia,401,514.7976736,0,0,0,2267530,0,0,0,0,Fiedler,2013,United States,2006,Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,5657,2267525,,0.002169515,0.869618158,2006 US$,401,,
,351,Nutrition,,"Fortification of sugar, oil, maize meal, & wheat flour with iron, vitamin A, and zinc",,"Fortification of sugar, oil, maize meal, & wheat flour with iron, vitamin A, and zinc",,No HRH time,,,,Zambia,Fiedler(2013);Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,,"Fortification of sugar, oil, maize meal, & wheat flour with iron, vitamin A, and zinc",,,,,0.003523826,0.458025329,0.003523826,0.588104522,166.894,Yes,2006 US$,Total population,,,,," 18,898,441 ",100.00%,Fielder et al (2013),18898441,,,82%,"Assumed to be the same as in Zambia in the paper (Fiedler et al, 2013) - based on consumption of various items",82%,,,,,0.47,Fiedler et al (2013); https://journals.sagepub.com/doi/pdf/10.1177/156482651303400413,0.47,,0.47,Not available,0.47,Uganda estimate (2020),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,No,Complete,Complete,Complete,Complete,New data available,,2013-01-00663-11,"Fortification of sugar, oil, maize meal, & wheat flour with iron, vitamin A, and zinc","Fortification of sugar, oil, maize meal, & wheat flour with iron, vitamin A, and zinc; 82% coverage (Scenario 18). Prevalence-based measures",,None,Zambia,130,166.8920139,0,0,0,4309600,0,0,0,0,Fiedler,2013,United States,2006,Assessing Zambia's industrial fortification options: getting beyond changes in prevalence and cost-effectiveness,33156,4309602,,0.003523826,0.458025329,2006 US$,130,,
,352,Respiratory disease including COVID-19,,Peri-operative pulse oximetry,,Peri-operative pulse-oximetry,Pulse oximetry,Laboratory - POC,,,,NA,Burn(2014);Peri-operative pulse oximetry in low-income countries: a cost-effectiveness analysis,,Peri-operative pulse oximetry with hand-held device,,,,,0.000725524,0.083041958,0.000725524,0.092259615,127.163,Yes,2013 US$,,,,,,,,,,,,,,,,,,,,,,,,0.323544,0.323544,New Malawi estimate (2021),0,1,0.819906439,4.180093561,5,0,0,0,0,0,0,,,,,,,,,,,No,Complete,Incomplete,Complete,Complete,Incomplete,,2014-01-02069-01,Peri-operative pulse oximetry with hand-held device,Peri-operative pulse oximetry with hand-held device,,None - No peri0operative monitoring,NA,115,127.7629133,0.83,0,0,0,0,0,0,0,Burn,2014,United States,2013,Peri-operative pulse oximetry in low-income countries: a cost-effectiveness analysis,,,,0.000725524,0.083041958,2013 US$,114.4578313,,
,353,Respiratory disease including COVID-19,,Pulse oximetry to reduce the incidence of fatal intra-operative hypoxic episode,,Improved oxygen systems for childhood pneumonia,,,,,,,,,Improved oxygen system (Oxygen concentrators and pulse oximeters),,,,,,,,0,,,,,,,,,,,,,,,,,,,,,,,,,,,Not available,,N/A,,,,,,,,,,,,,,,,,,,,,,No,NA,NA,NA,NA,NA,Remove - because CE evidence only against standard care,2008-01-01760-01,Improved oxygen system (Oxygen concentrators and pulse oximeters),Improved oxygen system (Oxygen concentrators and pulse oximeters),,Standard care,Papua New Guinea,50,64.18923611,0,0,0,0,0,0,0,0,Duke,2008,United States,2006,Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea,,,,,,,,CE evidence not appropriate,"""Using pulse oximetry to reduce the incidence of fatal intra-operative hypoxic episodes. We ignored non-fatal cases of hypoxic brain injury."" The target population should include all major surgeries performed under general anaesthesia"
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"Note: This sheet has been extracted from EHP Tool_07Mar22.xlsx. If you wish to understand data sources and formulas applied in more detail, please refer to the ""final_intervention_list"" sheet in the excel file. ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
